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Pulmonary hypertension (PH) is a pathological hemodynamic symptom that is 
defined by a mean pulmonary arterial pressure > 25 mmHg at rest as assessed 
by right heart catheterization. PH can be caused by a subset of conditions that 
are summarized in the Dana Point Clinical Classification of PH. (1) This PH classifi-
cation is based on clinical parameters, histopathology, and therapeutic response. 
Within the current classification Group 1 comprises of Pulmonary Arterial Hyper-
tension (PAH). Groups 2 through 5 are associated with the following underling 
conditions: left heart disease (Group 2), lung diseases and/or hypoxemia (Group 
3), chronic thromboembolic disease (Group 4) and lastly a variety of underlying 
conditions with unclear and/or multifactorial mechanisms (Group 5).
Pulmonary Arterial Hypertension
PAH is a life threatening pulmonary vasoproliferative disorder characterized by 
a severe form of pulmonary vascular remodeling including the development of 
so called neointimal lesions. These neointimal lesions cause intraluminal ob-
struction due to proliferation of endothelial and smooth muscle cells, fibrosis, 
and inflammation. PAH is considered irreversible when these neointimal lesions 
have formed. Unfortunately many patients present themselves when this form 
of irreversible vascular remodeling has already taken place. To date, no curable 
treatment is yet to be found for these patients. Inevitably, in these patients pulmo-
nary vascular remodeling progresses, resulting in increased pulmonary vascular 
resistance and increased right ventricular (RV) workload en eventual death due 
to RV failure. 
Epidemiology 
PAH is a rare disease. Incidence and prevalence of iPAH, the most frequent form 
of PAH, has been estimated to be between 1-3.3 and 5.5-25 cases per million 
respectively.(2, 3) Incidence and prevalence of PAH-CHD in adults has been de-
scribed to range between 0.4-2.2 and 1.7 -12 cases per million adults, respec-
tively. (2, 3) Recently van Loon et al have described epidemiological features for 
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Updated cl inical classif ication of pulmonary hypertension (DANA POINT) 
1 PAH 
   1.1 Idiopathic 
   1.2 Heritable 
   1.2.1 BMPR2 
   1.2.2 ALK-1, endoglin (with or without hereditary haemorrhagic telangiectasia) 
   1.2.3 Unknown 
   1.3 Drugs and toxins induced 
   1.4 Associated with: 
   1.4.1 Connective tissue diseases 
   1.4.2 HIV infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart disease 
   1.4.5 Schistosomiasis 
   1.4.6 Chronic haemolytic anaemia 
   1.5 Persistent pulmonary hypertension of the newborn 
   19 Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 
2 Pulmonary hypertension due to left heart disease 
   2.1 Systolic dysfunction 
   2.2 Diastolic dysfunction 
   2.3 Valvular disease 
3 Pulmonary hypertension due to lung diseases and/or hypoxia 
   3.1 Chronic obstructive pulmonary disease 
   3.2 Interstitial lung disease 
   3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
   3.4 Sleep-disordered breathing 
   3.5 Alveolar hypoventilation disorders 
   3.6 Chronic exposure to high altitude 
   3.7 Developmental abnormalities 
4 Chronic thromboembolic pulmonary hypertension 
5 PH with unclear and/or multifactorial mechanisms 
   5.1 Haematological disorders: myeloproliferative disorders, splenectomy 
   5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis,  
          lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
   5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
   5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
 
BMPR2: bone morphogenetic protein receptor, type 2; ALK-1: activin receptorlike 
kinase 1 gene; PAH: pulmonary arterial hypertension. 
the pediatric age group from a nationwide database in The Netherlands.(4) In this 
registry annual incidence and point prevalence rates for PAH-CHD and iPAH 
averaged, respectively 2.2 and 0.7 and 15.6 and 4.4 cases per million children.(4) 
Even though these rates for pediatric PAH_CHD are higher compared to adults, 
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one must take into consideration the that a low representation of PAH-CHD in 
adults has been described to be due to the incomplete referral of adults with PAH 
associated with CHD to specialized PAH centers. 
Pathology of PAH: are endothelial cells the ones to beat?
As mentioned, PAH is characterized by a disticnt form pulmonary vascular re-
modeling. Where thickening of the media and adventitia layer of the pulmonary 
arterioles is seen in many forms of PH (Group 2-5), PAH is additionally character-
Figure 1. Typical examples of pulmonary vascular remodeling as seen in PAH A) a normal intra-acinar 
vessel (<100μm). Note the thin vessel wall and non-occluded lumen. Red cells in lumen are red blood cells. 
B) vessel with media hypertrophy. Arrows indicate laminae elastiae. Intima proliferation is not observed. Media 
hypertrophy of the intra-acinar vessels can be found in all forms of PH including PAH. C) intra-acinar vessel 
with concentric laminar intimal fibrosis, characterized by intraluminal cellular proliferation and the occurrence 
of intimal fibrosis. Over time, intimal thickening can become more fibrotic with loss of cells resulting in an onion 
like appearance (arrows). D) example of a plexiform lesion in end-stage PAH. Plexiform lesions are described 
to occur at vascular branching points. They are characterized by destruction of the vessel wall (thin media lay-
er), cellular proliferation with the development of a plexus of narrow slit-like channels (arrows). Both concentric 
laminar intimal fibrosis and plexiform lesions are only seen in PAH. 
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ized by intimal proliferative and fibrotic changes with at the end of the spectrum 
the formation of plexiform lesions and concentric laminar intima fibrosis.(5-7) This 
pattern of vascular remodeling is called plexogenic arteriopathy and is not seen 
in other forms of pulmonary hypertension (Group 2-5). It is of importance to note 
that term plexogenic arteriopathy is descriptive for a pattern of vascular remod-
eling that eventually includes the formation of plexiform lesions. Therefore it is 
possible that in early stages of disease, only medial hypertrophy may be present 
and therefore may be difficult to differentiate from other types of arteriopathy in 
early stages of the disease.  
After three decades of PAH pathobiology research the focus of vascular remod-
eling has shifted from solely vasoconstriction towards a complex mechanism in 
which angioproliferation and apoptosis play a major role. In this concept cellular 
changes throughout the vessel wall (endothelial cell, smooth muscle cell and fi-
broblast) form the basis of disease development.(6, 8) Endothelial cells have been 
suggested to play a major role in this process due to their location bordering the 
lumen of the vessels.(9) In response to injury (changes in shear stress, hypoxia, 
inflammation, genetic susceptibility) endothelial cell dysfunction can result in pro-
liferation and apoptosis as well as changes in homeostasis (production of coagu-
lative and vasoactive agents). In PAH, disorganized endothelial cell proliferation 
is known to lead to vessel occlusion of the small (<100 µm) intra-acinar arteries. 
In addition, these endothelial cells have been described to have an apoptosis-re-
sistant phenotype. In combination with collagen deposition within these cellular 
layers, intimal fibrosis can occur. Over time concentric layers are formed eventu-
ally resulting in laminar concentric intimal fibrosis. 
Changes in the medial layer are also seen in PAH. The exact cellular process is 
incompletely understood, dysfunctional endothelial cells have been described to 
both stimulate smooth muscle cell proliferation and fail to produce agents that 
normally suppress smooth muscle cell proliferation.(8, 10) These changes result 
in increased wall thickness of the large (>100 µm) pre-acinar arteries and mus-
cularization of the normally non-muscularized intra-acinar arteries. In addition, 
migration of adventitial fibroblast into the medial and intimal layer, due to disrup-
tion of the extracellular matrix, has also been suggested to play a role in vascular 
remodeling in PAH.(8)
Having said all this, the pathogenic mechanisms underlying the formation of neo-
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intimal lesions is still poorly understood. Therefore, the complex pathogenesis of 
PAH needs to be further explored in order to identify potential therapeutic targets 
and improve future treatment possibilities. 
PAH associated with Congenital Heart Diseases: It’s the 
flow that matters
PAH is almost exclusively associated with certain congenital heart defects (CHD) 
that are accompanied with systemic-to-pulmonary (left-to-right) shunting (PAH-
CHD).(4, 11) These shunt defects can be categorized into pre and post tricuspid 
shunts, based on their anatomical localization and circulatory physiology. Re-
gardless of the underlying shunt defect, increased pulmonary blood flow (due 
to left-to-right shunting) is seen as an essential trigger for the development PAH 
(Figure 2). 
In the early stages of disease, when the vascular bed had been subjected to flow 
for a relatively short period of time, PAH and its pulmonary vascular lesions can 
be considered reversible. Hereby it is important to note that PAH associated with 
systemic-to-pulmonary shunting is the only form of PAH in which this early stage 
of pulmonary vascular disease can be clinically recognized. Namely this group 
Figure 2 Schematic hypothesis of the development of neointimal lesion in PAH. Increased pulmonary 
blood (i.e. systemic-to-pulmonary shunt) is an essential trigger for the occurrence of neointimal lesions and 
PAH development. Increased pulmonary blood flow is described to lead to endothelial dysfunction and media 
hypertrophy. If increased flow persists, pulmonary vascular remodeling can continue into neointimal develop-
ment. Also other triggers, such as increased pulmonary arterial pressure, genetic predisposition due to BM-
PR2-signaling defects, drugs, toxins, inflammation have been associated with induction or aggravation of this 
vascular disease process in PAH. 
 
Pulmonary Blood Flow 
neointimal lesion 
(PAH) 
normal lung arteriole 
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is predominantly formed by young pediatric patients with systemic-to-pulmonary 
shunting in whom closure of the shunt defect, resulting in normalization of pul-
monary blood flow, will result in reversal of the disease and cure of the patient.
However, when increased pulmonary blood flow persists due to delay in shunt 
closure or a diagnosis altogether, pulmonary vascular remodeling will evolve into 
an irreversible form. After this so called point of no return, removal of the trigger 
(i.e. increased pulmonary blood flow) for instance due to shunt closure will not re-
sult in reversal of the disease, and moreover is contra-indicated in these patients.
(12) At this point pulmonary  vascular remodeling will progress resulting in the 
pulmonary vascular resistance exceeding that systemic vascular resistance. This 
will cause the left-to-right shunt to reverse into a right-to-left or bidirectional shunt 
resulting in hypoxemia. This condition is called the Eisenmenger syndrome and 
is characterized by central cyanosis, erythrocytosis and multi organ involvement.
Figure 3 Targeting neointimal lesions: where is the off switch? PAH is considered irreversible and incura-
ble once neointimal lesions have occurred. Drug exploration should focus on targeting these neointimal lesions 
(anti-proliferation and pro-apoptosis), something that has not been accomplished so far. Further investigation in 
the role of disturbed blood flow can provide us with relevant clues that can lead to possible curative treatment 
options in PAH.
Other triggers such as increased pulmonary arterial pressure seem to accelerate 
the development of irreversible pulmonary vascular remodeling and PAH (Figure 
2). This is pointed out in clinical observations where only 10-20% of patients with 
a pre-tricuspid shunt, in which the vascular bed is solely subjected to increased 
pulmonary blood flow, but not to systemic pressure, will develop progressive PAH 
and this usually requires 30-40 years to develop.(13) In contrast, in patients with 
an unrestrictive post-tricuspid shunts, in which the pulmonary vascular bed is 
subjected to both increased blood flow and systemic pressure, PAH almost al-
ways develop and within the first year of life, if left untreated.(14, 15)  
Neointimal lesion 
(PAH) 





Still, it is yet unclear how increased pulmonary blood flow exactly induces pul-
monary vascular changes ultimately leading to advanced pulmonary vascular 
remodeling in PAH. Several mechanotransduction pathways linked to changes 
in pulmonary blood flow have been suggested to be involved in the pathobiology 
of PAH. These include direct induction of proliferation (through VEGF, PDGF, 
TGF-β pathways), apoptosis-resistance of endothelial cells, induction of inflam-
matory processes like mast cells, macrophages or lymphocytes recruitment, dif-
ferentiation of endothelial cells into mesenchymal cells, direct damage to the 
endothelial cell barrier and autocrine effects. Further investigation in the role of 
disturbed blood flow can provide us with relevant clues to further unravel the 
complex pathogenesis of PAH and in the future lead to possible curative treat-
ment options (Figure 3).
PAH treatment: are we there yet?
Currently PAH patients are treated, in addition to supportive medication, with 
either 1) calcium channel blockers or 2) one or a combination of the following so-
called second generation agents: prostacyclin-analogues, endothelin receptor 
antagonists and phosphodiesterase-5 inhibitors. These pathways are: Prostacy-
lin (prostaglandin I2) is a major arachidonic acid metabolite produced by endothe-
lial cells. Once released, its functions through a cascade that signals adenylyl 
cyclase to produce cyclic adenosine monophosphate (cAMP) in smooth muscle 
cells. cAMP results in inhibition of platelet activation, and vasodilatation through 
protein kinase A (PKA) induced smooth muscle cell relaxation. In PAH, prostacy-
clin synthase production is reduced in the pulmonary arterioles.(16) Prostacyclin 
analogues (iloprost, treprostinil) and synthetic prostacyclin (epoprostenol) play a 
major role in current PAH therapy and have shown to improve 6 minute walking 
distance and survival in iPAH patients.(17) However, the use of prostacyclin (ana-
logues) has some major drawbacks. First, its short half life (specifically that of the 
synthetic prostacyclin epoprostenol), making continuous intravenous administra-
tion mandatory. This type of treatment requires demanding care and can result in 
serious complications (infections, thrombo-embolic events) related to the use of 
intravenous administration.(17, 18) , and most importantly, prostacyclin treatment is 
not able to reverse or cure pulmonary vascular remodeling in PAH. 
Endothelin is the most potent vasoconstrictor known. Endothelin-1 is secreted 
from the endothelium and regulates pulmonary vascular tone and is described 
to influence cellular growth and survival in the vascular wall. These effects in the 
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pulmonary vasculature are mediated by two types of G protein coupled receptors 
endothelin-A and endothelin-B. These receptors are found on smooth muscle 
cells and activation results in vasoconstriction. In addition, the endothelin-B re-
ceptor is also found on endothelial cells where activation leads to vasodilatation. 
In PAH, endothelin-1 is increased in plasma and in pulmonary vessels.(19, 20) Cur-
rently, dual endothelin A and B receptor antagonists (bosentan) and selective 
endothelin-A receptor antagonists (ambristentan, sitaxentan) are used for PAH 
therapy.  Nitric oxide acts mainly by increasing intracellular levels of cyclic guano-
sine monophosphate (cGMP) resulting in smooth muscle cell relaxation and in-
hibition of platelet activation. These effects are abolished by phosphodiesterase 
5 (PDE-5), which breaks down cGMP in the pulmonary vasculature. PDE-5 in-
hibitors (sildenafil, tadalafil) are therefore currently used in the treatment of PAH. 
Before the use of second generation therapy, the 3-year survival rate for untreated 
adults with PAH was 48%.(21) Unfortunately, during the last 2 decades the survival 
rate has only shown moderate improvement(22), despite improving knowledge of 
the pathobiology of PAH and the introduction of PAH specific drugs. The general 
thought is that this is related to the severity of pulmonary vascular remodeling, 
which is considered irreversible once neointimal lesions have formed. Potential 
new therapeutical targets need to be further explored in order to improve future 
treatment possibilities. This future quest of drug exploration should focus on truly 
targeting neointimal lesions (anti-proliferation and pro-apoptosis), something that 
has not been accomplished so far (Figure 3).
PAH animal models: The search for true representation
Animal models remain to play a crucial role in studying both new biomolecular 
pathways as well as investigating new treatment effects in PAH. However, as for 
any preclinical model, the pathophysiological mechanisms and clinical course 
have to be comparable to the human disease that it is supposed to mimic. His-
torically the most widely used animal models of PH have been chronic hypoxia 
and the monocrotaline (MCT) induced PH rodent models. Although these models 
have added enormously to the understanding of the mechanisms of pulmonary 
vascular remodeling in PH, they are truly limited by 1) the lack of typical complex 
vascular neointimal lesions, 2) the severe PAH phenotype and 3) their relative 
ease to cure. Still, these models form a basis for other newer animal models (e.g. 
the monocrotaline/increased flow model) where additional hits (triggers) result 
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in more complex pulmonary vascular lesions. In this model the same trigger as 
in human PAH-CHD, namely increased pulmonary blood flow (combined with 
monocrotaline), results in the development of occlusive neointimal lesions con-
taining angioproliferative and apoptotic-resistant ECs and SMCs. Although not 
an exact copy, these vessels more closely reflect the typical form of pulmonary 
vascular remodeling seen in human PAH(7, 8) including their resistance to clin-
ically used PAH treatment.(23, 24) Therefore PAH models of increased pulmo-
nary blood flow – that more closely resemble the human trigger and histopathol-
ogy – are well suited for preclinical investigation of PAH. 
Aims of this thesis
In summary:
Pulmonary arterial hypertension is a leading cause of morbidity and mortality in 
patients with CHD. As described above, in PAH pulmonary vascular remodeling, 
specifically the development of pulmonary neointimal lesions, form the basis of 
disease progression. Although well described histopathologically, the pathogen-
esis of PAH and its neointimal lesions is largely unknown. To date, neointimal 
lesions are regarded incurable, making PAH irreversible once these lesions oc-
cur. To develop new therapies, the molecular mechanism of this specific form of 
pulmonary vascular remodeling, using preclinical models that resemble human 
disease must therefore be unraveled.
The aims of this thesis are to:
−Study the current knowledge of increased pulmonary blood flow as a trigger 
for pulmonary vascular remodeling in PAH; and determined the relevance of a 
preclinical PAH model of increased pulmonary blood flow compared to historical 
PH models.
−Explore molecular mechanisms that are specifically regulated by increased pul-
monary blood flow in flow-associated PAH.
−Determine the specific role of one of these molecules, Egr-1, in the develop-
ment of pulmonary vascular remodeling and PAH progression in both preclinical 
and human PAH.
In Chapter 2 we review the current knowledge of disturbances in pulmonary 
blood flow patters as trigger for pulmonary vascular remodeling as seen in PAH 
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patients associated with systemic-to-pulmonary shunting. Particular emphasis is 
put on the lessons we have learned from preclinical animal models.
Chapter 3 identifies pathways that are specifically involved in the pathogenesis 
of increased pulmonary blood flow induced pulmonary vascular remodeling in 
experimental PAH. 
Chapter 4 describes the spatiotemporal expression of transcription factor Egr-1 
(early growth response protein 1) in the pulmonary vasculature during experi-
mental PAH development
In Chapter 5 the pulmonary vascular and hemodynamic effects of selective inhi-
bition of Egr-1 using catalytic oligodeoxynucleotides are studied in experimental 
PAH.
Chapter 6 describes the expression of Egr-1 in human PAH associated with con-
genital heart disease and compare this expression with iPAH, hypoxic PH and 
control vessels
Chapter 7 focuses one of the current PAH treatment strategies: epoprostenol 
use and the complications associated with the use of totally implantable access 
ports in this setting.   
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CHAPTER 2
Abstract 
Pulmonary Arterial Hypertension (PAH) is a progressive pulmonary vasoprolif-
erative disorder characterized by the development of unique neointimal lesions 
including concentric laminar intima fibrosis and plexiform lesions. Although the 
histomorphology of neointimal lesions is well described, the pathogenesis of PAH 
and neointimal development is largely unknown. After three decades of PAH 
pathobiology research the focus has shifted from vasoconstriction towards a 
mechanism of cancer-like angioproliferation. In this concept the role of disturbed 
blood flow is seen as an important trigger in the development of vascular remod-
eling. For instance, in PAH associated with congenital heart disease, increased 
pulmonary blood flow (i.e. systemic-to-pulmonary shunt) is an essential trigger 
for the occurrence of neointimal lesions and PAH development. Still, questions 
remain about the exact role of these blood flow characteristics in disease pro-
gression. PAH animal models are important for obtaining insight in new pathobio-
logical processes and therapeutical targets. However, as for any preclinical mod-
el the pathophysiological mechanism and clinical course has to be comparable 
to the human disease that it mimics. This means that animal models mimicking 
human PAH ideally are characterized by: a hit recognized in human disease (e.g. 
altered pulmonary blood flow), specific vascular remodeling resembling human 
neointimal lesions, and disease progression that leads to RV dysfunction and 
death. A review that underlines the current knowledge of PAH due to disturbed 
flow is still lacking. In this review we will summarize the current knowledge ob-
tained from PAH animal models associated with disturbed pulmonary blood flow 




Pulmonary arterial hypertension (PAH) is a fatal and progressive form of pulmo-
nary hypertension with, so far, unknown origin (37, 56). PAH is characterized by a 
typical form of pulmonary vascular remodeling, i.e. plexogenic arteriopathy (Fig-
ure 1)(71). Where thickening of the medial and adventitial layer of the pulmonary 
arterioles is seen in many forms of PH (e.g. PH associated with hypoxemia), 
PAH is additionally characterized by the formation of complex cellular and fibrotic 
lesions with at the end of the spectrum the formation of concentric laminar intima 
fibrosis and plexiform lesions (Figure 1)(71, 88). These neointimal lesions cause in-
traluminal obstruction characterized by apoptotic dysregulation and proliferation 
of endothelial cells, smooth muscle cells, fibrosis, and inflammation.(36, 67) PAH 
is considered irreversible when these neointimal lesions have formed(67), result-
ing in increased pulmonary vascular resistance, increased right ventricular (RV) 
workload and eventual death due to RV failure(7, 11, 39). The complex pathogenesis 
Figure 1 Correlate of the Dana Point 2008 clinical classification with the characteristics of the pulmo-
nary vascular arteriopathy. Group 1, PAH, is characterized by formation of concentric laminar intima fibrosis 
and plexiform lesions. Typical examples of these lesions are presented in the right-sided column. Figure adapt-
ed from Wagenvoort and Mooi(87). 
Clinical Classification Group Characteristics of arteriopathy 
1. Pulmonary arterial hypertension 
    Pulmonary veno-occlusive   
     disease or pulmonary capillary  
     hemangiomatosis  
• Medial hypertrophy 
• Muscularization of arterioles 
• Cellular proliferation of intima layer 
• Concentric laminar intimal fibrosis 
• Plexiform lesions 
• Fibrinoid necrosis 
2. PH due to left heart disease • Medial hypertrophy 
• Muscularization of arterioles and veins 
• non-obstructive intimal fibrosis 
• moderate intima fibrosis veins 
3. PH due to lung disease or  
    hypoxia 
• Large arteries mostly normal 
• Medial hypertrophy 
• Muscularization of arterioles 
• similar changes to lesser extent in    
  small pulmonary veins  
4. Chronic Thromboembolic PH  
    (CTEPH) 
• Mild medial hypertrophy  
• Eccentric intimal fibrosis 
• Recanalization of lumen 
• recent thrombi rare 
 
 5. PH with unclear multifactorial  
     mechanisms 
• Muscularization of arterioles and  
  veins (fibrotic lung disease, tumors) 
• non-obstructive intimal fibrosis  
  (fibrotic lung disease, tumors) 
• vascular granulomas (sarcoidosis,  
  tuberculosis) 
• enlargement of bronchial arteries  
  (bronchiectasis) 
Adapted from Wagenvoort and Mooi 
Histological examples 
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of PAH needs to be further explored in order to identify potential therapeutic tar-
gets and improve future treatment possibilities. 
According to the typical histopathology, the progressive clinical course, and ther-
apeutic responses, PAH is classified in group I of the clinical classification (Dana 
Point) for PH(70). PAH is subdivided in idiopathic, heritable, drug-induced, and 
associated with other conditions including congenital heart disease (CHD).  Al-
though the histomorphology of PAH is well described, the pathogenesis of these 
progressive angioproliferative lesions remains largely unknown. 
After three decades of research on the pathobiology of PAH, the focus has shifted 
from vasoconstriction(38) towards a cancer-like mechanism of angioproliferation(58, 
67) in which the role of disturbed pulmonary blood flow is re-appreciated as an im-
portant trigger in the development of pulmonary vascular remodeling (Figure 2)
(81). In general, disturbed blood flow can be defined as any pattern of flow that is 
nonuniform and irregular.  Examples are recirculation or swirling flow, reciprocat-
ing flow and turbulent flow. These patterns can occur naturally at specific regions 
in the vascular system (e.g. branching points) or due to (pathological) changes in 
Figure 2 Schematic hypothesis of the effects of disturbed pulmonary blood flow patterns on the devel-
opment of pulmonary vascular remodeling in PAH. (a) Normal thin walled vessels with a supernumerary ar-
tery and a dichotomous bifurcation. (b) Increased pulmonary blood flow due to systemic-to-pulmonary shunting 
results in disturbed blood flow (including reciprocating and recirculating flow) at branching points. This leads to 
specific pulmonary vascular remodeling at specific sites: plexiform lesions predominantly at the origin of super-
numerary arteries vs. laminar concentric intimal fibrosis predominantly at dichotomous branching points. The 
resulting changes in vessel wall geometry further alter flow patterns, which lead to further vascular modeling. 
EC: endothelial cell, SMC: smooth muscle cell. 
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either vascular geometries (vessel stenosis or obstruction) or hemodynamic forc-
es (17, 20). Under pathophysiological conditions these changes can lead to specific 
vascular and cellular responses resulting in remodeling of the vascular wall(17, 20). 
Clinical observation has shown that in patients with CHD who develop PAH, 
characteristic vascular lesions occur almost exclusively in defects associated 
with increased pulmonary blood flow, qualifying this increased pulmonary blood 
flow as a trigger for the induction of neointimal development. Here, increased pul-
monary blood flow is regarded an inductor of disturbed blood flow patterns in the 
pulmonary vasculature. In these patients with increased pulmonary blood flow, 
additional increased pulmonary arterial pressure, as in non-restrictive post-tri-
cuspid shunts, accelerates the progression of pulmonary vascular remodeling, 
as an apparent second trigger(81). Disturbed blood flow patterns are likely to be 
one of the triggers in PAH. Also other triggers, such as genetic predisposition due 
to BMPR2-signaling defects, drugs, toxins, inflammation have been associated 
with induction or aggravation of the vascular disease process in PAH(36, 55). Apart 
from the initiating trigger, once PAH has developed, the elevated pulmonary ar-
terial pressure in itself leads to altered hemodynamic forces and flow patterns, 
that subsequently may propagate the vascular disease process. Still, questions 
remain about the exact role of blood flow disturbances in neointimal development 
and disease progression.
During the past decades animals models have had played a crucial part in this 
process and will continue to give people new insight through PH research in 
the future. Although much insight has been gained from “historical” PH models, 
such as hypoxic PH or monocrotaline-induced PH, most of these studies are 
hampered by the fact that these models do not truly reflect the typical features of 
PAH, i.e. the histopathology and progressive course(73). Indeed, while it is possi-
ble to “cure” many forms of PH in animal models, the clinical profile of patients 
with PAH is more resistant to therapy. Hence, there is an increasing interest in 
models that more reliable reflect the complex disease PAH. This review will sum-
marize and discuss current knowledge about models of PAH. Since increased 
pulmonary blood flow appears to be a crucial factor in disease development, 
particular emphasis will be put on models of increased pulmonary blood flow and 
the current knowledge of the role of disturbed flow patterns in the development 
of pulmonary vascular remodeling in PAH. 
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Animal models of PAH: general concept
Animal models remain to play a crucial role in studying both new biomolecular 
pathways as well as investigating new treatment effects in PAH. Although mate-
rial obtained from patients, – usually when the lungs are explanted – is valuable, 
the use of animal models allows for evaluation of disease development and anal-
ysis of processes in early stages of the disease, as well as testing of reversibility. 
However, as for any preclinical model, the pathophysiological mechanisms and 
clinical course have to be comparable to the human disease that it is supposed 
to mimic. 
For PAH this means that an ideal model would include the following:
i. An initiation or trigger(s) of pulmonary vascular remodeling that mimics the 
human situation, e.g. an increase in or redistribution of pulmonary blood flow.
ii. Pulmonary vascular remodeling that represents the development of com-
plex obliterative neointimal lesions of the small intra-acinar arteries, and me-
dia hypertrophy of the smaller pre-acinar arterioles.
iii. A progressive disease development that leads to RV dysfunction and 
eventually death.
In addition, the model has to be viable in an experimental setting regarding both 
functional (hemodynamic and histological assessment) and biomolecular analy-
sis, as well as having a workable period to disease progression.  To date no such 
ideal model for PAH exists. However, some recent animal models may resemble 
more closely both pathophysiological mechanisms and clinical course of human 
PAH compared to more historical animal models of PH.
Development of pulmonary vasculature: how do animals 
compare to humans?
In choosing a proper animal model for PAH research, first consideration has to 
been given to possible anatomical and developmental differences between spe-
cific animal species and humans. These differences could have consequences 
for disease progression and severity, and therapeutic response. In humans the 
pulmonary parenchym undergoes 6 developmental stages: embryonic, pseu-
do-glandular, canalicular, saccular, alveolar, and vascular maturation(93-95). Of 
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these changes only alveolar development and vascular maturation continue after 
birth(93, 94). Comparable with humans, rats and mice have little alveolar develop-
ment at birth, whereas for instance lambs have already well developed alveoli at 
birth. Such differences are likely to be of importance when studying changes in 
pulmonary blood flow and vascular remodeling perinatally. Rat lungs on the other 
hand show quite similar alveolar and capillary surface development after birth 
compared to humans (95). Mice have less pulmonary blood vessel walls and more 
alveolar space compared to rats (24, 95), and presumably less distal supernumerary 
arteries, which might explain the mild forms of vascular remodeling found in most 
murine PH models.(28). 
The pulmonary vasculature is lined by endothelial cells, which are the first struc-
ture to perceive changes in hemodynamic forces. The endothelium has an impor-
tant function in controlling vasomotor tone, regulating permeability, maintenance 
of homeostatic balance and immunity. As the pulmonary vascular tree branches 
and the size of the pulmonary arteries decreases, the endothelial cell phenotype 
progresses from pulmonary artery endothelial cells towards pulmonary microvas-
cular endothelial cells, which differ in their permeability and mechanical proper-
ties(17) These differences may reflect in the location-specificity of the pulmonary 
vascular histomorphological changes observed in pulmonary PAH. In the larger 
pre-acinar arterioles (100-500µm) only increased medial wall thickness and in-
tima proliferation is observed, whereas complex neointimal lesions progressive-
ly develop in the normally non-muscular arterioles (<100 µm), the so-called in-
tra-acinar arteries (Figure 3).(88). Laminar concentric intimal fibrosis and plexiform 
lesions are predominantly formed at distal dichotomous branching points and 
branching points of supernumerary arteries, respectively(18, 70, 91) (Figure 2). 
Historical PH models
Historically the most widely used animal models of PH have been chronic hypoxia 
and the monocrotaline (MCT) induced PH rodent models. Although these models 
have added enormously to the understanding of the mechanisms of pulmonary 
vascular remodeling in PH, they are truly limited by the lack of typical complex 
vascular neointimal lesions and severe disease phenotype seen in PAH.(73) Still, 
these models form a basis for other newer animal models where additional hits 
(triggers) result in characteristic pulmonary vascular lesions resembling human 
disease, e.g. the monocrotaline/increased flow model (28, 73) or the hypoxia/sugen 
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model(79). For more knowledge about these models the readers is referred to re-
views published recently(29, 57, 73).
Models of Increased pulmonary blood flow
Early chronic studies in large animals have shown that when either one lung (i.e. 
left pulmonary artery) (19, 24, 33) or a single lobe (13, 59, 69) is directly connected to the 
aorta, which induces both high pulmonary blood flow and increased pulmonary 
arterial  pressure, complex neointimal lesions develop comparable with human 
disease (Figure 4). Unfortunately, since extensive morphometric analysis was 
not conducted in these studies it is difficult to interpret the exact magnitude of this 
remodeling.  Many later animal studies inducing increased pulmonary blood flow 
have used restrictive shunts resulting in increased muscularization of the pulmo-
nary arteries, but no complex neointimal lesions. (10, 25, 26, 60, 62, 89).  An explanation 
for the relatively mild form of vascular remodeling found in these ‘increased-flow 
Figure 3. Distribution of the specific lesions seen in pulmonary hypertension throughout the pulmonary 
vascular tree. The pre-acinar pulmonary arteries mainly display a phenotype of media hypertrophy (a) and ne-
ointimal formation (b) whereas the intra-acinar arteries have typical occlusive lesions such as concentric intima 
fibrosis (c), and plexiform lesions (d). 
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only’ models is that shunts used in these models were restrictive shunts with no 
significant  rise in pulmonary arterial pressure.(10, 60, 89) This is in analogy to the 
clinical observation, that patients with untreated pre-tricuspid shunts, such as 
atrial septal defect, in general develop advanced pulmonary vascular remode-
ling only in 5-15% of the cases and only after 2-3 decades. In contrast, patients 
with untreated non-restrictive, post-tricuspid shunts, such as ventricular septal 
defects, develop advanced complex neointimal lesions in 1-2 years in 80-100% 
of the cases.(81) Whether longer duration of the increased pulmonary blood flow 
in these animal models (months/years in stead of weeks) or an associated in-
crease in pulmonary arterial pressure by a non-restrictive shunt, would have in-
duced advanced pulmonary vascular lesions, can only be speculated. However, 
the absence of advanced vascular remodeling in these restrictive-flow models 
makes them less suitable to study the typical features of human PAH and to 
extrapolate the therapeutic effects to patients with PAH.(64, 78) Despite the lack of 
relevant endpoints, the high-flow low-pressure models allow to study the role of 
Table 1. Summary of main findings of animal models mimicking PAH
BT shunt = classical Blalock-Taussig shunt (subclavian artery-pulmonary artery anastomosis), mBT shunt = 
modified Blalock-Taussig shunt = goretex conduit for  subclavian artery to pulmonary artery, AoC shunt = 
Aortocaval shunt, MCT = monocrotaline, ET = endotheli, TGF = transforming growth factor, ACE = angiotensin 
converting enzyme, Egr-1 = early growth response protein 1
 





 Trigger flow only 
Calf BT shunt ± - Not studied (24) 




  + - Not studied (71) 




Rat AoC shunt ± - Not studied (25, 33, 71) 
 Trigger Flow + second hit 
Rat MCT + BT shunt + + TGF- , ACE (76) 
 MCT + AoC shunt + + EGR1,  
mast cells 
(20, 81, 84) 
 mBT shunt + MCT - -  (47) 
 MCT + pneumectomy + + Tissue Factor (92) 
  + + Oxidative 
stress 
(21) 
 Trigger other 
Rat SU-5416 + hypoxia + - Apoptosis (1, 77) 
 ETBr deficiency - - none (41) 
 ETBr deficiency + MCT + - ETB (40) 
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various pathways known in human PH. First, several studies have reported that 
systemic-to-pulmonary shunting in young lambs and piglets results in alterations 
of the endothelin pathway (Table 1)(9, 10, 53, 60, 63). In these models Endothelin-1 
and Endothelin A receptor expression is first up regulated followed by increased 
Endothelin-B receptor expression after chronic (>8 weeks) shunting which were 
found on the smooth muscle cells of the pulmonary vessels.  Chronic increased 
flow has also been shown to increase endothelial nitric oxide synthesis (eNOS), 
but not inducible nitric oxide synthesis (iNOS), activity in lung tissue and the 
pulmonary arteries subjected to increased flow(49, 60) Interestingly, NO availability 
itself was reported to decrease after increased flow exposure, which has been 
suggested to be the result of peroxynitrite production that leads to scavenging of 
NO and decreased production of NO by eNOS. In addition to biomolecular inves-
tigation, several treatment effects have been reported in these models, including 
beneficial effects on pulmonary vascular resistance and vascular wall thickness 
after preventive treatment with PAH specific drugs endothelin receptor antag-
onists (ERAs)(61, 62) phosphodiesterase-5 inhibitors(61), prostacyclin and inhaled 
NO(89).
Increased pulmonary blood flow combined 
with an additional trigger
A second hit needed?
Tanaka and colleges were the first to show that combining vascular injury (via 
monocrotaline administration) with increased pulmonary blood flow (via an anas-
tomosis of the left subclavian artery to the distal left pulmonary artery(74) or by 
unilateral pneumonectomy (52)) resulted in an extended neointimal pattern of pul-
monary vascular remodeling in the lung after 5 weeks (Figure 4). In addition, 
increased pulmonary artery pressure and RV hypertrophy were reported. In this 
study either monocrotaline or anastomosis alone did not result in severe neoin-
timal vascular remodeling.(74) In a different model van Albada et al have shown 
that increased pulmonary flow via an aortacaval (av-) shunt, when combined with 
monocrotaline administration, results in 1) neointimal obliteration of the intra-ac-
inar vessels staining positive for eNOS and smooth muscle actin, 2) increased 
systolic pulmonary artery pressure and RV hypertrophy and 3) increased mortal-
ity after 5 weeks (Figure 4).(84)
Chapter 2
32
Cumulative data from this model confirmed that increased pulmonary blood flow, 
preceded by endothelial injury via MCT, is a prerequisite for the development of 
pulmonary neointimal lesions.(8, 21, 84) Interestingly, in an experimental study Nishi-
mura and colleagues showed that when monocrotaline was administered after 
induction of the av-shunt, pulmonary vascular remodeling was less pronounced.
This could possibly be explained by the fact that due to the increased blood flow 
through av-shunt the concentration of metabolized monocrotaline pyrrole (after 
activation in the liver) is lower in the venous system reaching the pulmonary cir-
culation compared to non-shunted rats.
Table 2. Summary of the therapeutic effects in animal models mimicking PAH
 
Species Trigger PAH 
lesions 
Therapy Strategy Findings ref 
Trigger flow only 
Pig mBT shunt - Bosentan prevent  media 
hypertrophy 
(62) 
 - Sitaxsentan prevent  media 
hypertrophy  PVR 
(65) 
 - Sildenafil prevent  pPA  (64) 
 - Losartan prevent  PVR (63) 
Trigger Flow + second hit 
Rat Mct+AV shunt + Cromolyn prevent  occlusion (10) 
 + EPO prevent  mPA (83) 
 + Trepostinil prevent  mPA (85) 
 + Prostacyclin, 
aspirin 





+ Quinapril prevent  occlusion score, 
pPA 
(51) 
 + DHEA prevent  occlusion score, 
pPA 
(34) 
  idem reverse No effect (34) 
 + Rapamycin prevent  occlusion score, 
pPA 
(49) 
 + idem reverse No effect (49) 








Trigger Other  
Rat SU-5416  
+hypoxia 










prevent No effect (78) 
mBT shunt = modified Blalock-Taussig shunt = goretex conduit for  subclavian artery to pulmonary artery, AoC 
shunt = Aortocaval shunt, MCT = monocrotaline, PA = pulmonary artery pressure, PVR = pulmonary vascular 
resistance, EPO = erythropoeietin, DHEA = dehydroepiandosterone.
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Figure 4  Effects of increased pulmonary blood flow on the pulmonary vasculature in large animals; 
differences in type and duration of shunt.  a) A sheep model of increased pulmonary blood flow in the left 
upper lobe, induced intimal proliferation after 2 months, but developed into more advanced lesions after 1.5 yr. 
Adapted from Schnader et al(69).b) A dog model of chronic increased pulmonary blood flow and increased pres-
sure (aorto-pulmonary anastomosis). Chronic shunting (4 years) of one lung resulted in severe pulmonary vas-
cular remodeling including intimal fibrosis and plexiform like lesions. Adapted from Heath et al.(33) c) Extensive 
neointimal proliferation in the pulmonary vessels of rats subjected a pneumonectomy combined with monocro-
taline. Adapted from Okada et al.(44). d) Neointimal proliferation in intra-acinar vessels of rats with an aorto-caval 
shunt combined with monocrotaline (left). Immunofluorescence staining shows proliferation of endothelial cells 
(green; vWF) and smooth muscle cells (red; αSMA). Immuno-staining shows increased expression of Egr-1 
a putative inductor of advanced lesions. Adapted from Dickinson et al(21). e) Typical examples of plexiform-like 
lesions in young rats subjected to a pneumonectomy and monocrotaline. These lesions stain positive for vWF 
(top right) and VEGFR-2 (bottom right). Adapted from White et al(90).
Neointimal lesions in models with increased pulmonary 
blood flow
Are the vascular lesions seen in “double-hit” models comparable with those in 
human disease (Figure 5)? In human PAH irreversible neointimal lesions are 
comprised of both ECs and SMCs with a reduction in apoptotic markers and in-
crease in inflammatory cells(43). In flow models, these obliterative lesions are com-
prised of cells that stain positive for the endothelial cell markers VEFG-R2(90), 
eNOS(84), von Willebrand Factor(59), CD31+ (47) and for SMCs staining positive for 
α-smooth muscle actin (Figure 4 and 6, Table 1)(21, 47, 84, 90). Longitudinal studies 
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using the av-shunt or unilateral pneumectomy combined with monocrotaline in 
rats have shown that these neointimal lesions start to form 1-2 weeks after in-
creased pulmonary blood flow (Figure 4)(21, 51, 52, 90). In these experimental models 
the exact role of apoptotic or pro-proliferative state of these vessels during vas-
cular remodeling is fairly unknown. In addition, questions still remain where in 
the smaller pulmonary vasculature these occlusive lesions are most prominent 
(i.e. at branching points of larger arteries or at more distal locations). Interesting-
ly, White and colleagues have reported in their model that when monocrotaline 
administration is combined with unilateral pneumonectomy in younger rats, more 
complex plexiform-like lesions are formed (Figure 4)(90). The authors suggested 
that younger rats were more prone to vascular proliferation after injury. These 
lesions stained positive for vWF, VEGFR-2 and α-SMA and, as shown by mi-
croangiography, to be part of the pulmonary vasculature. In this monocrotaline 
/ pneumonectomy model, the effects of unilateral pneumonectomy have to be 
taken into consideration, including compensatory proliferation (up to 35%) of the 
remaining lung parenchyma itself (15).
Increased pulmonary blood flow and inflammation
Inflammation has been suggested to play a role in PAH as well as in the develop-
ment of flow-induced neointimal formation in PAH patients with systemic-to-pul-
monary shunts(32, 80, 86). Proinflammatory cytokines and other inflammatory cells 
including mast cells(31), macrophages, lymphocytes(32), and dendritic cells(22) have 
all been linked to flow and non-flow PAH (Table 1). Accumulation of inflammatory 
cells in experimental PAH has also been linked to increased oxidative stress(22), 
which is also seen in pulmonary vessels of PAH patients(14). 
In animal models of increased pulmonary blood flow inflammation has also been 
suggested to play a role in neointimal development(8, 22, 80). Clearly, the effect of 
monocrotaline administration in vascular inflammation has to be taken into ac-
count in these experimental models(29) and questions remain whether inflam-
mation can be seen as the additional trigger for neointimal development in the 
increased pulmonary blood flow / monocrotaline models.
Still, reducing inflammation such as recently shown by mast cell stabilization 
or inhibition of chymase can attenuate the development of pulmonary vascular 
remodeling(50)(8). These results justify future exploration of the possible role of 
anti-inflammatory therapy for PAH. 
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Figure 5 Schematic representation of effects of increased flow on the development of pulmonary vas-
cular lesions in PAH models.Left side:7ULJJHUVVXFKDVLQFUHDVHGÀRZPRQRFURWDOLQHRUK\SR[LD LQGXFH
PHGLDK\SHUWURSK\DQGFDQLQGXFHHQGRWKHOLDOFHOOFKDQJHV+RZHYHULQPRVWDQLPDOPRGHOVWKHVHKLWVDORQH




In summary, in flow-models that combine a trigger such as vascular injury (mono-
crotaline) with either pneumonectomy or an av-shunt, increased pulmonary blood 
flow specifically induces severe, characteristic pulmonary vascular remodeling, 
including neointimal development, perivascular inflammation and plexiform like 
lesions with remarkable similarities with human plexogenic arteriopathy (ii) (Fig-
ure 4,5). In addition increased flow leads to more pronounced increases in pul-
monary artery pressure, RV hypertrophy and mortality (iii). 
Role of disturbed flow on vascular remodeling: les-
sons to be learned from the systemic circulation
In systemic vessels, blood flow, and the shear stress it inflicts, has been demon-
strated to play a critical role in vascular homeostasis and vessel remodeling. 
Shear stress imposed upon the luminal surface of the endothelial cell is de-
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Figure 6 Consequences of changes in flow: a) Schematic hypothesis how disturbed flow at branching points 
induces changes in shear stress downstream in PAH.  b) A histological example of a branching point lesion from 
a rat after MCT + increased pulmonary blood flow showing neointimal formation comprised of c) endothelial 
cells (positive for vWF), and d) in lesser form smooth muscle cells (aSMA). 
fined as the tangential force per unit area caused by flowing blood(46). Here, the 
concept is that physiological laminar flow (seen in the straight part of a healthy 
vessel) has athero-protective effects due to a physiological shear stress with a 
definite direction resulting in endothelial homeostasis{{696 Chiu,J.J. 2011; 828 
Davies,P.F. 2009}}. Changes in flow patterns (e.g swirling flow, turbulent flow or 
low flow) lead to changes in shear stress (e.g. reciprocating shear stress, a high 
shear stress gradient or reduced shear stress). These changes in shear stress 
are able to induce endothelial changes, specifically at predilection points (e.g. 
arterial branching points) where blood flow patterns are disturbed rather than 
laminar(4, 16, 17, 20).
In pathophysiological settings (such as increased blood flow, vascular stenosis 
or surgical intervention) disturbed blood flow at these predilection sites is am-
plified resulting in vascular remodeling due to upregulation of pro-atherogenic 
and pro-thombogenic genes in ECs, EC proliferation and inflammation and SMC 
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modulation(16, 17, 20). A vicious cycle is made when the consequential changes in 
vessel wall geometry at these sites (due to vessel wall proliferation) further dis-
turb flow patterns (and thus shear stress) resulting in propagation of vascular 
remodeling(17, 20). In addition, besides changes in local flow patters, other triggers 
such as oxidative stress, inflammation, hypercholesterolemia, and advanced gly-
cation end products can result in endothelial dysfunction thereby accelerating the 
process of vessel wall remodeling in the systemic vasculature(17).
Can these concepts of vascular remodeling triggers in systemic vessels be trans-
lated to the pulmonary vasculature? Of course, one needs to take into account 
that the pulmonary endothelium differs from its systemic counterpart in several 
aspects; for instance 1) angiogenic rather than vasculogenic development, 2) a 
transition from a low flow/high resistance environment towards a high flow/low 
resistance environment at birth and 3) the molecular heterogeneity of pulmonary 
endothelial cells within the pulmonary vascular bed(3, 4). Nevertheless, several 
concepts of hemodynamic changes in systemic vessels may also apply to the 
pulmonary circulation, supported by various observations.  
First, pathophysiological triggers that result in disturbed flow patterns in system-
ic vascular remodeling (e.g. increased pulmonary blood flow and/or increased 
pressure) are also seen to induce pulmonary vascular remodeling in PAH. For 
instance, as in systemic vessels, increased blood flow induces characteristic 
vascular lesions in pulmonary arterioles, as illustrated in patients with CHD and 
systemic-to-pulmonary shunt.
Also as in systemic vessels, in PAH pulmonary vascular remodeling is specific 
found at specific branching points where flow is disturbed (swirling or recipro-
cating flow) and shear stress is altered(18, 91). Conceptually, different branching 
points (dichotomous vs. supernumerary arteries) could then induce different flow 
pattern alterations, thereby inducing different forms of pulmonary vascular re-
modeling. This would explain why laminar concentric intimal fibrosis is described 
to form predominantly at dichotomous branching points and plexiform lesions 
predominantly at the origin of supernumerary arteries (Figure 2) (18, 91).
Finally, as in systemic vessels, additional triggers (such as increased pressure, 
genetic predisposition, inflammation) may add to endothelial cell injury there-
by accelerating the process of vascular remodeling. Still, it is yet unclear how 
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Figure 7 Summary of the main histopathological changes found in several experimental models used 
to study pathophsyiological mechanism of PAH a) Models with only increased blood flow typically show 
only increased medial wall thickness in the time frame studied. b) Double hit models with histology resembling 
human pathology (e.g. increased flow + additional hit) typically progress into advanced neointimal lesions with 
obliteration of the vascular lumen within the time frame studied. c) Severe prolongation of increase pulmonary 
blood flow can induce plexiform lesions, as is also observed in other double hit models using experimental 
stimuli.
changes in flow patterns (i.e. shear stress) exactly induce endothelial changes 
in the pulmonary vasculature ultimately leading to advanced pulmonary vascular 
remodeling in PAH. Several mechanotransduction pathways linked to changes 
in pulmonary blood flow have been suggested to be involved in the pathobiol-
ogy of PAH. These include direct induction of proliferation (through VEGF(27), 
PDGF(79), TGF-β(56) and pathways), apoptosis-resistance of endothelial 
cells(65), induction of inflammatory processes like mast cells(8), macrophages or 
lymphocytes(32) recruitment, differentiation of endothelial cells into mesenchymal 
cells(6), direct damage to the endothelial cell barrier and autocrine effects(77). 
This concept of disturbed flow patterns leading to neointimal development may 
also play a role in other animal models in which characteristic neointimal lesions 
have been reported. These models will briefly be described below.
The role of disturbed blood flow in the development of Pulmonary Arterial Hypertension
39
Other neointimal animal models
In addition to flow-associated PAH animal models, other models (mostly rodents) 
have also been reported to develop specific obliterative lesions, some with great 
resemblance to neointimal lesions in human PAH (figure 7). Murine models are 
of interest since they allow one to investigate the relevance of single genes using 
genetic manipulation. The main disadvantage of murine models however, is the 
mere mild degree of PH and RV dysfunction that usually is achieved in mice com-
pared to other animal models(28). In addition, possible differences in the vascular 
bed of mice and humans have to be taken into consideration when comparing 
these data, as described above. 
Sugen / hypoxia rat model
In both iPAH as well as PAH associated with congenital systemic-to-pulmonary 
shunts, VEGF is strongly expressed in plexiform lesions in end stage disease.(27) 
However, the exact role of VEGF in pulmonary vascular remodeling in PAH re-
mains unclear. Taraseviviene-Stewart et al have shown that by combining VEGF 
receptor 2 (VEGFR2) inhibition, using the compound Sugen-5416, with chronic 
hypoxia results in PAH with characteristic obstructive neointimal lesions in the 
arterioles, increased mPAP and right ventricular hypertrophy(75, 76). In addition, 
when these rats were subjected to normoxia for a longer period of time (up to 14 
weeks), more complex neointimal lesions did form(1). However, unlike in irrevers-
ible human PAH, the survival rate of Sugen-5416 / hypoxia rats  has been shown 
to be close to 100 percent even during long follow-up.(1) Apparently the degree 
and magnitude of arteriopathy in these rats is unable to induce RV failure which 
can raise the question whether the type of arteriopathy is representative for the 
human setting.
In addition, it is unclear how in these rats VEGFR2-inhibition, as additional “trig-
ger” to hypoxia, leads to the induction of neointimal lesions. Sugen-5416 injec-
tion or hypoxia alone both do not result in obliterative lesions of the intra-acinar 
vessels.(75). Unfortunately, little is known what the exact role is of Sugen-5416 in 
this process of SMC and EC proliferation and vascular occlusion. For instance, 
besides VEGF-R2 inhibition Sugen-5416 is also known for its inhibitory effect on 
other tyrosine kinases(66, 92). It is possible that other kinases also may play a role 
in the development of vascular remodeling in the 5416/hypoxia model. In other 
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words, in this model the trigger is already interfering with the pathobiological 
mechanisms of PAH. This hampers biomolecular analyses of PAH and evalu-
ation of treatment effects using this Sugen/hypoxia(/normoxia) model. Indeed, 
Moreno-Vinasco et al have shown that when comparing gene expression of Su-
gen/hypoxia rat lungs with human PAH lung tissue, only one similar hit comes up 
(Fyn: a protein-tyrosine kinase oncogene)(45). 
Endothelin-B receptor deficient rats
Ivy et al have reported in rats that Endothelin-B (ETB) receptor deficiency com-
bined with monocrotaline results in the development of neointimal lesions, in-
creased RV hypertrophy and reduced cardiac output compared to monocrotaline 
alone(40). The vascular lesions in this model are comprised of cells staining posi-
tive for both EC and SMC markers and show similarities with human PAH lesions 
as well as those in other PAH models. However, when ETB receptor deficient rats 
were subjected to hypoxia instead of monocrotaline (41) these neointimal lesions 
were not seen even though PH did occur. 
Other models of potential interest are the cell-specific BMPR-2 loss of function 
models in mice(35), Il-6 transgenic mice(72) and mice overexpressing a calcium 
binding protein S100A4Mts(30) (Figure 7). In these models, however, incomplete 
disease penetrance and the need for additional hits, may limit its use. 
Treatment effects in neointimal animal models
Currently PAH patients are treated, in addition to supportive medication, with 
either 1) calcium channel blockers or 2) one or a combination of the following 
agents: prostacyclin-analogues, endothelin receptor antagonists and phosphodi-
esterase-5 inhibitors. Despite improvements with these treatments, PAH still re-
mains a fatal disease(39). The general thought is that this is related to the severity 
of pulmonary vascular remodeling, which is considered irreversible once neointi-
mal lesions have formed. Therefore, future treatments should focus targeting on 
reversal of these so-called irreversible neointimal lesions, something that has not 
been accomplished so far. 
In general, although some positive effects have been described (predominantly 
in prevention studies), to date no cure for animals with established advanced le-
sions have been described. Nevertheless, several interesting “proof of principle” 
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studies may direct future research for development of novel therapies (Table 2). 
In monocrotaline / flow PAH rats inhibition of the vasoconstrictor tromboxane, a 
key player of vascular remodeling in PAH, using the prostacyclin analogue tre-
prostinil, resulted in a reduction in pulmonary artery pressure, although neointi-
mal development was not reduced(85). Similar resistance to vascular remodeling 
improvement was seen when using aspirin or iloprost(82), suggesting a vasodila-
tory effect rather than an anti-proliferative effect of the drug. 
Other studies have shown that ACE inhibition using Quinapril attenuated neo-
intimal formation of the intra-acinar vessels.(50) In the future, novel treatments in 
PAH may shift more towards targeting angiogenesis and inflammation. Indeed, in 
monocrotaline / flow PAH models simvastatin (also known for its anti-inflamma-
tory properties)(47), mast cell stabilization (via Cromolyn)(8), Dehydroepiandros-
terone (known to have antioxidant and anti-inflammatory effects)(34), rapamycin 
(an anti-angiogenic agent)(48) and EPO (erythropoietin; known for endothelial re-
pair by endothelial progenitor cell mobilization)(83) have shown to attenuate, or in 
part reverse, neointimal formation and/or increased pulmonary artery pressure. 
However, caution has to be taken when directly extrapolating these data to the 
human setting as illustrated a recent randomized controlled trial in PAH patients, 
in which simvastatin as add on therapy did not show a positive effect on 6 minute 
walking distance.(42) Unfortunately, the clinical endpoint of this study, 6-minute 
walk test, was not assessed in animal models. Indeed, most studies in animal 
models of PAH lack the use of clinical relevant endpoints, such as exercise ca-
pacity, although these end-points have been proven useful in studies addressing 
RV therapeutic strategies.(7, 12)
Possible novel pathophysiological pathways in PAH 
The pathogenesis of the complex pulmonary vascular lesions is likely a multifacto-
rial process, necessitating system biology approaches to identify novel targets(2). 
Using a microarray analysis, van Albada et al showed that increased pulmonary 
blood flow specifically induced the expression WNT-signaling genes and sever-
al other transcription factors including activating transcription factor-3 and early 
growth response factor-1 (Egr-1)(21, 80). Also, in the last years many new putative 
pathways have been discovered in non-neointimal models that could potentially 
affect PAH development. Examples are the PPAR gamma pathway in PAEC in 
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mice(5), tyrosine kinase inhibitors in hypoxic PH or monocrotaline induced PH(68), 
soluble GCs(23) and the possible role of microRNAs in PH(54). Although prom-
ising pathways, their roles have yet to be established in more clinically relevant 
neointimal models of PAH(67, 73). 
Concluding remarks
Pulmonary arterial hypertension is still a progressive disease with typical lesions 
characterized by neointimal formation, obliteration and plexiform lesions. The 
pathogenic mechanisms underlying the formation of these progressive pulmo-
nary vascular lesions is still poorly understood but might be the key to curative 
treatment. 
With PAH research shifting from a concept of mere vasoconstriction towards a 
mechanism of angioproliferation, the role of disturbed pulmonary blood flow is 
seen as an important instigator (both clinically and experimentally) in plexoge-
nic arteriopathy and PAH development. Further investigation in the role of dis-
turbed blood flow can provide us with relevant clues to further unravel the com-
plex pathogenesis of PAH. In this process PAH models of disturbed pulmonary 
blood flow – that more closely resemble the human trigger and histopathology 
– are well suited for further investigation. Using these models, new pathways are 
deemed to emerge which may lead to new therapeutic targets for patients with 
PAH in the future.
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CHAPTER 3
Abstract 
Pulmonary arterial hypertension (PAH) is a pulmonary angioproliferative disease 
with high morbidity and mortality, characterized by a typical pattern of pulmonary 
vascular remodeling including neointimal lesions. In congenital heart disease, 
increased pulmonary blood flow has appeared to be a key mediator in the devel-
opment of these characteristic lesions, but the molecular mechanisms underlying 
the pulmonary vascular lesions are largely unknown.  We employed a rat model 
of flow-associated PAH, which induced specific pulmonary neointimal lesions. 
We identified gene expression profiles in rats specifically related to the addition of 
increased pulmonary blood flow to monocrotaline and the associated occurrence 
of neointimal lesions. Increased pulmonary blood flow induced the expression 
of the transcription factors Activating Transcription Factor-3 (ATF3) and Early 
Growth Response factor-1 (Egr-1), which presence was confirmed in neointimal 
lesions. Monocrotaline alone induced increased numbers of activated mast cells 
and its products. We further identified molecular pathways that may be involved 
in treatment with the prostacyclin analogue Iloprost, a vasoactive compound with 
clinically beneficial effects in patients with PAH, which were similar to pathways 
described in samples from patient studies. These pathways, associated with the 
development of angioproliferative lesions as well as with the response to therapy 




Pulmonary arterial hypertension (PAH) is a progressive angioproliferative dis-
ease with high morbidity and mortality (4), associated with a characteristic pattern 
of vascular remodeling of the small pulmonary arteries. This vascular remodeling 
consists of proliferation of endothelial and smooth muscle cells, fibrosis, and in-
flammation, leading to formation of concentric neointimal lesions and plexiform 
lesions (37). These latter vascular lesions can be regarded pathognomonic for 
PAH (37). Although the histopathology is well described, the pathogenesis of the 
disease and its typical vascular lesions is largely unknown (28). In patients with 
congenital heart diseases that develop PAH, increased pulmonary blood flow has 
been clinically identified as a key mediator in the development of the pathogno-
monic vascular lesions of PAH (10, 33, 37), also through unknown mechanisms.
Prostacyclin, a vascular endothelium derived vasoactive compound with vasodi-
latory and antiproliferative properties, is believed to interfere with the pathogen-
esis, since prostacyclin analogues have been demonstrated to have beneficial 
clinical effects in patients with PAH (3, 30). These analogues have been suggested 
to be able to reverse the pulmonary vascular remodeling process of PH in exper-
imental settings (31), although the latter has not yet been demonstrated in patients 
(2). 
To identify pathways that are involved in the pathogenesis of the characteris-
tic neointimal lesions, we used a rat model of monocrotaline combined with in-
creased pulmonary blood flow (35). Monocrotaline in the rat induces pulmonary 
hypertension characterized by muscularisation of the small pulmonary arteries 
(23), whereas the addition of increased pulmonary blood flow to monocrotaline 
has been demonstrated to induce the development of neointimal proliferation  (5, 
26, 35), thereby resembling the histopathology characteristic for patients with PAH. 
We used this rat model of flow-associated PAH to identify pathways that are spe-
cifically induced by increased pulmonary blood flow and to test whether these 
pathways are affected by prostacyclin analogue treatment. For that purpose, we 
performed a semi-randomized cross-over design micro-array experiment with 
mRNA isolated from total lung tissue according to the MIAME standards (6). We 
verified the most relevant results by RT-PCR and immunohistology.
  




Twenty-four male Wistar rats (Harlan, the Netherlands weighing 250-300g were 
used. Animal care and experiments were conducted according to the Dutch An-
imal Experimental Act. The Institutional Animal Care and Use Committees ap-
proved the experimental protocols. 
Rats were randomly assigned to the four experimental groups: 1 control (CON; 
n = 6, 2) monocrotaline-treated rats (PH; n = 6; single dose of monocrotaline 60 
mg/kg sc, Sigma Chemical Co., St. Louis, MO, USA), 3) monocrotaline plus aor-
tocaval shunt (PH+Shunt; n = 6; monocrotaline injection followed by the creation 
of an abdominal aortocaval shunt one week later  (35)), 4) PH+Shunt treated with 
the prostacyclin analogue iloprost (PH+Shunt+ILO; n = 6). Osmotic minipumps 
(model 2004, Alzet, Palo Alto, CA, USA) with iloprost (72 µg/kg/day; a generous 
gift of Schering, the Netherlands) were implanted subcutaneously in the same 
operative session as the creation of the abdominal aortocaval shunt. 
Rats were weighed, and sacrificed when a 15% weight loss occurred. Matched 
rats in the other experimental groups were sacrificed simultaneously. The mean 
day of sacrifice was 36.5±0.6 days after the administration of monocrotaline. 
At the time of sacrifice, rats were anesthetized with pentobarbital (60 mg/kg in-
traperitoneally) and ventilated with room air. Pulmonary and systemic arterial 
pressures were measured as described by Rabinovitch (29), a technique that is 
routinely used in our laboratory (35). 
RNA isolation, probe construction, real time PCR analysis
For a detailed description of RNA isolation, probe construction and real-time PCR 
analysis see the online Data supplement.  
Micro-array
The micro-array experiment was designed to meet the MIAME criteria for mi-
cro-array data (6). For a detailed description of slide design and array analysis, 
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see the online Data supplement. To analyze the data, clustering of the signifi-
cantly regulated genes was performed on the basis of their differences as they 
appeared in different pair wise comparisons, according to a method described 
by Buermans et al (7). If a gene was significantly different between the control rats 
and the monocrotaline treated (PH) rats, it was denoted with a ‘1’, and if there 
was no difference observed as a ‘0’. This was also done for PH versus PH+Shunt 
and for PH+Shunt versus CON rats. With three pair wise comparisons, 7 combi-
nations are possible. A gene with no significant difference between controls and 
PH rats (0), a significant difference between PH rats and PH+Shunt rats (1) and 
a significant difference between PH+Shunt rats and control rats (1) would then be 
assigned to cluster 0-1-1. In the remainder of the article, these clusters will be 
addressed as cluster I-VII (table 1). 
Pulmonary and cardiac histopathology
The pulmonary histopathology in this rat model has been previously described (34, 
35). For a detailed description of pulmonary and cardiac histopathology, see the 
online data supplement. 
Statistical analysis
Data are presented as mean ± SEM. Group differences were analyzed using 
one-way ANOVA-testing with Fisher’s protected LSD post-hoc testing. Correla-




Monocrotaline treatment and the creation of an abdominal aortocaval shunt in-
duced pulmonary arterial hypertension at the hemodynamic, pathological and 
histological level, as described previously (34). Briefly, rats with PH and PH+Shunt 
had increased pulmonary arterial pressures and increased RV hypertrophy (Fig. 
1) and showed pulmonary vascular remodeling, including increased musculariza-
tion and in the PH+Shunt group neointimal lesions in the intra-acinar pulmonary 
vessels. Typical examples of histopathology are shown in Figure 2. Treatment 
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with Iloprost reduced pulmonary arterial pressure and RV hypertrophy (Fig.1), 
but not pulmonary vascular remodeling (34).
Microarray analysis
9559 Of the 22012 genes (43%) passed the criteria for further analysis. Of these 
genes, 383 showed significant changes in the analysis. 
Classification in clusters
Seven different clusters were formed based on the difference in expression pro-
files between the experimental groups (table 1). Clusters I, III, V, and VII con-
tained genes that were affected (in either way) when pulmonary blood flow was 
Fig. 1. Hemodynamic characteristics of the rats. A: mean pulmonary arterial pressure. n  5 per group. B: 
right ventricular (RV) hypertrophy was expressed as the ratio of RV weight to left ventricular and interventricular 
septum weight. n  6 per group. *P  0.05 vs. control (CON), †P  0.05 vs. monocrotaline plus aortocaval shunt 
monocrotaline plus aortocaval shunt [PHShunt; monocrotaline injection followed by the creation of an abdomi-
nal aortocaval shunt 1 wk later (35)]. Ilo, iloprost.
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added to monocrotaline. In cluster III, V, and VII pulmonary blood flow opposed 
previously induced effects by monocrotaline. Cluster II contained genes that were 
affected by monocrotaline, rather then pulmonary blood flow; in cluster IV and VI, 
pulmonary blood flow enhanced a monocrotaline-induced effect. Changes in the 
different genes per cluster are presented in graphs in figure 3. 
Cluster I contained those genes that were altered specifically by the addition of 
increased pulmonary blood to monocrotaline (Table 1), hence they are specific 
for flow-associated PAH. It included nine genes (for a complete list, see data 
supplement), five of these genes were also affected by iloprost therapy. Two of 
these genes are of particular interest since these have been shown to be impor-
tant transcription factors in systemic vascular disease (16, 25) but have not yet been 
linked to flow-associated PAH. These genes, activating transcription factor-3 
(ATF-3) and early growth response protein-1 (EGR-1) were both upregulated in 
the PH+Shunt rats (but not in the PH-rats), whereas they were downregulated 
in the PH+Shunt+Ilo rats. Real-time RT-PCR confirmed the changes shown by 
Fig. 2. Pulmonary histology of intraacinar vessels: A: normal vessel in rat from CON group B: medial hyper-
trophy in rat with PH (arrow). C and D: vascular occlusion by neointimal lesion (arrows) in rats with PHShunt.





































































CON MONO MONO+AV ILO
*
† 
Con             PH      PH+Shunt   PH+Shunt+Ilo 
Con             PH      PH+Shunt   PH+Shunt+Ilo 
Con             PH      PH+Shunt   PH+Shunt+Ilo 
on             PH      PH+Shunt   PH+Shunt+Ilo Con             PH      PH+Shunt   PH+Shunt+Ilo 
Con             PH      PH+Shunt   PH+Shunt+Ilo 











CON MONO MONO+AV ILO
*
Fig. 3. Gene expression plots for the 7 separate clus-
ters. Y-axis: log2 gene expression rations of the 4 groups. 
The expression in the CON group was set to 0. *P  0.05 vs. 
CON, †P  0.05 vs. PH, ‡P  0.05 vs. PHShunt.
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gene array (Fig 4A). The changes in expression in EGR-1 were even more pro-
nounced with real time RT-PCR as compared with the gene array. Immunohis-
tochemistry showed the presence of EGR-1 in endothelial layers of pulmonary 
neointima lesions (Fig 4B), but not in the control group. Of the other genes, three 
are yet unknown and one is a protein phosphatase.
Cluster II contained those genes that were altered specifically by monocrotaline 
(table I) and that were not affected by the addition of increased pulmonary blood 
flow. Eighteen genes were altered specifically by monocrotaline, of which only 
one was also affected by iloprost (a protein tyrosin phosphatase). Five of these 
genes play a role in inflammation (Immunoglobulin J chain precursor isoform 
2, IgE-Fc receptor high affinity I alpha polypeptide, complement component 1, 
heme oxygenase 1 and the immunoglobulin 4G6 heavy chain variable region), 
while two others are markers of mast cell activation, chymase 1 and tryptase 
beta 1. The monocrotaline-induced genes also included the potassium channel 
Kcnk1, previously described to be involved in PAH (13).
Cluster III contained genes that may be involved in flow-associated PAH. These 
gene expression profiles were affected by monocrotaline, but these effects 
were opposed by the addition of pulmonary blood flow. This cluster contained 
69 genes, of which the majority was down regulated by increased flow. Among 
these were previously described genes, as endothelin-1 and a serotonin recep-
tor, which was downregulated in PH and upregulated in PH+Shunt as compared 
to PH. Thirty-five percent of these genes (n=21) were also affected by iloprost 
treatment, mostly in the opposite direction of the effect of the shunt, including a 


























I 0 1 1 9 5/4 5 
II 1 0 1 18 16/2 1 
III 0 1 0 69 18/51 21 
IV 0 0 1 38 22/16 4 
V 1 0 0 75 67/8 3 
VI 1 1 1 1 1/0 1 
VII 1 1 0 15 13/2 6 
    Total 225 142/83 41 
 
Table 1: Gene cluster classification








































Fig. 4. Transcription factors induced by 
pulmonary blood flow. A: comparison of 
gene array and PCR data. The expression 
in the CON group was set to 0. *P  0.05 vs. 
CON, †P  0.05 vs. PH, ‡P  0.05 vs. PHS-
hunt. B: activating transcription factor-3 
(ATF3) and early growth response factor-1 
(EGR-1) staining (brown) in intraacinar 
vessels. a: No staining in normal vessel 
in rat from CON group. b: EGR-1 staining 
in a neointimal lesion in a rat with PHS-
hunt. c: EGR-1 staining perivascular and 
in endothelial layer of a partially occlud-
ed vessel in a rat with PHShunt. d: ATF-3 






Cluster IV contained genes that are also possibly involved in flow-associated 
PAH, but now additional pulmonary blood flow enhanced a (not-significant) effect 
induced by monocrotaline alone. These genes needed both stressors, monocro-
taline and increased flow, to be significantly induced. This cluster contained 38 
genes, of which only 4 were affected by Iloprost. A third of the genes in this clus-
ter were related to cellular proliferation and inflammation. Notably, some  genes 
participating in the Wnt-pathway were involved, among which frizzle-related pro-
tein (Frzb). 
Cluster V contained genes that, like cluster III and IV, may be involved in flow-as-
sociated PAH. In contrast to cluster III, the changes induced by monocrotaline, 
were partially offset by additional pulmonary blood flow, implying that pulmonary 
blood flow opposed the induced changes. This cluster contained a total of 75 
genes, most of which increase under the influence of monocrotaline. Only 3 of 
these genes were also influenced by iloprost treatment, of which 2 are yet un-
known, the remaining one is annexin, a calcium-binding protein that has also 
recently been described to be involved in idiopathic pulmonary fibrosis (19). 
Cluster VI contained genes that were induced by monocrotaline and reduced by 
additional pulmonary blood flow. However, this cluster contained only 1 gene, a 
helicase that plays a role in RNA metabolism.
Cluster VII contained genes, like cluster III and V that may be involved in mono-
crotaline induced PAH, but in contrast with cluster V, the altered expression of 
these genes with PH was offset by additional flow. This cluster contained 15 
genes. Carboxypeptidase Z, (homologous to Wnt-binding proteins) and caspase 
Function Nr of genes  
 Clusters Iloprost 
Proliferation:  





Inflammatio 36 16 
Structural/Membrane protein/Receptors 36 20 
Signal transduction 19 32 
Enzymes involved in other processes 38 32 
Ribosomal proteins & unknown 55 57 
Total 225 199 
 
Table 2.Functional classification of genes
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6 were up regulated in the monocrotaline model, and down regulated to control 
levels after addition of the shunt. Six of these 15 genes were also up regulated 
by iloprost treatment. 
Of the 225 clustered genes, a third was involved in proliferation and inflammation 
(Table 2), supporting the notion that PAH is a proliferative and inflammatory dis-
ease. In general, a total of 199 genes were altered due to iloprost treatment. For-
ty-one of these genes were also regulated by the model (cluster 1 to 7). Among 
the genes regulated by iloprost treatment were several involved in Wnt-signaling, 
namely Wnt-inhibitory factor 1, Wnt5a, catenin alfa 1, axin, secreted frizzled re-
lated protein (sfrp2) and frizzled homolog 5. 
Mast cell count
The results of the array showed an increase in expression of mast cell markers in 
monocrotaline induced PH with or without additional flow. Specifically, tryptase, 
chymase, mast cell protease 8, IG-Fc receptor, Interleukine 9 receptor were all 
increased in PH.  Mast cells have been suggested previously to play a role in the 
pathogenesis of PAH (12). We confirmed the array findings by real time RT-PCR 
(Fig 5A). Tryptase, a mast cell protease and Ig-Fc involved in mast cell activation 
were both upregulated after monocrotaline. To asses the presence of mast cells 
in our model, we counted the number of mast cells in the area of interest, that is 
in the intra-acinar vessels and in the pre-acinar vessels (Fig 5B,C). The number 
of mast cells per field was significantly increased in rats with PAH. Interestingly, 
the number of mast cells significantly decreased after Iloprost treatment, where-
as the expression of mast cell products did not.
Discussion
In this model of pulmonary arterial hypertension in rats, we identified specific 
gene expression profiles related to the initiation of PH using monocrotaline, to the 
addition of increased pulmonary blood flow and finally to the treatment with ilo-
prost. Specifically, we showed that increased expression of ATF3 and Egr-1 was 
associated with flow-induced neointimal lesions, while monocrotaline-induced 
pulmonary hypertension was associated with increased numbers of mast cell 
products and mast cells around small pulmonary arteries. Finally, members of 
the Wnt-pathway, recently suggested to be involved in human PAH, were affect-
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ed by Iloprost therapy in this model. The identification of these pathways, some 
not previously associated with the development of neointimal lesions in PAH, 
may provide new insights and therapeutic targets in this progressive pulmonary 
vascular disease. 
In this study we used semi-randomized cross-over design micro-array, which 
provides outcomes according to the MIAME agreements (6). To be absolutely sure 
of the validity of our data, we verified some key genes by real-time PCR. Indeed, 
in those genes all array findings could be confirmed. 
Our array analysis yielded several genes that have previously been suggested 
to be involved in the pathogenesis of PAH in humans (11, 13). Examples are the 
involvement of endothelin-1, potassium channel expression, serotonin signaling, 
pro-inflammatory and pro-apoptotic activation (13). On the other hand, this gene 
array also yielded several pathways that have not been connected yet with the 
development of angioproliferative lesions in pulmonary arterial hypertension . 
Finally, we identified genes specifically induced by increased pulmonary blood 
flow.
ATF3 and Early growth response protein 1
We identified two genes that were specifically induced by increased pulmonary 
blood flow and have never been identified in neointimal lesions in PAH: ATF3 and 
Egr-1. We confirmed the presence of the protein products in neointimal lesions 
in the rats (and absence of the protein products in control rats), suggesting that 
both transcription factors are involved in the neointima proliferation phase of the 
disease. These transcription factors are well suited candidates as inductors of 
the proliferative phase, since they both have been shown to be present in sys-
temic vascular endothelium (16, 25) and are both inducible by shear stress, inflam-
mation, and hypoxia (17, 22, 25, 38). Furthermore, both transcription factors induce 
inflammation and proliferation, two hallmarks of the characteristic pulmonary 
vascular remodeling  seen in PAH patients (13). Although both genes are present 
in vascular endothelium, they are not exclusive endothelial cell products, as they 
are also present in fibroblasts and vascular smooth muscle cells (16, 22). Indeed, 
Egr-1 has been shown to be up regulated in isolated fibroblasts after hypoxia-in-
duced pulmonary hypertension  (1). Yet, both genes were not activated in mono-
crotaline-induced PH, suggesting that vascular smooth muscle cell proliferation, 
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the characteristic vascular profile in monocrotaline models, was not induced by 
these transcription factors. It is still unknown which cell types contribute to the 
development of the characteristic neoinitimal lesions (32). Interestingly, both genes 
are known as early response genes, whereas in our model they appear to play 
a role also in the end-stage of the disease  (39). Further studies to the temporal 
expression and effects of inhibition of these genes are necessary to delineate 
their role in the development of pulmonary vascular remodeling in flow-associat-
ed PAH. 
Mast Cell involvement
Genes that were selectively regulated by monocrotaline were mainly associated 
with inflammation (e.g. heme oxygenase-1). This confirms that inflammation is 
important in the vascular remodeling that occurs as a consequence of monocro-
taline administration. Interestingly, several genes associated with the prolifera-
tion of mast cells (Il-9) or presence of mast cells (IgE-Fc receptor, tryptase beta 
1, chymase 1) were induced by monocrotaline, both with or without flow. These 
results were confirmed with RT-PCR. Moreover, we showed an increased pres-
ence of mast cells in the small intra-acinar pulmonary vessels that are known 
to be particularly involved in PAH. Also, their presence decreased after Iloprost 
therapy. Indeed, increased mast cell counts have been described in lung biopsies 
of patients with PAH associated with CHD (12).  We believe the increased mast 
cell count in this model is likely to reflect a mechanism in the pulmonary vascular 
remodeling, rather than a direct effect of monocrotaline itself, since Vaszar et 
al showed that mast cells and their related protein expression levels started to 
rise significantly as late as 21 days after monocrotaline injection, and not earlier 
(36).The involvement of mast cells in the development of PAH has received little 
attention, although they may be of specific interest since mast cells are known 
as potent angiogenic stimulators (8, 24). Mast cells may play a role in angiotensin 
II mediated vasoconstriction (18), supposedly via specific serine proteases from 
their granules (14, 21). Chymase, one of the serine proteases excreted by mast 
cells, is involved in the conversion of angiotensin I to angiotensin II (18) and of 
big-endothelin to endothelin-1 (9), two powerfull vasoconstrictors with mitogenic 
properties. Together, this data suggests that the excessive mast cells presence in 
pulmonary arteries of human and experimental PAH contributes to the develop-
ment of the disease. Interestingly, Iloprost treatment reduced mast cell presence 
but not their gene products (Fig 5). Further studies are necessary to delineate 
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the role of mast cell products in pulmo-
nary vascular remodeling in PAH and to 
investigate their potential in therapeutic 
strategies.
Wnt - signaling
In this study, we found that certain com-
ponents of the Wnt-pathway were af-
fected by iloprost therapy (i.e. Wnt in-
hibitory factor 1, Wnt5a, Sfrp2, F2d5, 
catenin a1, axin, calmodulin3). Recent-
ly, the Wnt-pathway, has been shown to 
be an important pathway in pulmonary 
development as well as in pulmonary 
inflammation and oncology (27), but had 
not been linked to PAH before. While 
this manuscript was under preparation, 
a study in lung explants of patients with 
iPAH was published that also showed 
involvement of the Wnt-pathway (20). In-
deed, we found similar members of sub-
families of gene pathways activated in 
our rat model (e.g. RAC1, Wnt11). The 
Wnt family controls a variety of process-
es including proliferation and migration 
(27). Target genes of the Wnt pathways 
include matrix metalloproteinases, cyc-
lo-oxygenase-2 and the VEGF-receptor. 
All of these substances are believed to 
play a role in the pathogenesis of pul-
monary hypertension. The factors of the 
Wnt system that were affected by ther-
apy in our model were both activators 
as well as inhibitors of the Wnt-pathway, 
hence, the net effect of iloprost interven-







































































Fig. 5. Mast cell involvement. A: comparison of 
gene array and PCR data. The expression in the 
CON group was set to 0. *P  0.05 vs. CON. B: mast 
cell counts in the lungs of the different rat groups. *P 
0.05 vs. CON, ‡P  0.05 vs. PHShunt. C: typical ex-
ample of mast cell staining in pulmonary vasculature 
of rats with PH.
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to predict (15). Of notice is that most of the Wnt-genes in our model were signifi-
cantly affected by Iloprost therapy, rather than by the disease itself. Our animal 
model allows for separation of gene products regulated by the disease process 
versus those regulated by the therapeutic regimen and is therefore an important 
addendum to interpret data derived from patients with end-stage PAH who in 
the current era are likely to be treated with antipulmonary-hypertensive drugs, 
including prostacyclin-analogues. Whether the Wnt-pathway is involved in the 
development of the pulmonary vascular lesions or in the effect of therapeutic 
strategies remains to be determined. 
Effects of therapy
When comparing our gene profiles with those obtained from patient studies (11, 20), 
it became apparent that most of the genes that have been described previously 
in humans were, in our model, affected by Iloprost rather than by the disease 
itself. For example, several oncogenes, and anion channels described by Geraci 
et al (11) were found to be affected by Iloprost (deadbox protein, shaker, chloride 
channel, cytochrome c oxidase), whereas the array in our model showed that 
they were not significantly induced by monocrotaline or pulmonary blood flow. 
Similarly, most of the genes involved in the Wnt pathway (20) were only significant-
ly affected by Iloprost. Hence, the question arises whether gene profiles found in 
patients with end-stage PAH are also influenced by therapeutic agents. It is yet 
unknown whether the beneficial clinical effects of Iloprost in patients with PAH 
are reached through vasodilatory properties or through actual reversal of pulmo-
nary vascular remodeling (34). This study illustrates that linking changes in gene 
and protein profiles to pulmonary vascular remodeling in vivo are necessary to 
address these issues.
In conclusion, in this rat model of flow-associated pulmonary arterial hyperten-
sion, we showed that increased expression of ATF3 and Egr-1 was associated 
with flow-induced neointimal lesions, while monocrotaline-induced pulmonary 
hypertension was associated with increased numbers of activated mast cell 
around small pulmonary arteries. Finally, members of the Wnt-pathway, recently 
suggested to be involved in human PAH, were affected by Iloprost therapy in 
this model. The identification of these pathways, some not previously associated 
with the development of neointimal lesions in PAH, may provide new therapeutic 
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RNA isolation and probe construction
RNA was isolated from total frozen lung tissue using a Qiagen RNeasy kit (Qiagen, Ven-
lo, The Netherlands) followed by a DNase treatment step (RNase free DNase, Qiagen). 
Integrity and concentration of RNA was controlled using the Agilent 2100 Bioanalyzer 
(Agilent, Palo Alto, CA, USA). For transcriptional profiling 2 µg of total RNA was used for 
linear amplification of mRNA transcripts according to the Dutch Cancer Institute protocol 
(www.nki.nl/nkidep/pa/microarray/protocols.htm). The resulting purified double stranded 
cDNA was transcribed in vitro with the T7 Megascript kit (Ambion, Huntingdon, UK) as 
described by the manufacturer with a final concentration of 7.5 mM for all NTPs and 
replacing UTP with aminoallyl-UTP/UTP (1:1). Amplified RNA (aRNA) was purified with 
the RNeasy kit (Qiagen). Subsequently, 5 µg of a RNA was labeled with monoreactive 
Cyanine-3 (2.5 nmol per reaction) or Cyanine-5 (2.5 nmol per reaction) fluorophores 
(Amersham Biosciences, Little Chalfont, UK) to the incorporated aminoallyl-modified nu-
cleotides. Labeled aRNA was separated from unincorporated Cyanine-3 or Cyanine-5 
molecules with Microspin G-50 column chromatography (Amersham Biosciences) as de-
scribed by the manufacturer. Hybridization was performed after mixing the labeled aRNA 
samples from the appropriate samples with 15 microg poly-dA DNA (Qiagen). Hybridiza-
tions were performed under lifterslips (Erie Scientific, Portsmouth, NH, USA) in hybrid-
ization chambers (Telechem, Sunnyvale, CA, USA). After hybridization the slides were 
washed, dried and scanned at 10 µm resolution in a GMS 428 laser scanner (Affymetrix, 
Santa Clara CA, USA). Image intensity data for each spot was extracted by ImaGene 
version 5.6 software (BioDiscovery, El Segundo, CA, USA).
Gene specific PCR primers were designed with Clone Manager v.5 and purchased from 
Biolegio (Nijmegen, The Netherlands). Primer sequences are available upon request. 
Changes in expression of  genes of interest were confirmed with real time two-step quan-
titative RT-PCR using SYBR green and an ABI PRISM 5700 Sequence Detection System 
(Applied Biosystems, Nieuwerkerk, The Netherlands). 
Micro-array
To minimize biases due to biological variation of the individual rats, each sample for mi-
cro-array analysis contained equal amounts of pooled RNA from 2 rat lungs from one of 
the experimental groups, yielding a total of 3 pooled samples per group or 12 samples in 
total. Each pooled sample was analyzed in two-fold either being labeled with Cyanine 3 
or Cyanine 5 in a semi-randomized cross-over design, where in 2 cases samples served 
as their own controls on one micro-array slide to determine variation due to dye type, 
while the other samples were hybridized in a random way. 
Micro-arrays contained 26,962 oligonucleotides available in the Operon-Rat Array list 
(V3.0, available at http://microarray.uc.edu/) representing genes from a diverse range 
of functionalities. Positive and negative controls were also represented on the arrays. 
Microarrays were obtained from the Genomics and Microarray laboratory (University of 
Cincinatti, Cincinatti, OH, USA). To account for dye bias, signal data were log-trans-
formed and normalized by intensity-dependent regression (Lowess). After filtering of 
empty spots, control spots, spots with high between-pixel-intensity variability and spots 
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designated as bad by eye, a scatterplot for the median signal intensity of both fluores-
cent labels was constructed. Moreover, a multivariate permutation test was applied to 
account for a false discovery rate of maximal 10 % in the set of significantly differentially 
expressed genes. Genes that showed a significant (P<0.005) change, taking into ac-
count both dyes and 3 samples per group, were considered candidates. Analyses were 
performed using BRB ArrayTools developed by Dr. Richard Simon and Amy Peng Lam 
(http://linus.nci.nih.gov/BRB-ArrayTools.html).
Pulmonary and Cardiac Histopathology
Heart and lungs were weighed and fixed in 3.6% formalin. Pulmonary sections (5 μm 
thickness) were stained with resorcin-fuchsin elastin stain for morphometric analysis of 
vascular dimensions as described previously  (1). 
Histology
In lung sections, all arteries .50 mm (pre-acinar) and 40 randomly chosen vessels ,50 
mm (intra-acinar) were assessed at 2006 and 4006 magnification using an image analy-
sis system (CZ KS400; Imaging Associates, Bicester, UK). Three different vascular areas 
were defined: outer vessel area, inner vessel area and luminal area. The outer vessel 
area was defined as the area within the lamina elastica externa. The area within the lam-
ina elastica interna was defined as the inner vessel area. The wall area was calculated 
by subtracting the luminal area from the outer vessel area. The medial area was defined 
as the outer vessel area minus the inner vessel area. The intimal area was calculated by 
subtracting the luminal area from the inner vessel area and expressed as a percentage 
of luminal area. Areas were transformed into diameters using the formula: diameter = 2 x 
√(area/n) (3). In the pre-acinar pulmonary arteries, the ratio between wall thickness and 
luminal diameter was calculated. Vessels ,50 mm usually do not have a clearly discerni-
ble internal elastic lamina. Therefore, a vascular occlusion score was calculated in these 
vessels as opposed to the calculation of a medial wall to lumen ratio in the larger pulmo-
nary arteries. Occlusion was calculated in the intra-acinar pulmonary vessels according 
to the following formula: (outer vessel area_luminal area)=(outer vessel area) <eth>3? 
Pulmonary arteries were excluded from measurement if they had a longest/shortest di-
ameter of .2, an incomplete circular shape or a collapse of more than one quarter of the 
vessel wall. Muscularisation of 40 small pulmonary vessels was assessed according to 
van Suylen et al (2). From the heart, the right and left ventricular free wall and septum 
were weighed separately. 
Mast cells: Data from the gene array revealed elevated mast cell marker genes. 
Therefore, the amount of mast cells in the pulmonary tissue of the rats was determined 
with toluidin blue staining. Mast cells were quantified in the pre-acinar (diameter > 50 
micrometer) and intra-acinar (diameter < 50 micrometer) pulmonary vessels. Per section 
mast-cells in five fields per category were counted with a magnification of 400 times.  
 
Immunohistology: Lungs fom rats were formalin-fixed and paraffine-embedded for 
H&E and Verhoeff staining. Next tissues were deparrafined and embedded with prima-
ry antibodies for egr-1 (anti-mouse, 1:150, Abcam nr 54966) or ATF3 (Sigma Aldrich-
HPA001562). Samples were next incubated with secondary antibodies and were stained 
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with Hematoxylin, according to the protocols from Abcam and Sigma. 
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CHAPTER 4
Abstract
Background: In flow-associated Pulmonary Arterial Hypertension (PAH), in-
creased pulmonary blood flow is an essential trigger for neointima formation. 
Using micro-array analysis, we recently identified that transcription factor Egr-1 
(early growth response protein-1) is upregulated in experimental flow-associat-
ed end-stage PAH. Its role in PAH development is unknown. Here, we aimed to 
assess the spatiotemporal expression of Egr-1 during neointimal development in 
flow-associated PAH. 
Methods: Flow-associated PAH was created in rats by combining monocrotaline 
administration with an aortocaval shunt. Animals were sacrificed 1 day before 
flow addition and 1 day, 1 week, 4-5 weeks after flow addition. Egr-1 expression 
was spatiotemporally assessed using laser-microdissection, qRT-PCR and im-
munohistochemistry. Additionally, Egr-1 expression was assessed in a non-neo-
intimal PH model and in human PAH associated with congenital shunt. 
Results: In 4-5 weeks rats subjected to increased flow developed PAH with ne-
ointimal lesions. Egr-1 mRNA was upregulated 1 day after flow addition and in 
end-stage PAH, whereas monocrotaline only did not result in Egr-1 mRNA up-
regulation. Directly after flow addition, Egr-1 was expressed in endothelial cells. 
During disease development, Egr-1 protein expression increased and migrated 
throughout the vessel wall. In PAH patients Egr-1 was expressed in vessels with 
media hypertrophy and neointimal lesions, including plexiform lesions.
Conclusions: These data indicate that Egr-1 may be an important regulator in the 





Pulmonary Arterial Hypertension (PAH) is a vasoproliferative disorder in which 
vascular obstruction of the small pulmonary arteries leads to an increased pul-
monary vascular resistance and eventually death.(1) PAH is considered irreversi-
ble when pulmonary vascular remodeling is characterized by the development of 
unique neointimal lesions, including concentric laminar intima fibrosis and plex-
iform lesions.(2-3) These neointimal lesions cause intraluminal obstruction due to 
proliferation of endothelial and smooth muscle cells, fibrosis, and inflammation.
(2,4,5)
In congenital heart disease increased pulmonary blood flow is an essential trig-
ger for neointimal lesions and disease development. Although neointimal devel-
opment is well described histopathologically, the pathogenesis of PAH and its 
typical vascular lesions is largely unknown. 
Several animal models have been described to investigate the pathogenesis of 
PAH.(6) The toxic alkaloid monocrotaline model is a commonly used experimental 
model of pulmonary hypertension. However, in this model neointimal lesions, typ-
ical for irreversible PAH (3), are not seen. We and other investigators have shown 
that combining monocrotaline with an increased pulmonary blood flow results in 
pulmonary neointimal lesions in end-stage disease.(7-10) Little is known about the 
development of these lesions during disease progression.
In a rat model of flow-associated PAH we recently identified Egr-1 (early growth 
response protein 1), by microarray analysis, to be upregulated in end-stage PAH 
only when increased pulmonary blood flow was added to monocrotaline admin-
istration.(8) Egr-1 is a transcription factor that is expressed in a variety of cardio-
vascular processes in systemic vessels, such as intimal thickening, vascular pro-
liferation and vessel inflammation.(11-14) Egr-1 is poorly expressed in the normal 
arterial wall but can be activated by various stimuli including fluid shear stress 
and hypoxia.(11,15-17) Once activated, Egr-1 is capable of activating or repressing 
gene transcription of numerous genes, including genes known to play a role in 
the pathogenesis of PAH such as TGF-β, PDGF and MCP-1.(11) 
Based on these observations we hypothesized that Egr-1 may be an important 
factor in the development of flow-induced neointimal lesions in PAH. In this study, 
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we therefore investigated the spatiotemporal expression of Egr-1 during the de-
velopment of pulmonary neointimal lesions in experimental PAH and compared 
this expression pattern with that in a non-flow-associated pulmonary hyperten-




Animal care and experiments were approved by the Institutional Animal Care and 
Use Committee. Seventy-one male Wistar rats (310-380 g) were used. Experi-
mental flow-associated PAH was created using a monocrotaline injection (60mg/
kg) followed by an abdominal aortocaval shunt one week later, as described 
previously.7
To investigate the evolution of neointimal lesions, rats were randomly assigned 
to the following groups: 1) M(onocrotaline) 7: 1 day before flow (n=12), one week 
after monocrotaline administration, sacrificed before flow addition; 2) M(onocro-
taline)+F(low) 8: Early activation (n=12), sacrificed after 1 day of flow addition; 
3) M+F 14: Early Stage PAH (n=12), sacrificed after 1 week of flow addition; 4) 
M+F 30: End Stage PAH (n=15), sacrificed when clinical signs of heart failure 
occurred, as described previously.(7) For each time point, 5 rats receiving either 
saline injection or saline injection and sham surgery served as control. Since 
the sham groups showed no differences in 1) hemodynamic measurements, 2) 
histology and 3) gene and protein expression, these groups were pooled as a 
Control group.
Further, as an additional control group, we investigated Egr-1 expression in a 
non-flow- associated, non-neointimal model of pulmonary hypertension. Rats 
were injected with monocrotaline only and assigned to 3 additional experimental 
groups: 1) M(onocrotaline) 8 (n=5): sacrificed 8 days after monocrotaline injec-
tion; 2)   M 14 (n=5): sacrificed 14 days after monocrotaline injection; 3) M 30 
(n=5): sacrificed 30 days after monocrotaline injection. The time points of sacri-





Directly before sacrifice invasive hemodynamic measurements were carried out 
using a closed chest technique that is routinely used in our lab.(7,8) Rats were 
anesthetized with 3-5% isoflurane inhalation. A fluid filled pressure catheter was 
inserted into the right internal jugular vein and guided to the pulmonary artery 
under pressure waveform monitoring using a bedside monitor. Mean right atri-
al pressure, right ventricular systolic pressure and pulmonary arterial pressures 
were measured
Pathology
After hemodynamic measurements organs were harvested and prepared for 
further analysis. The left lateral liver lobe was excised for wet/dry weight ratio 
measurement as an indication for right ventricular failure. Heart and lungs were 
excised and weighed separately. The right lung was frozen in liquid nitrogen for 
molecular analysis. The left lung was fixated by filling the airways with 3.6% for-
malin and embedded in paraffin.
Pulmonary vascular morphology (n=5 rats per experimental group; n=2 per sham 
group) was qualitatively and quantitatively analyzed as described previously by 
van Suylen et al and our lab.(7,8,18) Intra-acinar vessels without a clearly defined 
internal lamina elastica combined with luminal occlusion were defined as neointi-
mal lesions. Intra-acinar vessels with a double lamina elastica for more than half 
of its circumference were defined as completely muscular. Intra-acinar vessels 
with a double lamina elastica for less than half of its circumference were defined 
as partially muscular. Normal, non-muscular, intra-acinar vessels had a single 
lamina elastica and no luminal occlusion. Muscularization per time point was 
assessed and presented as the percentage of vessels per degree of musculari-
zation (including neointimal lesions).
Laser Microdissection
Cryo-sections (9 μm) from rat lung tissue were mounted on membrane-covered 
slides (PEN membrane, PALM Microlaser Technologies). Intra-acinar vessels 
(1x106 μm2 of tissue per rat) from the M+F 30 group (n=5 rats) and Control group 
(n=2 rats) were dissected using the Laser Robot Microbeam System (LMD6000, 
Egr-1 expression during neointimal development in flow-associated pulmonary hypertension
77




For real-time RT-PCR of whole lung samples (n=5-8 per group), commercially 
available kits were used. Total RNA was isolated from pulmonary tissue using 
TRIzol reagent (Invitrogen). Real-time RT PCR experiments were performed 
on a CXF384 real time system C1000 Thermal cycler (BioRad Laboratories, 
Veenendaal, The Netherlands). cDNA was synthesized using QuantiTect Re-
verse Transcription Kit (Qiagen, Benelux). Real-time RT PCR was conducted 
using SYBR Green PCR Master Mix according to the manufacturer’s instructions 
(Eurogentec, San Diego, CA). Primer sequences are available on request. Ex-
pression levels were obtained from a dilution standard curve and compared with 
those of cyclophilin or 36B4 RNA in order to calculate the relative expression 
levels. 
Laser dissected material
Total RNA was extracted from laser dissected tissue using the RNAeasy Mini Kit 
(Qiagen, Leusden, Netherlands). DNA was removed using a RNase-free DNase 
set (Qiagen, Leusden, Netherlands). RNA was quantified using the Nanodrop 
ND-1000 Spectrofotometer (Thermo Scientific, Waltham, MA). cDNA was synthe-
sized using QuantiTect Rev. Transcription Kit (Qiagen, Leusden, Netherlands). 
Primers and fluorogenic probes were purchased as assay-on-demand (Applied 
Biosystems Europe BV). Realtime RT-PCR was performed using an ABI 7900HT 
Sequence Detector (Applied Biosystems, Carlsbad, CA). Gene expression was 
normalized to the expression of the reference gene GAPDH.
Immunohistochemistry
Paraffin-embedded lung sections were microwave heated for antigen retrieval. 
To reduce non-specific staining, sections were preincubated in 0,3% hydrogen 
peroxide. Sections were then embedded for 1h at room temperature with prima-
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ry antibodies for Egr-1 (rat: Cell Signaling, 1:50 dilution; human: Abcam, 1:150 
dilution), vWF (rat: Abcam, 1:250 dilution), SMA (rat: DAKO, 1:400 dilution) and 
CD68+ (AbD Serotec, 1:300 dilution). Species-specific immunoglobulin G cou-
pled to peroxidase was used as a secondary antibody (DAKO, 1:100 dilution). 
The sections were stained with diaminobenzidine for 10 min and counterstained 
with hematoxylin. For immunofluorescence staining, the following secondary an-
tibodies were used: Chromeo™ 488 IgG (Abcam, 1:400 dilution) Chromeo™ 546 
IgG (Abcam, 1:50 dilution). Nuclei were stained with DAPI (Vector Laboratories 
Inc.). 
For positive control for Egr-1 staining, prostate adenocarcinoma samples were 
used. Negative control (by replacing the primary antibody with phosphate buff-
ered saline) showed no staining for all secondary antibodies. 
Figure 1 Development of pulmonary vascular remodeling and neointimal lesions. A) Occlusion percent-
age of the intra-acinar vessels per experimental group (methods). B) Muscularization per experimental group: 
percentage of intra-acinar vessels per degree of muscularization (including neointima lesions). C) Typical ex-
amples (400x) of intra-acinar vessels per experimental group stained with Verhoeff. Note at M+F 30 the neoin-
timal lesion with destruction of inner elastic membrane and disorganized cell proliferation. D) Typical examples 
of immunofluorescence double staining (400x) of intra-acinar vessels per experimental group. anti-SMA (red; 
smooth muscle cells), anti-vWF (green; endothelial cells), DAKO (blue; nuclei). Note at M+F 30 luminal ob-
struction due to endothelial proliferation.  Data are presented as mean ± SEM. * p<0.05 vs. CON. CON: pooled 
sham groups; M 7:  1 day before flow; M+F 8: early activation; M+F 14: early-stage PAH; M+F 30: end-stage 
PAH. Scale bars represent 50 μm.
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Quantification of immunohistochemical analysis
Egr-1 staining was investigated (n=5 rats per experimental group; n=2 per sham 
group) to characterize spatiotemporal Egr-1 protein expression. Ten intra-acinar 
vessels were randomly selected per rat. Vessels were scored as followed: 1) 
positive Egr-1 expression (0: no staining; 1: positive staining) and 2) localization 
of Egr-1 expression (0: no staining; 1: mainly positive staining of endothelium, 
2: mainly positive staining of media and 3: diffuse positive staining (both), or 
perivascular staining). Endothelium was defined as the cell layer bordering the 
vessel lumen. Media was defined as the layer between outer elastic layer the cell 
layer bordering the vessel lumen. In addition, the number of positive Egr-1 cells / 
10 vessels was counted per experimental group.
For macrophage (CD68+) count 3 rats per experimental group were analyzed. 
10 intra-acinar vessels per rat were captured at 400x magnification and the num-
 
 Con M 7 M+F 8 M+F 14 M+F 30 
Hemodynamics      
meanRAP (mmHg) 3±1 3±1 3±1 3±1 9±2* 
sRVP (mmHg) 25±4 23±2 23±4 33±3* 64±12* 
sPAP (mmHg) 25±4 22±5 22±3 32±3* 60±10* 
dPAP (mmHg) 11±4 12±4 14±5 17±4* 29±7* 
mPAP (mmHg) 18±3 17±3 18±2 25±2* 42±6* 
Heart rate (beats/min) 343±60 317±40 341±46 351±20 246±35* 
Pathology      
 Body weight at day 1 (g) 346±20 382±10 336±13 332±12 330±16 
 Body weight at sacrifice (g) 373±24 379±7 338±14  327±35  380±35 
 RV weight (g) 0.22±0.03 0.21±0.03 0.22±0.03 0.26±0.09 0.48±0.04 * 
 Fulton index; RV/(IVS/LV) 0.29±0.04 0.26±0.04 0.3±0.02 0.33±0.02 0.57±0.08 * 
Liver wet/dry weight ratio  2.8±0.3 3.0±0.2 3.1±0.1 3.0±0.2 3.4±0.1 * 
Pulmonary vascular remodeling      
Intra-acinar vessels (<50 μm)      
 Wall thickness (μm) 0.1±0.1 0.5±0.2 1.0±0.2 2.6±1.0 9.3±2.1* 
 Wall/lumen ratio 0.003±0.002 0.022±0.010 0.030±0.015 0.112±0.067 1.806±1.562* 
 Muscularization      
  Non-muscularized (% of vessels) 91.8±5.9 65.5±5.9* 44.7±10.3* 22.8±11.1* 0.0±0.0* 
  Partially muscularized (% of vessels) 7.4±5.2 23.7±6.5 32.9±9.0* 27.4±3.5* 2.5±4.3 
  Totally muscularized (% of vessels) 0.8±1.1 6.9±2.8 18.0±7.0 43.0±5.5* 22.4±9.9* 
  Neointima (% of vessels) 0.0±0.0 0.5±1.1 0.5±1.1 4.7±4.3 75.1±11.0* 
Pre-acinar vessels (>50 μm)      
 Wall thickness (μm) 7.1±2.4 11.1±2.6 10.3±1.5 11.0±3.2 19.6±11.5 
 Wall/lumen ratio  0.07±0.02 0.14±0.03 0.11±0.05 0.13±0.06 0.19±0.08* 
Table 1. Animal Characteristics
Table 1. mRAP: mean right atrium pressure; sRVP: systolic right ventricular pressure; sPAP: systolic pulmo-
nary artery pressure; dPAP: diastolic pulmonary artery pressure; mPAP: mean pulmonary artery pressure; RV: 
right ventricle; IVS: interventricular septum; LV: left ventricle; RA: right atrium; LA: left atrium. Muscularization 
per experimental group is presented as the percentage of intra-acinar vessels per degree of muscularization 
(including neointima formation). Data are presented as mean ± SD from 5-10 rats per group. P<0.05 vs. CON. 
CON: pooled sham groups; M 7: 1 day before flow; M+F 8: early activation; M+F 14: early-stage PAH; M+F 30: 
end-stage PAH (see methods and materials).
Chapter 4
80
ber of macrophages was counted per field. For all analyses, slides were blinded 
making the experimental group unknown for the observers (MD and HS).
Patient material  
Human lung tissue samples were obtained from explanted lungs from 5 patients 
with PAH associated with congenital cardiac shunts that underwent lung trans-
plantation. For control, lung tissue from 2 patients with disease free lung paren-
chyma was obtained from autopsy. 
Statistics
Data are presented as mean ± standard error of the mean. Differences between 
groups were determined by one-way analysis of variance (ANOVA) with Bonfer-
roni post-hoc test. For data not normally distributed, Mann Whitney U test was 
performed. A P-value of less than 0.05 was considered to be significant. Statisti-
cal analyses were performed using SPSS (version 16).
Results
Development of experimental flow-associated PAH
Surgery was performed successfully in all but 4 rats, which died due to perioper-
ative complications – 1 rat assigned to the M+F 14 (Early Stage PAH) group, and 
3 rats assigned to the M+F 30 (End Stage PAH) group. In addition, in the M+F 
30 group three spontaneous deaths were seen in week 2 after increased flow 
induction. Necropsy revealed a considerable amount of pleural fluid in all three 
rats, which was presumed to be the cause of death. 
In rats that received monocrotaline administration and an aortocaval shunt (M+F) 
increase in mean pulmonary arterial pressure (mPAP) and peak systolic right 
ventricular pressure (sRVP) did not occur at M+F 8 (Early Activation; 1 day after 
flow induction), but were was first seen at M+F 14 (Early Stage PAH; 1 week af-
ter flow induction) (Table 1). mPAP and sRVP further increased at M+F 30 (End 
Stage PAH) (Table 1). Increased right ventricular hypertrophy (Fulton index), 
right atrial pressure and liver congestion (indications for right ventricular failure) 
were only seen at M+F 30 (End Stage PAH)  (Table 1). The duration for rats in 
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M+F 30 group to develop severe, symptomatic PAH leading to sacrifice was 4-5 
weeks (30±3 days).
Development of pulmonary vascular remodeling
Rats that received monocrotaline administration and an aortocaval shunt (M+F) 
showed progressive pulmonary vascular remodeling during PAH development 
(Table 1, Figure 1). Wall thickness and muscularization of the intra-acinar ves-
sels occurred already one week after administration of monocrotaline and pro-
gressively increased over time. At M+F 14  (Early Stage PAH) most intra-acinar 
vessels showed muscularization and sporadic neointimal lesions were observed. 
At M+F 30 (End Stage PAH) complex vascular lesions were seen in the majority 
of intra-acinar vessels. These lesions caused vessel obliteration through both 
endothelial and smooth muscle cell proliferation (Figure 1C,D). Immunofluores-
cence staining showed clear distinction between smooth muscle cells and en-
dothelial cells within these lesions (Figure 1D). Vascular occlusive lesions were 
not seen in the pre-acinar vessels.
Increased Egr-1 expression after increased blood flow
One day before flow addition (M 7, i.e. 7 days after monocrotaline administration) 
Egr-1 levels were not increased (Fig 2A). The induction of increased pulmonary 
blood flow was followed by a nearly 3-fold increase of pulmonary Egr-1 mRNA 
expression (P<0.05 vs Control; Figure 2A). At M+F 14 (Early Stage PAH), Egr-1 
mRNA levels were decreased back to control level. At M+F 30 (End Stage PAH), 
Egr-1 mRNA expression increased again although not reaching significance us-
ing Bonferroni post hoc analysis. 
To investigate specifically the vascular expression of Egr-1 at End Stage PAH, 
we investigated mRNA expression in laser dissected intra-acinar vessels. These 
vessels showed a 2.5-fold increase in Egr-1 at M+F 30 (End Stage PAH) com-
pared with Control (P<0.05) (Figure 2B).
Two corepressors of Egr-1, NAB1 (constitutive) and NAB2 (inducible), block 
Egr-1 activation through direct interaction. NAB1 mRNA expression showed a 
biphasic decrease, parallel with Egr-1 mRNA increase, namely at M+F 8 (Early 
activation) and at M+F 30 (End Stage PAH; Figure 2C). At the same time points 
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NAB2 mRNA expression showed a similar upregulation compared to Egr-1, how-
ever only reaching significance (P<0.05 vs Control) at M+F 30 (End Stage PAH; 
Figure 2D).
Progressive increase Egr-1 protein expression and shift in 
localization 
Immunohistochemistry revealed only sporadic Egr-1 protein staining in pulmo-
nary vessels of Control rats and 1 day before flow addition (M 7). In contrast, 
strong Egr-1 staining was observed in intra-acinar vessels at M+F 8 (Early acti-
vation; 1 day after induction of increased pulmonary blood flow) (Figure 3). Dur-
ing disease development 
Egr-1 protein expression increased progressively with more than 90% of vessels 
Figure 2 mRNA expression during pulmonary vascular remodeling in flow-associated PAH. A) Egr-1 
expression relative to 36B4 per experimental group in whole lung. Bars indicate mRNA increase compared to 
CON. Expression levels in the CON group are set to 1. Bars indicate mRNA increase compared to CON. B) Egr-
1 expression relative to GAPDH in laser dissected intra-acinar vessels at M+F 30 compared to laser dissected 
intra-acinar vessels of CON. NAB1 expression relative to 36B4 (c) and NAB2 relative to cyclophilin (d) per 
experimental group in whole lung. Data are presented as mean ± SEM. * p<0.05 vs. CON. CON: pooled sham 
groups; M 7: 1 day before flow; M+F 8: early activation; M+F 14: early-stage PAH; M+F 30: end-stage PAH.
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staining positive for Egr-1 in end-stage disease (P<0.05 vs Control). Qualitative 
analysis revealed that one day after increased pulmonary blood flow (M+F 8) 
Egr-1 was located mainly in endothelial cells (Figure 3B,C). During disease de-
velopment, Egr-1 showed a shift in localization. At M+F 14 (Early stage PAH) 
Egr-1 was mainly observed in the media layer of the vessel (p<0.05 vs Control). 
At M+F 30 (End Stage PAH) Egr-1 was seen throughout the intima and media 
layer (p<0.001 vs Control) with high production of Egr-1 in neointimal lesions. 
In the larger pre-acinar vessels, Egr-1 staining was only seen at M+F 30 (End 
Stage PAH; data not shown).
Only sporadic Egr-1 expression in non-neointimal pulmo-
nary vascular remodeling
To check whether Egr-1 expression is specifically upregulated during flow-in-
duced neointimal development, we investigated Egr-1 expression in a non-ne-
ointimal, non-flow-associated model of pulmonary hypertension, namely mono-
crotaline only.  Four weeks after monocrotaline injection (M 30) rats developed 
pulmonary hypertension (mean SRVP: 50 mmHg ± 14; mean Fulton index; 0.32 
± 0.03). Wall thickness and vessel occlusion increased over time (mean wall 
 
 Con M 7 M 8 M 14 M 30 
Pathology      
Body weight at day 1 (g) 346±20 382±10 314±7 310±8 253±16 
Body weight at sacrifice (g) 373±24 379±7 323±6 318±12 340±18 
RV weight (g) 0.22±0.03 0.21±0.03 0.22±0.04 0.18±0.01 0.24±0.03 
Fulton index; RV/(IVS/LV) 0.29±0.04 0.26±0.04 0.27±0.04 0.27±0.03 0.32±0.03 
Liver wet/dry weight ratio 2.8±0.3 3.0±0.2 3.2±0.09 3.3±0.1 3.2±0.2 
Pulmonary vascular remodeling      
Intra-acinar vessels (<50 μm)      
  Wall thickness (μm) 0.1±0.1 0.5±0.2 0.9±0.3* 1.5±0.2* 3.0±0.6* 
  Wall/lumen ratio 0.003±0.002 0.022±0.010 0.035±0.01* 0.05±0.008* 0.13±0.03* 
Muscularization      
  Non-muscularized (% of vessels) 92±6 66±6* 59±17* 36±6* 13±6* 
  Partially muscularized (% of vessels) 7±5 24±7* 34±8* 42±5* 28±10* 
  Totally muscularized (% of vessels) 0.8±1 6.9±3* 7±2* 22±3* 60±9* 
  Neointima (% of vessels) 0.0±0 0.5±1.1 0±0.0 0±0.0 0±0.0 
Pre-acinar vessels (>50 μm)      
  Wall thickness (μm) 7±2 11±2 5±1 6±2 9±2 
  Wall/lumen ratio 0.07±0.02 0.14±0.03* 0.07±0.04 0.09±0.01 0.08±0.02 
Table 2. Animal Characteristics (monocrotaline only)
Table 2. Muscularization per experimental group is presented as the percentage of intra-acinar vessels 
per degree of muscularization. Data are presented as mean ± SD from 5-10 rats per group. P<0.05 vs. CON. 
CON: pooled sham groups; M 7: 7 days after monocrotaline administration; M+F 8: 8 days after monocrotaline 




thickness: M 30 3.0 µm ± 0.6 vs CON 0.1±0.1; occlusion score: M 30 18.2% ± 
3.0 vs CON 0.5% ± 0.2, Figure 4E, Table 2) Neointimal lesions did not develop 
at M 30 (30 days after monocrotaline administration; Table 2).  Egr-1 mRNA ex-
pression did not increase at the selected time points (M7, M 8, M 14, M 30 group; 
Figure 4A). Also no changes were seen in NAB1 or NAB2 expression after mono-
crotaline injection only (See Supplemental Figure S1).
Immunohistochemistry revealed a moderate increase in Egr-1 protein expression 
only at M 30 (Figure 4B). This increase in Egr-1 positive vessels (Figure 4B) was 
Figure 4: Egr-1 expression during pulmonary vascular remodeling in non-neointimal PH To further em-
phasize the relationship between increased flow, Egr-1 upregulation and neointima development, we inves-
tigated Egr-1 expression in a non-flow, non-neointmal PH model (monocrotaline-only rats) SEE DETAILED 
DESCRIBTION IN METHODS AND MATERIALS SECTION.  A) Egr-1 expression relative to 36B4 per exper-
imental group in whole lung. Bars indicate mRNA increase compared to CON. Expression levels in the CON 
group are set to 1. Egr-1 mRNA expression is not upregulated in whole lung in monocrotaline induced vascular 
remodeling. B) Percentage of intra-acinar vessels staining positive for Egr-1 per experimental group. The num-
ber of vessels that show positive Egr-1 staining is increased in the M 30 group (* p<0.05 vs. CON). However 
this number is far less compared to the number of vessels in the M+F 30 group (monocrotaline + flow) as seen 
in Figure 3A. Also the number of positive Egr-1 cells per vessel in the end-stage groups differ (4C). In addition, 
localization of Egr-1 staining differed in the M 30 group compared to M+F 30 group as seen in  D): Typical 
example (x400) of Egr-1 staining in the M 30 group where Egr-1 staining was mainly found perivascularly. E) 
Typical example (x400) a Verhoeff staining of a peri-acinar vessel with media hypertrophy seen in the M 30 
group. Administration of monocrotaline only never resulted in neointima formation. Data are presented as mean 
± SEM. * p<0.05 vs. CON.  CON: pooled sham groups; M 7: 7 days after monocrotaline injection; M 8: 8 days 
after monocrotaline injection; M 14: 2 weeks after monocrotaline injection early-stage PAH; M+F 30: 4 weeks 
after monocrotaline injection. MCT: monocrotaline. Scale bars represent 50 μm.
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Figure 3  Egr-1 staining in intra-acinar vessels in flow-associated PAH. A) Percentage of intra-acinar ves-
sels staining positive for Egr-1 per experimental group. B) Localization of Egr-1 staining in intra-acinar vessels 
per experimental group. C) Typical examples (x400) of Egr-1 staining (arrows) in intra-acinar vessels per exper-
imental group. Note that Egr-1 staining is located in endothelial cells 1 day after flow addition (T8). During dis-
ease development, Egr-1 staining is seen in the intima and media layer with strong Egr-1 staining in neointimal 
lesions. Data are presented as mean ± SEM. * p<0.05 vs. CON.  CON: pooled sham groups; M 7: 1 day before 
flow; M+F 8: early activation; M+F 14: early-stage PAH; M+F 30: end-stage PAH. Scale bars represent 50 μm
far less compared to the number of vessels in the M+F 30 group (Figure 3A). 
In addition the number of positive Egr-1 cells per vessel in the M 30 group was 
much lower compared to the M+F group (Figure 4C). When Egr-1 expression did 
occur, these cells were mainly located perivascularly (Figure 4D). 
Increased MCP-1 expression and macrophage activation in 
End Stage PAH
Monocyte chemottractant protein 1 (MCP-1) is described as a downstream gene 
of Egr-1. MCP-1 mRNA expression increased during vascular remodeling (M+F 
30 group P < 0.05 vs Con; Figure 5A). MCP-1 was also increased in the M 30 
group (monocrotaline only; P < 0.05 vs Con; Figure 5A). One of the effects of 
MCP-1 is macrophage infiltration. Macrophage count was highly increased in 
M+F 30 group compared to Control (P < 0.05) as well as compared to the M 30 
group (monocrotaline only; P < 0.05; Figure 5C-D). 
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Increased Egr-1 expression human PAH associated with a 
congenital shunt
To study whether Egr-1 expression is also upregulated in human disease, we 
investigated Egr-1 expression in pulmonary vascular lesions of patients with 
end-stage PAH associated with congenital cardiac shunts. Egr-1 expression was 
hardly found in pulmonary vessels from the controls (Figure 6A,D).  In contrast, 
strong Egr-1 staining was found in pulmonary vessels of end-stage flow-associ-
ated PAH patients (Figure 6B,C,E-H). In vessels with media hypertrophy (Figure 
6B,E) and plexiform lesions Egr-1 was mainly found in the endothelial cells bor-
dering the lumen (Figure 6C,F,G). In vessels with concentric intima fibrosis Egr-1 
expression was found in cells throughout the vessel wall (Figure 6H).
Figure 5 MCP-1 expression and macrophage infiltration during pulmonary vascular remodeling. MCP-1 
expression relative to 36B4 per experimental group in whole lung of monocrotaline + flow (A) and monocrotaline 
(B). Bars indicate mRNA increase compared to CON. Expression levels in the CON group are set to 1. Bars 
indicate mRNA increase compared to CON. C) Perivascular macrophage count per field at 400x magnification. 
D) Typical examples (400x) of CD68+ staining. Note the marked increase in macrophage infiltration around the 
neointimal lesion in the M+F 30 group compared to a normal vessel in the CON group and a vessel with media 
hypertrophy in the M 30 group. Data are presented as mean ± SEM. * p<0.05 vs. CON.  CON: pooled sham 
groups; M 7: 7 days after monocrotaline injection; M 8: 8 days after monocrotaline injection; M 14: 2 weeks 
after monocrotaline injection early-stage PAH; M+F 30: 4 weeks after monocrotaline injection; M+F 8: early ac-
tivation; M+F 14: early-stage PAH; M+F 30: end-stage PAH. MCT: monocrotaline. Scale bars represent 50 μm.
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Discussion
In this study in experimental flow-associated PAH we investigated the spatio-
temporal expression of Egr-1 during the development of pulmonary neointimal 
lesions. In our PAH model, induction of increased pulmonary blood flow was fol-
lowed by a biphasic response in Egr-1 gene expression, namely a rapid response 
early after flow induction and a late response in end-stage PAH. During disease 
progression Egr-1 protein expression in the intra-acinar vessels gradually in-
creased. Moreover, with disease progression, Egr-1 protein expression migrated 
through the pulmonary vessel wall, from the endothelial cell layer to the media, 
with strong Egr-1 staining in neointimal lesions in end-stage PAH. Rats that were 
Figure 6 Egr-1 staining in human PAH lesions.  A) Egr-1 staining of a normal lung vessel from a control 
subject free of lung disease. (200x). D) Enlarged view of the same vessel showing no Egr-1 staining. B) Egr-1 
staining of vessel with media hypertrophy in PAH patient associated with a congenital cardiac shunt (x200). 
E) Enlarged view of the same vessel showing marked Egr-1 staining in the endothelial layer. C) Egr-1 staining 
of plexiform lesion in PAH patient associated with a congenital cardiac shunt (x200). F) Enlarged view of the 
plexiform lesion showing Egr-1 staining mainly in endothelial cells bordering the lumen (arrows). G) Egr-1 
staining of a larger plexiform lesion (100x) showing as similar pattern of Egr-1 expression (arrows) compared 
to F. H) Egr-1 staining of a concentric intima lesion with diffuse staining throughout the vessel wall  Scale bar 
represents 100 μm. 
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subjected monocrotaline only, did not show Egr-1  mRNA upregulation, showed 
sporadic perivascular Egr-1 staining and did not develop end stage neointimal 
lesions. Increased Egr-1 expression during increased pulmonary blood flow was 
confirmed in end-stage lesions of PAH patients with a congenital cardiac shunt. 
These results suggest that Egr-1 plays an important role in the development of 
pulmonary vascular remodeling in flow-associated PAH, including the formation 
of neointimal lesions. 
Egr-1 transcription during pulmonary vascular remodeling
Using microarray analysis, we recently identified Egr-1 to be specifically upregu-
lated by increased pulmonary blood flow in end-stage PAH.(8) However, the spa-
tiotemporal expression of Egr-1 during the development of neointimal lesions in 
flow-associated PAH has not yet been described.
Here, we show that during pulmonary vascular remodeling in flow-associated 
PAH, Egr-1 transcription is biphasic. It is plausible that in pulmonary vascular 
remodeling in flow-associated PAH, early Egr-1 upregulation (after 24 hours) in 
endothelial cells is due to the direct increase in shear stress in the pulmonary 
vascular bed after the induction of increased flow. This is supported by the fact 
that we did not see Egr-1 upregulation in the monocrotaline only group on day 
8 (M 8, Figure 4). Also, previous studies have shown Egr-1 upregulation in en-
dothelial cells of the systemic vasculature directly after vessel injury – including 
vessel injury due to shear stress.(19-21) In flow-associated PAH shear stress – 
caused by increased pulmonary blood flow – is a prerequisite for neointimal de-
velopment.(1,7) Since we here show that 1) Egr-1 is upregulated specifically after 
flow induction and 2) Egr-1 is seen to progress throughout the vessel wall during 
which neointimal lesions develop, we suggest that early Egr-1 activation may 
play an important role in turning on the process of neointimal vascular remode-
ling in flow-associated PAH. 
Egr-1 may also play a role in chronic phases of neointimal development. In End-
Stage PAH (both human and experimental) Egr-1 is strongly expressed in both 
rat and human neointimal lesions. However the location of Egr-1 positive cells in 
humans and rats appears different, especially in human plexiform lesions, where 
Egr-1 expression is predominantly seen in endothelial cells. This difference could 
be attributed to the fact that, even though the neointimal PAH rat model shows 
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great similarities to the human disease, it obviously is not identical, illustrated by 
the fact that the typical plexiform lesions have not been described in a flow-asso-
ciated rat model. Another possible explanation between the differences in Egr-1 
expression could be formed by the fact that the human lung samples used were 
from end-stage PAH patients who all had previously received specific PAH treat-
ment. This might have affected the pattern of Egr-1 expression in humans.
Besides Egr-1 being produced by endothelial cells subjected to high flow in end-
stage disease, Egr-1 transcription is also seen in cells throughout the vessel wall 
(human concentric intima fibrosis, rat neointimal lesions) which are not subjected 
to flow (i.e. shear stress). This shows that Egr-1 could also be upregulated by 
other stressors at this time point, for instance specific Egr-1 downstream genes, 
such as platelet derived growth factor (PDGF), or hypoxia. Both have been sug-
gested to contribute to vascular remodeling in end-stage disease in PAH pa-
tients.(3-5) In hypoxia, Egr-1 has been shown to be upregulated in lungs (22,23) and 
isolated fibroblasts (24) subjected to chronic hypoxia. Focusing on the pulmonary 
vessels, Yan and colleagues have shown that in lungs of mice subjected to hy-
poxia, Egr-1 is specifically produced in pulmonary vessel smooth muscle cell.(22) 
However these studies failed to show typical neointimal lesions, which indicates 
that hypoxia driven Egr-1 expression alone does not lead to neointimal devel-
opment. Interestingly, in another model, TGF-α induced pulmonary vascular re-
modeling is shown to worsen in Egr-1-/- mice.(25) Future interventional studies 
are justified to investigate the role of these specific triggers in chronic phases of 
neointimal development and the effect of Egr-1 upregulation on pulmonary vas-
cular remodeling in flow-associated PAH.
In our study, Egr-1 mRNA expression showed a different pattern compared to 
that of Egr-1 protein expression. While transcriptional expression in whole lung 
decreased in Early Stage PAH, Egr-1 protein expression in the intra-acinar ves-
sels gradually progressed. A possible explanation for this difference is that Egr-
1 mRNA expression was assessed in whole lung tissue, whereas protein ex-
pression was investigated specifically in the pulmonary vessels. This could have 
made protein expression more profound, as supported by the more profound 
Egr-1 expression in the laser dissected vessels. In addition, Egr-1 itself is known 
to bind to its own gene allowing Egr-1 to downregulate its own transcription.(26) 
This negative feedback could be a possible explanation for the downregulation 
of Egr-1 transcription seen at Early Stage PAH. 
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Effects of Egr-1 upregulation
For activity, Egr-1 is also dependent on the expression of its repressors NAB1 
and NAB2. NAB2 is a downstream target gene of Egr-1 and is able to directly re-
press Egr-1 activity.(26,27) The fact that NAB2 showed a similar expression pattern 
compared to Egr-1 illustrates that the Egr-1 product is active during its upregu-
lation. NAB2 may have its direct effect on preventing a permanent transcription 
of Egr-1, as seen at Early Stage PAH (T14). In normal conditions Egr-1 upregu-
lation is suppressed by the constitutive expression of NAB1.(26,27) Little is known 
about factors that regulate NAB1 expression. However, the fact that NAB1 mRNA 
levels in whole lung were seen to decrease at the same time as Egr-1 mRNA 
levels increased suggests that NAB1 expression could be downregulated by the 
same stressors that induce Egr-1 expression. 
We also aimed to investigate MCP-1 transcription during disease development. 
MCP-1 is a target gene of Egr-1 and a pro-inflammatory cytokine known to play 
a role in PAH.(28) Although we observed an increase in MCP-1 expression in end-
stage PAH, this increase could not solely be attributed to Egr-1 upregulation due 
to increased flow.  Namely MCP-1 was also increased by monocrotaline only. 
Previously studies have also shown that MCP-1 plays a role in monocrotaline 
induced media hypertrophy.(29) Apparently in the described flow-associated PAH 
model MCP-1 is also activated by other factors than Egr-1. Interestingly though, 
perivascular macrophage infiltration, a known result of MCP-1 activation, was 3 
fold higher after increased pulmonary blood flow (M+F 30 vs M 30) and seen to 
be located around neointimal lesions. This shows that inflammatory processes, 
in this case macrophage infiltration, may contribute to neointimal development as 
seen in end stage vascular remodeling in human PAH.(29,30-31)  
Egr-1 is also located upstream of numerous other genes that are known to play 
a role in PAH, including PDGF (3,5,32) and tissue factor.(9) Egr-1 could thus be an 
important early factor in PAH by regulating different genes involved in neointimal 
development. In systemic vessels, the importance of Egr-1 expression during 
vascular remodeling has been confirmed given that neointima formation is re-
duced when Egr-1 expression is blocked.(33-36) In addition, these studies demon-
strate that Egr-1 induced neointima formation is mediated through both prolifera-
tive and inflammatory pathways.(33-36) 
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Taken together, this is the first study to demonstrate the spatiotemporal correla-
tion between increased Egr-1 expression and increased pulmonary blood flow, 
as an inductor of neointimal development. This data suggests that Egr-1 may 
be able to initiate as well as maintain the process neointimal development in 
flow-associated PAH, and therefore also justifies further exploration of the exact 
role of Egr-1 in pulmonary vascular remodeling in PAH.  
Conclusion
The spatiotemporal expression of Egr-1 in flow-associated PAH, as described 
for the first time in this study, identifies Egr-1 as a candidate gene to master the 
flow-induced pulmonary vascular remodeling process associated with the devel-
opment of neointimal lesions. Further studies are needed to study the specific 
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Rationale: Pulmonary arterial hypertension (PAH) is characterized by vascular 
proliferation and apoptosis dysregulation resulting in the development of unique 
neointimal lesions. PAH is considered irreversible when neointimal lesions have 
formed. Therefore, novel therapeutic strategies are needed that target these ne-
ointimal lesions. We recently found that the transcription factor Egr-1 is upreg-
ulated early in experimental neointimal PAH and in human PAH. However, it is 
unknown whether downregulation of Egr-1 beneficially affects disease develop-
ment.
Objective: We aimed to uncover a novel role for Egr-1 as a molecular inductor for 
neointimal development in experimental PAH.
Methods and results: In experimental flow-associated PAH in rats, we investi-
gated the effects of Egr-1 downregulation on pulmonary vascular remodeling, 
including neointimal development, and disease progression. Intravenous ad-
ministration of catalytic oligodeoxynucleotides (DNAzymes) resulted in down-
regulation of pulmonary vascular Egr-1 expression. Compared to vehicle or 
scrambled-DNAzymes, DNAzymes attenuated pulmonary vascular remodeling, 
including the development of occlusive neointimal lesions. Mechanistically, im-
provement in vascular remodeling was attended by increased vascular apopto-
sis and a reduction of proliferation via PDGF-B inhibition. DNAzyme treatment 
further attenuated pulmonary vascular resistance, right ventricular systolic pres-
sure and right ventricular hypertrophy. In contrast, in non-neointimal PH rodents 
DNAzyme treatment had no effect on pulmonary vascular and RV remodeling. 
Finally, pharmacological inhibition of Egr-1 with pioglitazone, a PPAR-γ ligand, 
attenuated vascular remodeling including of neointimal development.
Conclusions: These results indicate that Egr-1 governs pulmonary vascular re-
modeling and the development of characteristic vascular neointimal lesions in 





Pulmonary arterial hypertension (PAH) is a fatal and progressive form of pul-
monary hypertension with, so far, unknown origin.1 It is characterized by the 
development of unique so called neointimal lesions that result from apoptotic 
dysregulation, proliferation of endothelial and smooth muscle cells, and fibrosis.2 
PAH is considered irreversible when these neointimal lesions have formed3, and 
results in progressively increased pulmonary vascular resistance, increased right 
ventricular (RV) workload and eventually death due to RV failure.4-6 Current treat-
ment strategies may beneficially affect disease progression but certainly do not 
result in curing of the disease. Therefore, new treatment strategies are needed 
that target this irreversible form of pulmonary vascular proliferation.
In PAH, the role of increased pulmonary blood flow is seen as an important trigger 
(both clinically 7 and experimentally 8-10) for the development of pulmonary vascu-
lar remodeling. In experimental PAH models the addition of increased pulmonary 
blood flow has extensively been shown to lead to neointimal development that re-
flects human PAH more truly than the monocrotaline or chronic hypoxia PH mod-
els in which pulmonary vascular remodeling is characterized solely by medial 
hypertrophy.8, 10-13 Still, questions remain about the mechanisms by which blood 
flow disturbances lead to neointimal development and disease progression.
For this study, we hypothesized that the transcription factor Egr-1 (early growth 
response protein 1) is an important pathogenic inductor for neointimal develop-
ment in PAH. Recently, in a neointimal model that closely mimics human PAH, we 
identified Egr-1 to be upregulated specifically induced by increased pulmonary 
blood flow in the pulmonary vessels of.10, 14 In addition, we confirmed Egr-1 up-
regulation in human end-stage PAH.10
Egr-1 is a transcription factor known to play a major role in a variety of cardiovas-
cular processes including vascular remodeling in systemic vessels.15-17 Howev-
er, it is unknown whether in vivo downregulation of Egr-1 will beneficially affect 
pulmonary vascular disease progression in PAH, specifically the development of 
neointimal lesions. Targeting Egr-1 in vivo has previously been described using 
pharmacological treatment (including PPAR-γ ligands 18-20) or using specific gene 
silencing methods, including so called DNA enzymes (DNAzymes).21-23 DNA-
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zymes are catalytic oligodeoxynucleotides that are able to bind to specific RNA 
sequences resulting in RNA degradation.24, 25 These DNAzymes exhibit greater 
catalytic efficiency than oligonucleotides such as ribozymes and are more stable 
in serum in vivo.24, 26 For this study we therefore investigated whether in vivo 
downregulation of Egr-1, using both DNAzymes and the PPAR-γ ligand pioglita-




DNAzymes were commercially synthesized (Double RP-HPLC purification; Tri-
link Biotechnologies, Santa Cruz CA, USA) with a phosphodiester backbone and 
inverted T at 3’ terminus for increased stability. The oligonucleotide sequences 
were as followed: Egr-1 DNAzyme (ED5; Figure 1A): 5’-CCG CTG CCA GGC 
TAG CTA CAA CGA CCC GGA CGT Ti-3’; scrambled DNAzyme (SCR): GCC 
AGC CGC GGC TAG CTA CAA CGA TGG CTC CAC Ti-3’, as described previ-
ously.21 For in vivo DNAzyme administration we first tested 2 different transfec-
tion carriers – 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP; Avanti Polar 
Lipids, Alabaster, Alabama, USA) and polyethylenimine (in vivo jetPEI; Polyplus 
transfection, Illkirch, France) – known for targeting the pulmonary vasculature. 
DOTAP revealed to be the most suitable transfection carrier (online supplement). 
Therefore, DOTAP was used as the transfection carrier in the main study. 
Pilot study: Egr-1 DNAzyme (ED5) delivery to pulmonary 
vasculature
In a pilot study we aimed to determine whether intravenous administration of 
the DNAzyme ED5/DOTAP complex would lead to delivery into the pulmonary 
vasculature and downregulate pulmonary vascular Egr-1 protein expression. To 
test this, flow-PAH rats (n=4) received a single injection of ED5/6FAM-DOTAP 
solution (500ug DNAzyme/500ug DOTAP) directly after shunt creation, whereas 
3 flow-PAH rats received saline injection. Rats were sacrificed after 1 and 3 days. 
In contrast to the saline-injected animals, the ED5/6FAM-DOTAP-injected rats, 
showed ED5 in the endothelial layer of the pulmonary vessels (Figure 1) at day 1 
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that had diminished at day 3. Accordingly, in these rats ED5 transfection indeed 
resulted in downregulation of vascular Egr-1 protein expression at day 1 and this 
effect was lost 3 days after injection (Figure 1C and D). Therefore, in the main 
study rats received treatment every 48 hours.
Animal procedures and groups
PAH Animal model
Animal care and experiments were approved by the Institutional Animal Care 
and Use Committee. One hundred twenty-three male Wistar rats (Charles River, 
The Netherlands; 270-300g) were used. Experimental flow-associated PAH was 
Figure 1 ED5 in the pulmonary vasculature A) Schematic representation of the DNAzyme sequence target-
ing Egr-1 (ED5). This molecule, with a phosphodiester backbone and an inverted T at 3’ terminus, consists of a 
catalytic core (underline) and 2 recognition arms that attaches to the Egr-1 translational start site.21 B) Vascular 
localization of ED5 24 hours after injection. ED5 was commercially labeled with 6FAM, combined with DOTAP 
and injected into the jugular vein. Positive fluorescent signaling was mainly seen in the vascular bed. Both pre- 
and intra-acinar vessels showed positive signaling for ED5. C) Single ED5 injection resulted in a decrease of 
vascular Egr-1 expression after 1 day. This effect was lost 3 days after injection. D) Localization of both ED5 
signaling and Egr-1 expression in the intra-acinar vessels. Data are presented as mean values ± SEM.  = 
P<0.05.  Scale bare represents 50µm.
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created using a monocrotaline injection (60 mg/kg) followed by an abdominal 
aortocaval (av) shunt one week later.10, 11, 14
Egr-1 downregulation in PAH animal model
For the main DNAzyme study 82 rats were used. Blood was drawn peri-oper-
atively for baseline blood analyses. A pilot study revealed that rats needed to 
receive ED5 treatment every 48 hours (Figure 1C and D and online Supple-
mental Figure S1). Rats were randomly divided to receive intravenous treatment 
of either: 1) NaCl 0.9% (PAH_VEH; n=24), 2) scrambled DNAzyme-DOPTAP 
solution (PAH_SCR; n=18), 3) DNAzyme ED5-DOPTAP solution (PAH_ED5; 
n=20). Treatment started directly after shunt creation (=induction of increased 
flow) (Figure 2A). Rats received treatment every 48 hours through an externally 
fixed jugular vein catheter. Randomization was blinded for the investigators. Re-
peated ED5 delivery did not result in a systemic immune response or decreased 
liver function (Supplemental Figure S2). For each group, rats were sacrificed 1 
week (n=6-12 per group) or 3 weeks (n=10-12 per group) after shunt creation. 
Sham operated rats served as control and received either NaCl 0.9% (n=12) 
or ED5-DOTAP solution (n=8). Since no differences were seen between these 
groups, they were pooled as control (Supplemental Figure S3). 
Egr-1 downregulation in non-neointimal PH animal model
In addition, to investigate the effects of Egr-1 downregulation in a non-neointimal 
PH model, additional rats received a single injection of monocrotaline only. One 
week later, rats were randomly divided to receive either NaCl 0.9% (MCT_VEH; 
n=3) or DNAzyme ED5-DOTAP solution (MCT_ED5; n=3) via externally fixed 
jugular vein catheters. Rats were sacrificed 3 weeks after monocrotaline injec-
tion.
Pioglitazone treatment in PAH animal model
To investigate the effects of the PPAR-γ ligand pioglitazone on pulmonary vas-
cular Egr-1 downregulation in PAH, 24 additional flow-PAH rats were randomly 
divided to receive either: 1) vehicle treatment (n=6), 2) pioglitazone 20mg/kg 
(n=9), 3) pioglitazone 100mg/kg (n=9). Treatment was mixed into rat chow and 
rats were fed ad libitum. Rats were sacrificed 1 day (n=3-5 per group) and 1 week 
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(n=3-4 per group) after start of increased blood flow. Vehicle treated sham rats 
from the main study served as control.
Echocardiography
Echocardiography was performed 1 and 3 weeks after start of increased pulmo-
nary blood flow, and in sham operated animals using a Vivid Dimension 7 system 
and 10S-transducer (GE Healthcare, Waukesha, WI, USA) as described previ-
ously27 and in more detail in the online supplement.  
Hemodynamic measurements and pathology
Directly before sacrifice invasive hemodynamic measurements were carried out 
using a closed chest technique that is routinely used in our lab 10, 11, 14 and de-
scribed in more detail in the online supplement. Pulmonary vascular resistance 
was estimated by dividing the assessed mean pulmonary arterial pressure by the 
cardiac output as described previously.28
 
Pathology 
After hemodynamic measurements, blood was drawn, and organs were harvest-
ed and prepared for further analysis. Pulmonary vascular morphology (n=6-7 
rats per experimental group) was qualitatively and quantitatively analyzed as de-
scribed previously10, 11, 14 and in more detail in the online supplement. 
PAH_1wk PAH_3wks 
Con VEH SCR ED5 VEH SCR ED5 
Body weight at sac (g) 361(7 306(6* 304(11 309(6 327(5* 323(5 328(3 
RV weight (mg) 0.19(0.00 0.25(0.01* 0.25(0.01 0.19(0.01† 0.49(0.02* 0.49(0.02 0.39(0.02† 
LV+IVS weight (mg) 0.68(0.01 0.74(0.17 0.69(0.03 0.71(0.02 0.83(0.02* 0.81(0.02 0.66(0.03 
RV/BW (mg/g) 0.53(0.01 0.83(0.01* 0.81(0.04 0.60(0.02† 1.49(0.07* 1.53(0.06 1.2(0.06 † 
LV+IVS/BW (mg/g) 1.92(0.02 2.44(0.04* 2.33(0.14 2.30(0.05 2.53(0.07* 2.50(0.05 2.53(0.04 
atria/BW (mg/g) 0.27(0.01 0.61(0.02 0.48(0.04 0.38(0.02† 0.71(0.04* 0.78(0.02 0.64(0.03† 
CO (ml/min) 103(5 131(9* 134(16 135(11 108(9 123(5 127(10 
PAAT (ms) 30(1 28(2 24(2 21(3 15(3* 15(2 17(1 
TAPSE (mm) 3.0(0.2 3.5(0.1* 3.6(0.6 3.8(0.09 2.5(0.24 2.6(0.2 2.6(0.2 
PAH: Pulmonary arterial hypertension; Con: control; VEH: vehicle treatment; SCR: scrambled DNAzyme treat-
ment; ED5: DNAzyme treatment; Sac: sacrifice; RV: right ventrile LV: left ventricle; IVS: intraventricular septum; 
BW: body weight; CO: cardiac output; PAAT: pulmonary artery acceleration time; TAPSE: tricuspid annular 
plane systolic excursion. * P<0.05 Con vs VEH; † P<0.05 SCR vs ED5. Data presented as mean ± SEM.
Table 1. Animal characteristics
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Immunohistochemistry 
For immunohistochemistry, sections were embedded for 1h at room temperature 
with primary antibodies for αSMA (DAKO, 1:50), von Willebrand Factor (vWF; 
Abcam, 1:300), Egr-1 (rat: Cell Signaling, 1:50 dilution; human: Abcam, 1:100 di-
lution), Platelet derived growth factor (PDGF)-B (Abcam, 1:100), Caspase 3 (Cell 
Signaling, 1:100 dilution) and Ki67 (Abcam, 1:50 dilution). A detailed description 
of immunohistochemical techniques can be found in the online supplement.
Immunohistochemical staining was semi-quantified (n=4-6 rats per experimen-
tal group) to characterize spatiotemporal Egr-1, PDGF-B, Caspase 3 and Ki67 
pulmonary vascular protein expression as described previously10 and in more 
detail in the online supplement. For all analyses, slides were blinded making the 
experimental group unknown.
Real-time RT-PCR
For PPAR-γ activation, gene expression of PGC1α (co-activator of PPAR-γ) and 
MCAD (downstream gene of PPAR-γ) were measured. For real-time RT-PCR of 
whole lung samples (n=3-5 per group), commercially available kits were used. 
A detailed description of Real-time RT-PCR methods can be found in the online 
supplement 
Statistics
Data are presented as mean ± standard error of the mean. Differences between 
groups were determined by one-way analysis of variance (ANOVA) with Bonfer-
roni or Dunnet post-hoc test where applicable. For data not normally distributed, 
Mann Whitney U test was performed. A P-value below 0.05 was considered to 
be significant.
Results
Disturbed pulmonary blood flow resulted in progressive 
PAH with development of occlusive intra-acinar vessels
Rats that received monocrotaline administration and an aortocaval shunt (flow-
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PAH) showed progressive pulmonary vascular remodeling over time (Figure 2A; 
Table 1). One week after shunt creation (PAH_1wk) intra-acinar vessels exhib-
ited muscularization, and sporadic neointimal lesions were observed. In end-
stage disease (PAH_3wks) occlusive vascular lesions were seen in the majority 
of intra-acinar vessels (Figure 2; Table 1). These cellular lesions showed simi-
larities with human neointimal lesions, with the occurrence of vessel occlusion, 
destruction of the lamina elastica and dilatation of surrounding capillaries (Figure 
2) Occlusive vessels consisted of vWF positive endothelial cells surrounded by 
αSMA positive smooth muscle cells (Figure 2C).
Vessel occlusion resulted in symptomatic PAH 3 weeks after increased blood 
flow including increased peak right ventricular systolic pressure (pRVSP), in-
Figure 2 Development of flow-associated PAH Pulmonary vascular remodeling and disease development 
in experimental flow-PAH. A) Typical examples of the progression of pulmonary vascular remodeling, including 
the formation of neointimal lesions after increased pulmonary blood flow. Note the degradation of the lamina 
elastica interna and the cellular luminal in these neointimal lesions. B) Progressive worsening of vascular 
remodeling, RV hypertrophy and hemodynamic measurements. C) Occlusive neointimal lesions consisted of 
ECs (staining positive for vWF) surrounded by SMCs (staining positive for αSMA). Data are presented as mean 
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creased pulmonary vascular resistance, and right ventricular hypertrophy (RVH) 
(Figure 2B). These parameters correlated with pulmonary vascular remodeling 
(Supplemental Figure S4).
Four rats did not reach the endpoint of the study: 1 died perioperatively (ED5 
group), 3 rats were sacrificed (2 ED5 group; 1 SCR group) because of severe 
dyspnoea due to an air embolus during intravenous injection. These rats were 
excluded from further analyses. 
Intravenous ED5 delivery reduced vascular Egr-1 expres-
sion in flow-PAH.
Compared to control, pulmonary vascular Egr-1 protein expression increased 1 
week after increased pulmonary blood flow (PAH_1wk) and progressed during 
disease development (PAH_3wks) (Figure 3). 3 weeks after start of increased 
flow, Egr-1 expression was located throughout the vessel wall in PAH_VEH and 
PAH_SCR rats and showed similar vascular Egr-1 expression compared to hu-
man PAH (Figure 3B and 3C). , Chronic ED5 delivery (PAH_ED5) reduced pul-
monary vascular Egr-1 protein expression with 35% and 43% at 1 and 3 weeks 
after increased flow, respectively (Figure 3D). Egr-1 was targeted throughout the 
vessels wall (Supplemental Figure S5). Reduction in Egr-1 protein expression 
was accomplished without reducing the total number of intra-acinar vessels that 
PAH_1wk PAH_3wk 
 Con VEH SCR ED5 VEH SCR ED5 
Pre-acinar 
   Outer diameter ( m) 101(8 96(15 104(11 106(10 124(16 115(13 110(10 
   Wall thickness ( m) 6(1 6(1 5(1 6(1 14(1 13(1 9(1† 
Intra-acinar  
  Outer diameter ( m) 28.3(0.6 36(1* 37(1 35(1 34(1 36(1 35(1 
  Wall thickness ( m) 0.3(0.0 2.3(0.4* 2.1(0.2 1.0(0.1† 5.6(0.7 5.8(0.7 3.0(0.4† 
 Remodeling (% of total vessels) 
   Non-muscularized (%) 79(1 22(3* 24(1 31(8† 13(3 10(2 18(2† 
   Partially muscularized (%) 26(1 35(3* 35(3 43(3† 13(2 12(2 22(5† 
   Totally muscularized (%) 6(1 35(3* 33(5 20(2.5† 39(5 41(4 48(4 
   Occlusive lesions (%) 0(0 12(2* 11(1 2(1† 33(3 32(3 11(2† 
PAH: Pulmonary arterial hypertension; Con: control; VEH: vehicle treatment; SCR: scrambled 
DNAzyme treatment; ED5: DNAzyme treatment
* P<0.05 Con vs VEH; † P<0.05 SCR vs ED5. Data presented as mean ± SEM.
Table 2. Pulmonary vascular remodeling
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stained positive for Egr-1 (Figure 3E). Pulmonary vascular Egr-1 expression cor-
related with pulmonary vascular remodeling (Figure 3G).
Egr-1 downregulation attenuated intra-acinar vessel occlu-
sion and flow-PAH development
Vascular Egr-1 downregulation due to ED5 delivery (PAH_ED5) attenuated pul-
monary vascular remodeling and occlusive vessel formation during disease de-
velopment (Figure 4, Table 1). Egr-1 downregulation reduced vessel occlusion 
and wall lumen ratio of the intra-acinar vessels at both 1 week and 3 weeks after 
increased blood flow (Figures 4A). Egr-1 downregulation furthermore resulted in 
Figure 3 Downregulation of pulmonary vascular Egr-1 expression  A) Schematic overview of the study de-
sign. All rats received MCT injection on day 1. At time of av-shunt creation (day 7) rats were randomly divided to 
receive vehicle, scrambled DNAzyme or ED5 treatment. Rats were sacrificed at 1 week and 3 weeks after shunt 
creation. B) Egr-1 expression in vehicle and scrambled DNAzyme treated rats showed similarities with Egr-1 
expression in human PAH associated with congenital heart disease. C) Egr-1 was located in both the medial 
and endothelial vessel layer in end stage disease (F). D) Chronic ED5 delivery (PAH_ED5) reduced pulmonary 
vascular Egr-1 protein expression with 35% and 43% at 1 and 3 weeks, respectively. This reduction in Egr-1 
protein expression was accomplished without reducing the total number of intra-acinar vessels that stained 
positive for Egr-1 (E). G) Pulmonary vascular Egr-1 expression correlated with pulmonary vascular remodeling. 
Data are presented as mean values ± SEM.  = P<0.05. Scale bare represents 50µm. VEH: vehicle treated rats, 
SCR: scrambled DNAzyme treated rats, ED5: DNAzyme treated rats.
A critical role for Egr-1 during neointimal development in pulmonary arterial hypertension
107
a reduction of the pRVSP, pulmonary vascular resistance and RVH (Figure 4B). 
Scrambled DNAzyme treatment (PAH_SCR) had no effect on any of the vascular 
remodeling or hemodynamic parameters analyzed. ED5 treatment had no effect 
on left ventricular mass (Table 1). 
Egr-1 downregulation attenuated vessel occlusion through 
early attenuation of vascular cell proliferation and end 
stage increase of apoptosis 
To investigate the molecular basis of Egr-1 inhibition on vascular remodeling, 
we studied the temporal expression of Ki67 (proliferation) and cleaved caspase 
3 (apoptosis) in the pulmonary vasculature during PAH development and ED5 
intervention. In vehicle and scrambled DNAzyme treated rats, both proliferation 
and apoptosis peaked one week after increased flow (Figure 5A). At 3 weeks 
after flow, vascular proliferation and apoptosis decreased although remaining 
higher than control (Figure 5A). Egr-1 downregulation caused a different kinetic 
Figure 4 Effects of pulmonary vascular Egr-1 downregulation  At 1 and 3 weeks after increased flow, 
Egr-1 downregulation using ED5 significantly attenuated both (A) pulmonary vascular remodeling and (B) PAH 
development as shown by a reduction in pulmonary vascular resistance, pRVSP and RV hypertrophy. Data are 
presented as mean values ± SEM.  = P<0.05 ED5 vs VEH and SCR.
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profile of vascular apoptosis (Figure 5A). At 3 weeks Egr-1 downregulation sig-
nificantly increased vascular apoptosis which was mainly seen in the endothelial 
layer (Figure 5B and Supplemental Figure S6). Egr-1 downregulation reduced 
the initial peak in vascular proliferation at 1 week after increased flow. This reduc-
tion was mainly in the endothelial layer (Figure 5B and Supplemental Figure S6). 
Since PDGF, a known downstream target of Egr-1, is known to induce vascular 
proliferation in human PAH, we investigated the effects of ED5 treatment on pul-
monary vascular expression of PDGF-B.29, 30 Pulmonary vascular PDGF-B ex-
pression was increased during vascular remodeling (PAH_VEH and PAH_SCR) 
at both 1 and 3 weeks (Figure 5C and 5D). Egr-1 inhibition resulted in a reduction 
of PDGF-B expression compared to vehicle and scrambled treatment (Figure 5C 
and 5D).
Figure 5 Mechanisms of pulmonary vascular changes due to Egr-1 downregulation A) Egr-1 downreg-
ulation resulted in a significant reduction of vascular proliferation (KI67) 1 week after flow and a significant 
increase in vascular apoptosis (Caspase3) 3 weeks after flow. B) Typical examples of the localization of Ki67 
and Caspase3 staining in intra-acinar vessels of the different study groups. Vascular proliferation and apoptosis 
was mainly in the intimal layer. C) Typical examples of PDGF-B staining (arrows) in intra-acinar vessels of the 
different study groups. D) PDFG-B expression was downregulated due to Egr-1 inhibition. Data are presented 
as mean values ± SEM. = P<0.05. Scale bare represents 50µm.
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ED5 delivery has no effect on vascular remodeling in non-neointimal non-flow PH
We have previously shown that Egr-1 expression is specific for flow-induced ne-
ointimal development.10 To further test whether the effects of Egr-1 downreg-
ulation are specific for flow-induced neointimal formation, we investigated the 
effects of ED5 delivery in a non-neointimal, non-flow-associated model of pulmo-
nary hypertension, namely monocrotaline only model (MCT_VEH vs MCT_ED5). 
In MCT-only PH rats vascular Egr-1 expression was only sporadically seen com-
pared to its expression in flow PAH rats (Figure 6A). Also, neointimal lesions 
were not observed (Figure 6B). MCT injection (MCT_VEH) resulted in a signifi-
cant increase in vessel wall thickness, increased pRVSP and RVH compared to 
Figure 6 ED5 treatment in non-flow non-neointimal PH  A) Egr-1 protein expression and localization (B) in 
the intra-acinar vessels at 3 weeks. In rats where pulmonary blood flow was not increased (MCT-only rats), 
Egr-1 was only sporadically seen and no neointimal lesions were formed. C) In these non-flow non-neointimal 
rats, ED5 administration had no effect on vascular remodeling, RV hypertrophy or pRVSP. Data are presented 
as mean values ± SEM.  = P<0.05. Scale bare represents 50µm.
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control (Figure 6C). ED5 treatment (MCT_ED5) did not alter vascular remode-
ling, pRVSP or RVH (Figure 6C) in MCT-only PH rats. 
Pharmacological downregulation of Egr-1 using pioglita-
zone also attenuates vascular remodeling in flow-PAH
Several currently used drugs, including peroxisome proliferator-activated recep-
Figure 7 Egr-1 downregulation using the PPAR-γ ligand pioglitazon A) Egr-1 protein expression in the in-
tra-acinar vessels 1 day and 1 week after increased flow. B) Typical examples of Egr-1 expression 1 week after 
increased blood flow. C) Preventive pioglitazon treatment attenuated pulmonary vascular remodeling, pRVSP 
and RV hypertrophy 1 week after increased flow. Data are presented as mean values ± SEM. = P<0.05. Scale 
bare represents 50µm. PIO 20: 20mg/kg/d pioglitazon treatment, PIO 100: 100mg/kg/d pioglitazon treatment. 
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tor-γ (PPAR-γ) ligands, have shown to inhibit Egr-1 expression in vivo.18-20 
Using the PPAR-γ ligand pioglitazone, we investigated whether Egr-1 could be 
pharmacologically inhibited and what its effects were on vascular remodeling. 
First, pioglitazone treatment activated PPAR-γ, as confirmed by increased PG-
C1α (co-activator of PPAR-γ) and MCAD (downstream gene of PPAR-γ) gene 
expression (Supplemental Figure S7). Pioglitazone reduced vascular Egr-1 ex-
pression in a dose dependent matter 1 day and 1 week after increased pulmo-
nary blood flow (Figure 7A and B). This was accompanied with attenuation of pul-
monary vascular remodeling (Figure 7C), including less extensive development 
of occlusive neointimal vessels and a reduction in RVH compared to vehicle 
treated flow-PAH rats (Figure 7C).
Discussion
In this study in experimental flow-associated PAH we investigated the effects of 
in vivo Egr-1 downregulation on pulmonary vascular remodeling including occlu-
sive neointimal development, and disease progression. Egr-1 downregulation, 
both via intravenous administration of catalytic oligodeoxynucleotides (DNA-
zymes) and pharmacological intervention using pioglitazone, attenuated pul-
monary vascular remodeling including the development of occlusive neointimal 
lesions, and reduced PAH progression. These results indicate that Egr-1 plays 
an important role in the induction and development of pulmonary vascular re-
modeling in flow-associated PAH. Egr-1 is therefore a promising target for future 
PAH treatment. 
Egr-1 is a transcription factor with pleotropic effects. Egr-1 is poorly expressed in 
the normal arterial wall but can be activated by various stimuli including chang-
es in shear stress.15, 31 In endothelial cells shear stress responsive elements 
(SSRE) on the 5’-flanking region of Egr-1 can be activated through activation of 
mitogen activated protein kinases (MAPKs) particularly extracellular regulated 
kinase (ERK) 1/2.15, 32, 33 In systemic vessels, Egr-1, once activated, has been 
shown to act as an early ‘master switch’ during vessel wall remodeling including 
intimal thickening, vascular proliferation and vessel inflammation.34-36 A role 




Here we demonstrate, for the first time, a functional role for the transcription 
factor Egr-1 in pulmonary vascular remodeling in PAH. Our results indicate that 
Egr-1-inhibition in vivo induces an increase in vascular apoptosis, and a reduc-
tion of vascular proliferation via PDGF-B downregulation. In human PAH de-
velopment, vascular proliferation and apoptosis resistant endothelial cells are 
recognized hallmarks of pulmonary neointimal formation.3, 37, 38 Egr-1 has been 
previously shown to induce neointimal formation in systemic arteries, in athero-
sclerotic disease and in-stent restenosis, mediated through both anti-apoptosis 
and pro-proliferative pathways.15, 21, 35 PDGF is known to induce proliferation of 
both smooth muscle cells and endothelial cells and is upregulated in human 
PAH.29, 39 Egr-1 is known to bind to the promoter region of PDGF-B resulting in 
increased expression of this isoform.30 The results of the current study, showing 
increased PDGF-B expression in experimental PAH and its reduction through 
inhibition of Egr-1, support the working mechanism of Egr-1 induced vascular 
proliferation through PDGF.  
Egr-1 could be a putative therapeutic target for future PAH treatment. We have 
previously shown that Egr-1 is present in human end-stage PAH associated with 
congenital heart disease.10 In these patients Egr-1 is located at sites that are 
interesting for treatment targeting, namely in vessels with media hypertrophy 
and in neointimal lesions.10 The positive effects of Egr-1 inhibition on vascular re-
modeling and PAH progression in this study supports future outlook of Egr-1 as a 
treatment target. The fact that these effects were seen in a PAH model that mim-
ics 1) a human pathological trigger, 2) complex vascular occlusion of intra-acinar 
vessels and 3) human PAH progression makes the critical role of Egr-1 in PAH 
development more convincing.13
Egr-1 could also be a putative target in other forms of PAH (e.g. idiopathic PAH) 
which would be important to test in future pre-clinical settings. However, a mod-
el that clearly mimics human iPAH (comparable pathological trigger, complex 
pulmonary vascular remodeling and progressive development) is currently lack-
ing.13 Still, increased Egr-1 expression has recently been found in remodeled 
arteries of idiopathic PAH patients, which suggests that Egr-1 could also form a 
target in iPAH patients.40 Combined, these observations in both human and now 
in experimental PAH justify future investigation in Egr-1 intervention either via 
gene silencing techniques or pharmacological treatment in PAH. 
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The rapid developments in the design of gene silencing agents could facilitate a 
novel approach for therapeutic intervention for the treatment of PAH. First anti-
sense oligonucleotide-based drugs have reached the clinic and have proved to 
be effective against for instance CMV infections and hypercholesterolemia.41, 
42 New generations of oligonucleotides such as DNAzymes or small interfer-
ing RNAs (siRNAs) have entered the clinical stage.24 In the current study we 
demonstrated that in PAH Egr-1 can be interfered in vivo using RNA interfering 
agents. Several types of clinically suitable carriers for siRNA delivery into pulmo-
nary endothelial cells have been developed 43 and could serve as an alternative 
for DOTAP mediated delivery in the future and increase specificity. In this study, 
even though we show that intravenous (jugular) ED5 infusion results attenuation 
of neointimal development, a causal link between vascular remodeling and im-
provement of RV function (lower pRVSP combined with less RV hypertrophy) is 
difficult to make. For instance, ED5 could possibly have a direct effect on pres-
sure induced RV hypertrophy. However, since we show Egr-1 downregulation 1) 
attenuates pulmonary vascular resistance in flow-PAH rats 2) has no effect on 
RV hypertrophy in MCT only treated rats and 3) has no effect on LV mass, it is 
most likely that the positive effects of ED5 treatment are to Egr-1 downregulation 
in the pulmonary vasculature.
Pharmacological downregulation of Egr-1 with clinically used drugs could also 
be an interesting pursuit. One of these pharmacological possibilities is the use of 
PPAR-γ ligands, such as pioglitazone. PPAR-γ ligands have previously shown to 
inhibit Egr-1 expression in vivo.18-20 These studies describe Egr-1 as a key re-
pressive target gene of PPAR-γ in different pathophysiological mechanisms. Ac-
tivation of PPAR-γ has been shown to prevent ERK phosphorylation in endothe-
lial cells 44 and SMCs45 which may affect Egr-1 activation pathways. In addition, 
recent studies have suggested that BMPR2 signaling dysfunction in PAH leads 
to failure of PPAR-γ activation resulting, in SMC proliferation in PAH.46 PPAR-γ 
ligands are also shown to have a positive effect on vascular remodeling in other 
pulmonary hypertension models.47, 48 However, these studies were conducted 
in a hypoxic PH model that is known to fail to induce the typical neointimal le-
sions and progressive PAH development, which limits translation to human dis-
ease. Our results in a neointimal model of PAH show that pioglitazone prevents 
pulmonary vascular remodeling and that this positive effect is associated with a 
downregulation of vascular Egr-1 expression. 
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This study was set up to investigate the role of Egr-1 in the development of neo-
intimal lesions. Therefore the question whether targeting Egr-1 also results in re-
versal of PAH (when neointimal lesions are already present) cannot be answered 
with the current study design. However, since Egr-1 is expressed in remodeled 
vessels of both experimental and human end-stage PAH, Egr-1 could very well 
be a target in established pulmonary vascular remodeling. The next step would 
therefore be assessing the effects of Egr-1 targeting in established disease. 
Conclusions
This study indicates that the transcription factor Egr-1 governs flow-induced pul-
monary vascular remodeling and the development of the characteristic vascular 
neointimal lesions in flow-associated PAH. Egr-1 therefore is a potential target 
for future PAH treatment. 
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Supplemental material and methods
DNAzyme preparation and transfection carrier 
For in vivo DNAzyme administration we first tested 2 different transfection carriers – 1,2-di-
oleoyl-3-trimethylammonium-propane (DOTAP; Avanti Polar Lipids, Alabaster, Alabama, 
USA) and polyethylenimine (in vivo jetPEI; Polyplus transfection, Illkirch, France) – known for 
targeting the pulmonary vasculature.(1) Sterile DOTAP solution (0.5 mg/ml) was prepared as 
follows. DOTAP stock solution in chloroform: methanol (9:1) was dried under reduced nitro-
gen pressure for 10 min and further dried under high vacuum for 30 min. Subsequently, dried 
lipid film was hydrated in sterile HN buffer (150 mM NaCl, 20 mM HEPES) pH 7.4 for 10 min 
and vortex vigorously. DOTAP solution was stored at 4 °C under argon gas and used within 
4 days. DNAzyme-DOTAP complex was prepared by mixing DOTAP solution with DNAzyme 
in 1:1 ratio w/w (500ug DNAzyme/500ug DOTAP) and allowing complex to form for 10 min 
before use. ED5-jetPEI complexes were prepared in 5% glucose according to manufactur-
er’s protocol using 7:1 ratio w/w (DNAzyme/PEI).  
In this study we demonstrated that, compared to ED5-jetPEI, a single injection of ED5-DO-
TAP solution (500ug DNAzyme/500ug DOTAP) in the jugular vein resulted in a significant 
ED5 uptake in the pulmonary vasculature and a reduction of vascular Egr-1 expression after 
24 hours (n= 4 rats; Supplemental Figure E1). For the detection studies of DNAzyme in vivo, 
6FAM was used as fluorescent label on the 5’ terminus of ED5 (Figure 1).
Echocardiography
Briefly, cardiac output (CO) was calculated using systolic aorta diameter and pulsed wave 
Doppler of aorta flow as (aorta diameter)2 × 3.14 × velocity time integral (VTI) x heart rate. 
Pulmonary artery acceleration time (PAAT) was measured in the RV outflow tract, and tricus-
pid annular plane systolic excursion (TAPSE) was measured in apical 4-chamber view. 
Pathology and morphometric analysis 
Heart and lungs were excised and weighed separately. The right lung was frozen in liquid 
nitrogen for molecular analysis. The left lung was fixated by passive filling of the airways with 
3.6% formalin and embedded in paraffin. Pulmonary vascular morphology (n=6-7 rats per 
experimental group) was qualitatively and quantitatively analyzed.
Intra-acinar vessels without a clearly defined internal lamina elastica combined with luminal 
occlusion were defined as occlusive neointimal lesions. Intra-acinar vessels with a double 
lamina elastica for more than half of its circumference were defined as completely muscular. 
Intra-acinar vessels with a double lamina elastica for less than half of its circumference were 
defined as partially muscular. Normal, non-muscular, intra-acinar vessels had a single lamina 
elastica and no luminal occlusion. 
Five-ten randomly chosen pre-acinar vessels (> 50 μm) and 40 randomly chosen intra-acinar 
vessels (< 50 μm) were assessed using Image Scope (Aperio Technologies version 10). 
Three different vascular areas were defined: outer vessel area, inner vessel area and luminal 
area. The outer vessel area was defined as the area within the lamina elastica externa. The 
inner vessel area was defined as the area within the lamina elastica interna. The medial area 
was defined as the outer vessel area minus the inner vessel area. 
The occlusion score for the intra-acinar pulmonary vessels was calculated according to    the 
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following formula: (outer vessel area – luminal area) / (outer vessel area) and presented as 
the mean (± SD) percentage of vessel occlusion per time point.
Muscularization per time point was assessed and presented as the percentage of vessels per 
degrees of muscularization (including neointimal formation).
Immunohistochemistry 
Paraffin-embedded rat lung sections were microwave heated for antigen retrieval. To reduce 
non-specific staining, sections were preincubated in 0,3% hydrogen peroxide. Sections were 
then embedded for 1h at room temperature with primary. Species-specific immunoglobulin G 
coupled to peroxidase was used as secondary and tertiary antibodies (DAKO, 1:100 dilution). 
Sections were stained with diaminobenzidine for 10 min and counterstained with hematoxy-
lin. For immunofluorescence nuclei were stained with DAPI (Vector Laboratories Inc.).  As an 
example for Egr-1 staining in human PAH, a human lung tissue sample was obtained from an 
explanted lung from a patient with PAH associated with congenital cardiac shunt (VSD+PDA) 
that underwent lung transplantation.
Egr-1 positive control staining was performed on prostate adenocarcinoma samples. In ad-
dition, bronchial staining of Egr-1 served as positive control within the sample. Negative con-
trols for all secondary antibodies were tested. 
Staining was semi-quantified (n=4-6 rats per experimental group) to characterize spatiotem-
poral expression of the proteins Egr-1, Caspase 3 and Ki67. Twenty intra-acinar vessels were 
randomly selected per rat. Vessels were scored as followed: a) positive Egr-1 expression (0: 
no staining; 1: positive staining), b) localization of Egr-1 expression (0: no staining; 1: positive 
staining mainly in endothelium, 2: positive staining mainly in media and 3: diffuse positive 
staining) and c) amount of positive Egr-1 cells per vessel. Endothelium was defined as the 
cell layer bordering the vessel lumen. In non-neointimal vessels, media was defined as the 
layer between outer elastic layer the cell layer bordering the vessel lumen. 
Real-time RT-PCR
For PPAR-γ activation, gene expression of PGC1α (co-activator of PPAR-γ) and MCAD 
(downstream gene of PPAR-γ) were measured. For real-time RT-PCR of whole lung sam-
ples (n=3-5 per group), commercially available kits were used.  Total RNA was isolated from 
pulmonary tissue using TRIzol reagent (Invitrogen). Real-time RT PCR experiments were 
performed on a CXF384 real time system C1000 Thermal cycler (BioRad Laboratories, 
Veenendaal, The Netherlands). cDNA was synthesized using QuantiTect Reverse Transcrip-
tion Kit (Qiagen, Benelux). Real-time RT PCR was conducted using SYBR Green PCR Mas-
ter Mix according to the manufacturer’s instructions (Eurogentec, San Diego, CA). Primer se-
quences are available on request. Expression levels were obtained from a dilution standard 




Figure S1 Pilot study: targeting pulmonary vasculature with DNAzyme ED5 A) Pulmonary vascular locali-
zation of ED5 (6FAM fluorescent signaling) after a single injection combined with either DOTAP of PEI for facil-
itation of cell transfection. Note the strong presence of ED5 in the combination with DOTAP at 6 and 24 hours 
post injection. PEI did not result in pulmonary vascular cell transfection. B) transfection of ED5 with DOTAP 
(PAH_DOTAP) resulted in a reduced pulmonary vascular Egr-1 expression compared to saline injected rats 
(PAH_VEH). PEI (PAH_PEI) had no effect on Egr-1 expression. Data are presented as mean values ± SEM. 
= P<0.05. Scale bare represents 50µm.
Figure S2 Peripheral blood work results ED5 treatment did not result in a systemic immune response (as 
measured by leucocyt count, hematocrit (Ht), hemoglobin (Hb)) or decreased liver function (as measured by the 
liver enzymes aspartate transaminase (ASAT), alanine transaminase (ALAT); and albumin production) meas-
ured in peripheral blood. Data are presented as mean values ± SEM. Dotted lines indicate normal range for 
each parameter.
A critical role for Egr-1 during neointimal development in pulmonary arterial hypertension
121
Figure S3 Similarities in sham operated animals Pulmonary vascular remodeling (occlusion score, wall 
thickness), RV hypertrophy (RV/IVS+LV) and peak systolic right ventricular pressure (pRVSP) in sham oper-
ated rats that received either vehicle treatment of ED5. ED5 treatment had no effect on pulmonary vascular 
remodeling, RV remodeling or pRVSP in control animals. Data are presented as mean values ± SEM. 
Figure S4 Correlation between the wall thickness of the intra-acinar vesssels and hemodynamic parameters 
and right ventricular hypertrophy. Data are presented as mean values ± SEM.  = P<0.05.
Chapter 5
122
Figure S5 Localization of Egr-1 expression in pulmonary vasculature
Figure S6 Localization of Ki67 and Caspase 3 expression in pulmonary vasculature. Proliferation and 
Caspase 3 was mainly found in the intimal layer of the pulmonary vessels.
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Figure S7 PPAR-γ activation. Expression of peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (PGC1α) and medium-chain acyl-CoA dehydrogenase (MCAD) as a readout for PPAR-γ activation. 
Pioglitazon treatment increased PGC1α (co-activator of PPARγ) and MCAD (downstream gene of PPARγ) 
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Background: In pulmonary arterial hypertension (PAH) due to congenital heart 
disease, increased pulmonary blood is an essential trigger for pulmonary vas-
cular remodeling, specifically neointimal development. We have recently shown 
that the transcription factor Egr-1 plays a critical role in the development of neo-
intimal lesions in experimental flow-PAH. However, it is unknown whether Egr-1 
is also associated with neointimal development in human PAH.
Methods: Using immunoshitochemistry, pulmonary vascular Egr-1 expression 
and localization was studied in lung samples of end stage PAH patients associat-
ed with congenital shunt (flow PAH; n=12) and iPAH (n=18); and compared with 
non-neointimal PH (hypoxic PH; n=4) and healthy controls (n=10). 
Results: Pulmonary vascular Egr-1 expression was specifically increased in ne-
ointimal remodeling both in patients with flow-PAH and in those with iPAH com-
pared to control patients, whereas it was not increased in hypoxic (non-neointi-
mal) PH. In PAH, increased Egr-1 expression was seen in both pre-acinar and 
intra-acinar vessels with the strongest expression in the intimal layer. In addition, 
flow-PAH showed even more increased Egr-1 intimal expression compared to 
iPAH.
Conclusions: Here we identify pulmonary vascular Egr-1 to be specifically up-
regulated in patients with neointimal-type of vascular remodeling in PAH when 
compared to non-neointimal remodeling in hypoxic PH and to control vessels. 
This data adds to the accumulating evidence that Egr-1 could play a major role 




In Pulmonary Arterial Hypertension (PAH) remodeling and obstruction of the 
small pulmonary arteries leads to an increased pulmonary vascular resistance, 
right ventricular failure and eventually death. Where thickening of the medial and 
adventitial layer of the pulmonary arterioles is seen in many forms of PH (e.g. 
PH associated with hypoxemia or left heart disease), PAH is additionally char-
acterized by the development of typical neointimal lesions, including concentric 
laminar intimal fibrosis and plexiform lesions.(1) When these neointimal lesions 
have formed PAH is considered irreversible.(2) Although the histomorphology of 
neointimal lesions is well described, the pathogenesis of PAH and neointimal 
development is largely unknown. 
PAH occurs idiopathically (iPAH), associated with genetic defects (heritable) or 
associated with specific conditions (3), such as congenital heart diseases.(4) In 
patients with congenital heart disease who develop PAH, increased pulmonary 
blood flow (i.e. systemic-to-pulmonary shunt) is seen as an essential trigger for 
the development of neointimal lesions and disease progression.(5, 5) Here, in-
creased pulmonary blood flow is regarded an inductor of disturbed blood flow in 
the pulmonary vasculature, resulting in the development of neointimal lesions.(3) 
Still, the pathogenic mechanism behind flow-induced neointimal development in 
PAH is insufficiently known. Recently we identified the transcription factor Egr-1 
(early growth response protein 1) to be upregulated specifically by increased pul-
monary blood flow in the pulmonary vessels and strongly expressed in neointimal 
lesions in end stage disease of experimental, flow-associated PAH.(6, 7) Egr-1 is a 
transcription factor that is known to be upregulated by specific triggers, including 
changes in pulmonary blood flow.(8, 9) In systemic vessels, Egr-1 has shown to 
play a major role in a variety of cardiovascular processes such as intimal thicken-
ing, vascular proliferation and vessel inflammation.(10-12) However, it is unknown 
whether Egr-1 is also associated with neointimal development in human PAH.
For this study, we hypothesized that 1) Egr-1 expression is upregulated in human 
PAH associated with congenital heart disease (flow-PAH) compared to control, 
2) Egr-1 is also upregulated in other forms of human PAH (iPAH) and 3) Egr-1 is 
not upregulated in hypoxic (non-neointimal) PH. 
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Materials and Methods
Study population and tissue preparation
Thirty-one PAH subjects (12 PAH associated with congenital cardiac shunt (flow-
PAH) and 19 subjects with i(diopathic) PAH) who underwent lung transplanta-
tion for end stage disease in the University Medical Center Groningen Between 
1991 and 2009 and from whom lung tissue were available, were included in this 
study.  For the investigation of Egr-1 in hypoxic PH, 4 subjects were included with 
pulmonary hypertension due to lung disease / hypoxia (COPD) who underwent 
lung transplantation due to end-stage disease. For control (n=10), lung tissue 
from subjects with disease free lung parenchyma was obtained from autopsy and 
lobectomy. Patient data were collected from hospital medical records according 
to a standardized case report form and included diagnosis, functional class and 
capacity, invasive hemodynamic measurements and treatment. From each sub-
ject 2 blocks of formalin fixed, paraffin embedded lung tissue were used. From 
each block 10 serial sections of 5 µm thickness were obtained. For morphometric 
identification sections were stained with both hematoxylin/eosin and Verhoeff’s 
Stain. Pulmonary vascular vessels were identified as either pre-acinar (large; 
>150 µm) or intra-acinar (small; <150 µm). Our Institutional Medical Ethics Com-
mittee waived the need of patient consent in this retrospective study, because 
individual patients were not identified.
Immunohistochemistry and quantification analysis
Paraffin-embedded lung sections were microwave heated for antigen retrieval. 
To reduce non-specific staining, sections were preincubated in 0,3% hydrogen 
peroxide. Sections were then embedded for 1h at room temperature with pri-
mary antibodies of Egr-1 (Abcam, 1:100 dilution) αSMA (DAKO, 1:50 dilution) 
CD31+ (Invitrogen, 1:00 dilution). Species-specific immunoglobulin G coupled 
to peroxidase was used as a secondary antibody (DAKO, 1:100 dilution). The 
sections were stained with diaminobenzidine for 10 min and counterstained with 
hematoxylin. For positive control for Egr-1 staining, prostate adenocarcinoma 
samples were used. In addition, bronchial staining of Egr-1 served as positive 
control within the sample. Negative control (by replacing the primary antibody 
with phosphate buffered saline) showed no staining for all secondary antibodies. 
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As described, pulmonary arteries were divided in two groups: pre-acinar vessels 
(>150 µm) or intra-acinar vessels (<150 µm). For each vessel, the intimal layer 
and the medial layer were separately assessed. The intimal layer was defined 
as the cell layer between the vessel lumen and the lamina elastica interna. The 
medial layer was defined as the layer between the lamina elastica interna and 
the lamina elastica externa. Vessels were semi-quantatively scored for Egr-1 
expression, as follows: 1) positive Egr-1 expression (0: no staining, 1: minimal 
staining, 2: medium staining, 3: strong staining) and 2) quantification of numbers 
of cells with Egr-1 expression (1: less than 50% of cells positive for Egr-1 per 
vessels layer, 2: 50-80% of cells positive for Egr-1 per vessel layer, 3: more that 
80% positive for Egr-1 per vessel layer). For total Egr-1 score, Egr-1 expression 
(1-3) was multiplied by Egr-1 quantification (1-3) for a maximum score of 9. Plexi-
form lesions and vessels that were severely occluded were excluded from the 
semi-quantative analysis since these vessels show distinct differences in mor-
phology prohibiting comparison with control and hypoxic PH. For all analyses, 
slides were blinded making the diagnosis of the patient unknown.
Statistics
Data are presented as mean ± standard error of the mean. Differences between 
groups were determined by one-way analysis of variance (ANOVA) with Bonfer-
roni post-hoc test. A P-value of less than 0.05 was considered to be significant. 
Statistical analyses were performed using SPSS (version 20).
Results
Patient characteristics
Forty-four patients were enrolled in the current study. Twelve subjects with flow-
PAH, 18 subjects with iPAH, 4 subject with PH due to COPD and 10 control sub-
jects. One iPAH subject was excluded from the study due to insufficient quality 
of the tissue specimen. The clinical and hemodynamic characteristics of the pa-
tients are listed in Table 1. Anatomic diagnoses of the congenital heart diseases 
of the flow-PAH group are shown in table 2.
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Morphology pulmonary vessels
Intra-acinar pulmonary vessels in PAH subjects (flow-PAH and iPAH) showed 
characteristic vascular remodeling, as described previously.(1) Intra-acinar ves-
sels were characterized by advanced pulmonary vascular remodeling including 
vessels with media hypertrophy, intimal proliferation, laminal concentric intimal 
fibrosis and plexiform lesions (Figure 1) Pre-acinar vessels revealed mainly in-
creased muscularization combined with intimal proliferation and fibrosis. 
In subjects with hypoxic PH, increased muscularization of pre– and intra-acinar 
vessels was observed without the occurrence of intimal fibrosis (Figure 1). In 
control subject intra-acinar vessels were mainly non-muscularized. Pre-acinar 
pulmonary vessels in control subjects were muscular with a single layer of en-
dothelial cells (Figure 1).
Increased expression of pulmonary vascular Egr-1 in flow-
PAH
To test whether Egr-1 is specifically upregulated in neointimal remodeling in PAH 
associated with congenital cardiac shunting, we compared pulmonary vascular 
Egr-1 expression in flow-PAH subjects with control subjects. 
In flow-PAH, pulmonary vascular Egr-1 expression score was increased com-
 
Characteristics Con Hypoxic PH Flow-PAH iPAH 
Gender (% male) 50 100 33 44 
Age (years) 63(3 58(2 32 (3 42(3 
BMI 25(1 25(2 20(1 22(1 
WHO 3 / 4 - - 4 / 8 13 / 5 
6mWT (m) - - 226 ± 78 333 ± 140 
Systemic pressure (mmHg)         
    systolic - - 116 ± 12 111 ± 16 
    diastolic - - 66 ± 3 71 ± 3 
mPAP (mmHg) - - 69 ± 16 (8) 64 ± 13 (18) 
Cardiac Index     2,8 ± 0,5 2,4 ± 0,1 
Qp (l) - - 4,2 ± 2,3 (6) 4,2 ± 1,5 (18) 
Qp/Qs ratio - - 0,8 ± 0,1 (10) 1,0 ± 0,13 (18) 
PVR (dyn/s/cm5) - - 899  ± 462 (6) 1024 ± 428 (18) 
Con: control; PH: Pulmonary Hypertension; PAH: Pulmonary Arterial Hypertension; BMI: body mass index; 
6mWT: 6 minute walk test; mPAP: mean pulmonary artery pressure; Qp: pulmonary blood flow; Qs: systemic 




Figure 1 Representative pulmonary vascular arteries in control, hypoxic PH and flow-PAH subjects. A) 
Pre-acinar vessels (>150µm) in the different groups. Note the marked intimal proliferation (arrow) in the flow-
PAH group. In these vessels Egr-1 expression was clearly seen throughout the vessel wall. In both Control and 
hypoxic PH neointimal formation was not seen.  B) Intra-acinar vessels (<150µm) with characteristic neointimal 
lesions in flow-PAH. In these vessels Egr-1 expression (arrows) was seen both in the endothelial and medial 
layer. The intimal layer showed the strongest Egr-1 expression.
pared to controls (Figure 1-3).  In these PAH-subjects vascular Egr-1 expression 
was found in a wide spectrum of vessels, ranging from intra-acinar vessels with 
muscularization to neointimal lesions (Figure 2). Strongest Egr-1 expression was 
found in advanced lesions (laminar concentric intimal fibrosis and plexiform le-
sions; (Figure 3,4). In control subjects with normal pulmonary vessels Egr-1 ex-





Hypoxic PH Flow-PAH 
A. 
B. Control 
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Flow-PAH 
subject 
Anatomical Diagnosis  Time diagnosis 




1 VSD+PDA 33 0 1 
2 TGA+AVSD+SV 31 0 1 
3 ASD II 10 0 1 
4 VSD+PDA 21 0 0 
5 ASD II 33 0 1 
6 TGA+AVSD 24 0 1 
7 TGA 41 1 1 
8 VSD+PDA 16 1 1 
9 ASD II+TAPVD 2 0 1 
10 ASD II 2 0 1 
11 VSD 9 0 0 
12 TGA+SV 22 0 0 
 PAH: Pulmonary Arterial Hypertension; LTx: lung transplantation; VSD: ventricular septum defect; PDA: per-
sistent ductus arteriosus; TGA: transposition of the greater arteries; AVSD: atrioventricular septum defect; SV: 
single ventricle; TAPVD: total anomalous pulmonary venous drainage.
Table 2
pression was only found sporadically throughout the vessel wall (Figure 2).
In flow-PAH, Egr-1 expression was most abundant in the intimal layer bordering 
the vessels lumen (Figure 1,3). In addition, Egr-1 was also expressed in the me-
dial layer (Figure 1,3). In these subjects, quantification analysis revealed a higher 
Egr-1 expression score in the intra-acinar vessels compared to the pre-acinar 
vessels. (Figure 3). In vessels with concentric intima fibrosis Egr-1 expression 
was found in cells throughout the vessel wall (Figure 2,3). In the most advanced 
lesions, Egr-1 was strongly expressed in plexiform lesions (Figure 4A). Immu-
nostaining for CD31+ and αSMA in serial sections showed that strong Egr-1 
expression was found in endothelial cells lining the plexus channels (Figure 4B). 
Increased expression of pulmonary vascular Egr-1 
in iPAH
To study whether Egr-1 expression is also upregulated in other forms of PAH, we 
investigated Egr-1 expression in pulmonary vascular lesions in iPAH. In these 
subjects, strong Egr-1 staining was also found in both pre- and intra-acinar ves-
sels (Figure 5).,Quantification analysis revealed that Egr-1 expression score in 
the intimal layer of the intra-acinar vessels was higher compared to controls, but 
lower when compared to flow-PAH (Figure 3. In iPAH subjects, the strongest ex-
pression was found in plexiform lesions, specifically in the intimal layer bordering 
the lumen, as in flow-PAH (Figure 5). 
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Figure 2 Different forms of pulmonary vascular remodeling in flow-PAH. Egr-1 expression is seen in all 
these different forms of vascular remodeling (black arrow). Note the occasional negative cells in the medial 
layer of vessels with media hypertrophy and in neointimal lesions (dotted arrow) whereas in the intimal layer, 
almost all cells stain positive for Egr-1. 
Pulmonary vascular Egr-1 expression is not increased in 
hypoxic PH
Finally, Egr-1 expression was studied in pulmonary vessels of hypoxic PH pa-
tients to test whether Egr-1 is also expressed in non-neointimal form of PH. 
In hypoxic PH, Egr-1 expression was only found sporadically throughout the ves-
sels wall (Figure 1). Egr-1 expression score did not differ in hypoxic PH when 
compared to control subjects and, concordantly, was lower compared to PAH 
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Figure 3 Semi-quantative scoring of Egr-1 in both the intimal layer and the medial layer of pre- and in-
tra-acinar vessels in control, hypoxic PH and flow-PAH subjects. In flow-PAH, pulmonary vascular Egr-1 ex-
pression was increased compared to both hypoxic PH and control. Egr-1 expression was most abundant in the 
intimal layer of the small intra-acinar vessels. * P<0.05  vs Con, † P<0,05 flow-PAH vs iPAH, ‡ vs hypoxic PH.
Discussion
In this study we investigated differences in pulmonary vascular Egr-1 expression 
between different types of pulmonary arteriopathy (flow-PAH, iPAH and hypoxic 
PH) and controls vessels Pulmonary vascular Egr-1 expression was specifically 
increased in neointimal remodeling both in patients with flow-PAH and in those 
with iPAH compared to control patients, whereas it was not increased in hypox-
ic (non-neointimal) PH. In PAH, increased Egr-1 expression was seen in both 
pre-acinar and intra-acinar vessels with the strongest expression in the intimal 
layer. In addition, flow-PAH showed even more increased Egr-1 intimal expres-
sion compared to iPAH. These results confirm that increased pulmonary vascular 
Egr-1 expression is specifically associated with neointimal remodeling in PAH.
Egr-1 has been suggested to play a major role in the development of pulmonary 
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Figure 4 Egr-1 expression in plexiform lesions in flow-PAH. A) Representative Egr-1 expression in different 
plexiform lesions. Note the strong staining of the cells bordering the lumen. B) Examples of different staining 
(H&E, αSMA, CD31+) of a plexiform lesion show that these cells expressing Egr-1 are predominantly CD31+ 
endothelial cells. 
vascular remodeling in PAH. Egr-1 is a transcription factor that can be activated 
by triggers known to play a role in PAH including changes in vascular wall shear 
stress. In the normal arterial wall Egr-1 is poorly expressed but is known to be 
activated, via the extracellular regulated kinase (ERK) 1/2 pathway(8, 9, 13), by 
disturbed shear stress as seen in PAH associated with systemic-to-pulmonary 
shunting.(8, 10) Once activated, Egr-1 is capable of activating or repressing gene 
transcription of a wide variety of genes, including genes known to play a role in 
the pathogenesis of PAH such as TGF-β, PDGF and Tissue Factor. (14-17) 
The concept of Egr-1 as factor in flow-associated PAH was already supported by 
our previous observations in a PAH rodent model where we identified Egr-1 to be 
specifically upregulated in pulmonary vessels directly after induction of increased 
pulmonary blood flow but also in advanced disease.(7) In the latter study, Egr-1 
was found in pulmonary endothelial cells in early stages of the disease, whereas 
it was found throughout the wall in end–stage disease. Subsequently, we recent-
ly showed in this animal model,  that inhibiting Egr-1 directly using catalytic de-
oxynucleotides, resulted in attenuation of neointimal development and PAH pro-
gression.(18) Attenuation of neointimal development due to Egr-1 inhibition was 
accompanied by a reduction of vascular proliferation and an increase in vascular 
apoptosis, both hallmarks of vascular remodeling in human PAH.(18) These pre-
H&E 
Egr-1 CD31+ 
SMA A. B. 
Egr-1 CD31+ 
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Figure 5 Localization of Egr-1 in iPAH Representative example of Egr-1 expression in advanced pulmonary 
vascular lesions in iPAH. Note the strong Egr-1 staining of the cells bordering the lumen similar to flow-PAH 
subjects
clinical results suggest that Egr-1 plays a crucial role in neointimal development 
in PAH. The current study now indicates that also in human PAH, Egr-1 may be 
specifically involved in the characteristic neointimal-type of pulmonary vascular 
remodeling, seen in PAH.
This study found increased Egr-1 expression in patient with advanced PAH (both 
flow-PAH and iPAH), suggesting that besides the ability to initiate neointimal vas-
cular remodeling in PAH, Egr-1 could also maintain the process of neointimal 
development,. These results are in line with recent observations of Kwapisze-
wska et al that showed Egr-1 mRNA and protein expression to be increased in 
remodeled arteries of iPAH patients.(19) We now describe for the first time the 
localization of Egr-1 expression in the vessel wall in human PAH. The localization 
of Egr-1 throughout the vessel wall in end-stage lesions was previously report-
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ed in our experimental PAH model.(7) Also, Egr-1 expression in this pre-clinical 
PAH model was neointimal specific, since Egr-1 was only sporadically detected 
in non-neointimal PH rodents (monocrotaline injected rats), and thus far less 
that PAH rodents with neointimal lesions. These findings are also in line with our 
current results where Egr-1 expression is increased in PAH vessels character-
ized by neointimal remodeling compared to hypoxic PH characterized solely by 
muscularization. These studies combined suggest that 1) Egr-1 is specific for 
neointimal remodeling and is plays an important role in both early induction and 
later maintenance of neointimal development in flow-PAH and 2) Egr-1 could 
also play a critical role in other forms of PAH.
Could Egr-1 be a target for future PAH treatment? The fact that recent Egr-1 
downregulation in an experimental neointimal PAH model showed a positive ef-
fect on neointimal and disease attenuation(18) is a first step, justifying the con-
sideration of Egr-1 targeting in human disease. In order to be feasible as a target 
in PAH treatment, Egr-1 downregulation must not only prevent, but also be able 
to reverse neointimal development. Future studies are required to prove this po-
tential in vivo. 
In our study in hypoxic patients, Egr-1 was only sporadically expressed within 
pulmonary vessels characterized by media hypertrophy. Paradoxically, Egr-1 has 
been shown previously to be upregulated in lung tissue(20, 21) and isolated fi-
broblasts(22) subjected to chronic hypoxia. Yan and colleagues showed that Egr-
1 can be expressed in lungs of mice subjected to a various range of hypoxia(21) 
However, that study quantified Egr-1 expression levels in whole lung material 
and not selectively in the pulmonary vessels. In addition, the oxygen levels in 
this study (6-10%) were far lower than in human disease settings which makes 
translation of these results to human hypoxic PH difficult. 
In this study we show that increased Egr-1 expression is specific for the neoin-
timal-type of vascular remodeling in PAH, in end-stage disease. Experimental 
data has shown us that Egr-1 is also increased in very early stages of pulmonary 
vascular remodeling in PAH.(7) In this respect human data is still lacking. There-
fore, future studies investigating early reversible stages of PAH are needed to 
better understand the actual temporal expression of Egr-1 in human PAH. Unfor-
tunately, iPAH is mostly diagnosed in an advanced stage of the disease and lung 
tissue of early stage will not likely be available. However, PAH associated with 
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CHD, is rather unique in this respect, since it is the only form of PAH in which an 
early, reversible stage of the disease can be clinically recognized. This makes it 
feasible to collect lung biopsy tissue during the surgical correction of the heart 
defect. PAH associated with CHD is therefore a suitable form of PAH for further 
investigation of Egr-1-expression in the early stages of the disease. 
Conclusions
In the current study we identify pulmonary arterial Egr-1 to be specifically upreg-
ulated in patients with neointimal-type of vascular remodeling, both in flow-PAH 
and in iPAH, when compared to medial, non-neointimal remodeling in hypoxic 
PH and to control vessels. This data adds to the accumulating evidence that Egr-
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Abstract
Background: In patients with advanced pulmonary arterial hypertension (PAH), 
receiving epoprostenol treatment, complications due to the delivery system are 
known to be a cause of serious morbidity and mortality. 
Objective: To outline the complications associated with the use of a totally im-
plantable access port (TIAP) and their consequences in continuous intravenous 
epoprostenol treatment and to identify related risk factors
Methods: 111 pulmonary hypertension (PH) patients treated with epoprostenol 
through a TIAP between May 1998 and July 2006 at three Dutch PH referral 
centers were retrospectively studied.
Results: During a mean follow-up period of 946 days ± 719, TIAP-related com-
plications included local port site infections, bloodstream infections, port site skin 
perforations and incorrect port placement, with incidence rates of 0.11, 0.15, 0.06 
and 0.04 per patient-year respectively. Fatal, serious, moderate and minor con-
sequences of these complications had incidence rates of 0.01, 0.50, 0.09 and 
0.01 per patient-year, respectively. The median complication-free survival was 
371 days. Staphylococcus aureus was the dominant infectious agent. The me-
dian TIAP life was 677 days. Female patients showed a significantly longer first 
TIAP survival (P = 0.004).
Conclusions: The use of a TIAP showed a long-lasting port survival and relatively 
low complication rates. Our data suggests that the TIAP is well suited for contin-




Pulmonary hypertension (PAH) is a life-threatening disorder characterized by el-
evated pulmonary artery pressure and pulmonary vascular resistance, and can 
eventually lead to right ventricular failure and death.(1-4) Without treatment, the 
median survival of patients with PAH is 2.8 years.(4) Continuous intravenous ad-
ministration of epoprostenol, a prostacyclin analogue, is an effective therapy for 
selected patients with this disorder.(6-10)
This type of treatment, however, requires demanding care from both the pa-
tient, as well as the healthcare infrastructure. In general, percutaneous tunneled 
catheters, such as the Hickman or Broviac catheter, are used for continuous 
administration of epoprostenol.(1-14) Complications related to the use of indwell-
ing catheters represent a substantial risk for these patients. This can result in 
a significant decline in catheter life and extra hospital admissions, affecting the 
patient’s quality of life. 
The totally implantable access port (TIAP) is an alternative device for central ve-
nous access and has been extensively used for intermittent drug delivery in on-
cology.(15) This subcutaneously implanted port has a silicone membrane, which 
is punctured transcutaneously with a small needle. Using the TIAP, the natural 
barrier of the skin is left relatively intact and the risk of infectious complications 
has been demonstrated to be lower compared to percutaneous tunneled cathe-
ters in settings of intermittent drug delivery.(15-21) 
Due to the ports’ easy-to-handle features and the benefits seen in intermittent 
use, three referral centers for pulmonary hypertension (PH) in The Netherlands 
have been using these subcutaneous ports over the last ten years in patients 
requiring continuous intravenous epoprostenol therapy. 
The TIAP, however, has not been primarily designed for chronic, continuous use, 
and until now efficacy and complication rates of continuous intravenous epo-
prostenol therapy using an implantable port in patients with advanced pulmonary 
hypertension have not been reported. 
We therefore retrospectively studied 111 consecutive patients with pulmonary 
hypertension who were treated with chronic, continuous epoprostenol using a 
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TIAP. The aims of this study were to describe complication rates – and the con-
sequences of these complications – due to TIAP use in the treatment of PH with 
continuous intravenous epoprostenol and to identify risk factors for TIAP-related 
complications. 
Materials and methods 
Patients
Our Institutional Medical Ethics Committee waived the need of patient consent in 
this retrospective study, because individual patients were not identified. Between 
May 1998 and July 2006, 111 consecutive patients – 93 PAH patients and 18 pa-
tients with PH associated with chronic thromboembolic lung disease – were treat-
ed with epoprostenol (Flolan·, GlaxoSmithKline BV, The Netherlands) through 
a TIAP (Port-a-Cath®, Smiths Medical Inc. Benelux) at three referral centers for 
pulmonary hypertension in The Netherlands. 
TIAP placement was performed using hospital protocols. Ports were placed sub-
cutaneously with the port line inserted into the subclavian or internal jugular vein. 
All patients were trained in sterile technique and catheter care by a standardized 
hospital and home care program. The non-coring Huber needle was replaced 
once every 3 weeks. A transparent autocollant dressing (Tegaderm®) – replaced 
once a week – covered the needle insertion point. The pump line was replaced 
once a week under aseptic conditions with both ends sterilized before being re-
attached. Indication for blood culture was based on clinical suspicion for infection 
by the treating physician.
Patient treatment and follow-up were performed in the same centre. According to 
standardized treatment protocol, all complications related to the use of the TIAP 
requiring medical attention were reported to and treated in (or in cooperation 
with) the referral centre. Therefore, no complications requiring medical attention 
occurred unnoticed. 
Data collection
Patient data (Table 1) were collected from hospital medical records according to 
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a standardized case report form. Documentation of complications included type 
of complication, date of onset, clinical symptoms, local and blood culture results, 
date of resolution and consequences. The start and – if applicable – end date of 
epoprostenol treatment were recorded. The number of TIAPs per patient was re-
corded including insertion dates, TIAP removal and reason(s) for removal. Death 
was recorded, including date and cause.  
 
 
 N (%*) Mean ( SD† 
Age in years (mean) 44    
     Range 2-74    
Sex    
     Male  25 (23)  
     Female   86 (77)  
WHO classification     
     II 4  (4)  
     III 53 (48)  
     IV 54 (49)  
Cause of PAH    
     Idiopathic 45 (41)  
     Familial  11 (10)  
     Collagen vascular disease  16 (14)  
     Congenital heart disease  11 (10)  
     Portal hypertension / liver disease 7  (6)  
     HIV infection 1  (1)  
     Drugs / toxins  1  (1)  
     Gaucher disease type 1 1  (1)  
     PH associated with chronic 
thromboembolic disease  
18 (16)  
    
Clinical characteristics‡    
     MPAP 108  59 ( 14 
     Blood pressure     
       Systolic  109  113 ( 20 
       Diastolic 110  74 ( 13 
     tcSat. % 103  91 ( 6 
     Borg dyspnoea 51  5 ( 2 
     6 min WT 66  305 ( 127 
     BMI 85  24 ( 5 
Table 1. Summery of patient characteristics at initiation of epoprostenol  
treatment
* Percentages do not always add up to 100, due to rounding.
† Mean ± standard deviation.
‡Numbers do not add up to 111, due to data missing.
mPAP indicates mean pulmonary arterial pressure; blood pressure was measured non-invasively; 
tcSat indicates systemic arterial saturation measured transcutaneously; 6 min WT indicates 6 
minute walk test; BMI indicates Body Mass Index. 
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Definitions of complications and consequences
Based on previous literature (8-10) and clinical experience, complications and their 
consequences were defined as shown in table 2.
Statistical analysis
Patient characteristics are presented as either mean ± standard deviation or me-
dian and range. Kaplan-Meier analyses were used for catheter survival and com-
plication-free survival studies. Cox regression models were carried out to identify 
patient characteristics as risk factors for infectious and non-infectious complica-
tion, catheter survival and complication-free survival. All patient characteristics, 
as shown in table 1, were analyzed. For analyses, age and clinical characteristics 
were divided into tertiles.  For survival analyses, death, therapy discontinuation 
or end of follow-up were defined as a censored event. A confidence interval of 




During the study period, 191 TIAPs were implanted in 111 patients. None of the 
patients were excluded from the study. The mean follow-up period was 946 ± 
719 days. Patient characteristics are summarized in Table 1. Sixty-one patients 
received a single TIAP, 29 patients received 2, 14 patients received 3, 5 patients 
received 4 and 2 patients received 5 TIAPs, respectively, making the mean num-
ber of devices 1.72 per patient. 50 patients died, including 3 TIAP-related deaths: 
2 cases of sepsis and 1 death due to a peri-operative complication. Causes of 
non-TIAP related death were progressive heart failure (n=25, 50% of all deaths), 
respiratory insufficiency (n=4, 8%), pulmonary hypertensive crisis (n=5, 10%), 
balloon septostomy (n=3, 6%) and non-PH related death (n=10, 20%). The over-




Complications and consequences 
Seventy-three patients experienced a combined total of 175 complications during 
a cumulative follow-up period of 104,992 days, resulting in an overall complica-
tion rate of 0.61 per patient-year (ppy) – table 3. The median complication-free 
survival was 371 days (Figure 1).  Based on their consequences, 2% of all com-
plications (0.01 ppy) were fatal, 82% (0.50 ppy) were serious and 16% (0.10 ppy) 
were either moderate or minor (table 3). 
Infectious complications 
Bacterial infections accounted for the most frequent cause of TIAP related com-
plications (45%, n=78). Seventy-eight infections were documented in 46 patients 
consisting of 33 local port site infections (0.11 ppy) and 45 BSIs (0.15 ppy), in-
cluding 7 cases of sepsis (0.02 ppy) – table 3. Of these 7 cases, 2 were fatal – 1 
Staphylococcus aureus-related sepsis and 1 Pseudomonas aeruginosa-related 
sepsis. The microbiological isolates of the infectious complications are shown in 
table 4. 
Figure 1. Complication-free survival of 111 pulmonary hypertension patients that received epoprostenol through 
a TIAP. For complication-free survival, any kind of TIAP-related complication was defined as an event. Death, 
treatment discontinuation or end of follow-up was defined as a censored event
 


























Non-infectious, cutaneous complications accounted for 24% (n=43) of all com-
plications. Twenty patients experienced 25 cases of skin irritation at the port site 
(0.09 ppy) and 15 patients experienced 18 cases of skin perforation at the port 
site (0.06 ppy) – table 3. Skin perforations resulted in 16 of the 18 ports having 
to be replaced. Two patients received an additional TIAP due to persisting skin 
irritation or skin perforation. This allowed alternate use of the TIAP and healing of 
the skin above the non-used port. Both cases resulted in TIAP salvage. 
Functional port complications
Twenty-five patients experienced 31 complications related to the TIAP itself (0.11 
Complications: 
 Bloodstream infection (BSI). Defined as a positive blood culture (port or peripherally aspirated) 
with or without erythema, tenderness, induration, exudate at the port site. If a positive blood 
culture was associated with clinical signs of a systemic infection (temperature above 38 °C, 
tachycardia, tachypnea, chills, general malaise, low blood pressure), the infection was defined as 
sepsis. 
  Local port site infection. Defined as at least one of the following: erythema, tenderness, 
induration, exudate at port site, combined with: (1) a positive skin swab, exudate or needle tip 
culture; and/or (2) raised infection parameters, raised peripheral white blood cell count, CRP 
and/or ESR level and (3) a negative blood culture sample. 
 Cutaneous complications. Defined as: (1) erythema, tenderness, induration or plain irritation at 
the port site as indicated by the patient, without exudate at the port site and/or with negative 
micro-organism culture sample; and (2) skin perforation at port site (figure 2).  
 Functional port complications. Defined as: (1) malfunction, defined as catheter breakage, 
obstruction, inability to infuse medication, needle dislodgment requiring medical intervention or 
any other failure of the device resulting in the interruption of epoprostenol infusion; (2) 
dislocation, defined as displacement of the port within or out of the port pocket; (3) port site 
haematoma; and (4) severe bleeding at the port site. 
 Implantation procedure related (peri-operative) complications. Included: (1) haematoma 
around the port site due to port placement; (2) incorrect port placement; (3) pneumothorax during 
the port placement; and (4) plexus brachialis injury due to port placement. 
 
Consequences: 
a) Fatal consequences were defined as complications causing the death of a patient. 
b) Serious consequences were defined as complications resulting in port removal or hospitalization 
over 48 hours. 
c)  Moderate consequences were defined as complications resulting in hospitalization less than 48 
hours or switching the epoprostenol treatment from port to a peripheral intravenous line or 
antibiotic therapy without hospitalization. 
d) Minor consequences were defined as complications that did not result in any form of 
hospitalization or medical treatment. 
 
Table 2. definition of complication and consequences
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ppy) –table 3. These consisted of 23 TIAP malfunctions, 4 haematomas near the 
port site, 3 port displacements and 1 case of late, severe bleeding from the port 
site. 
Peri-operative complications     
Twenty patients had 23 complications related to the TIAP placement procedure 
(13% of complications; 0.08 ppy). The majority of these complications were in-
correct TIAP placements (12 cases) with a TIAP placement failure of 6% (table 
3). Peri-operative problems included: one fatality due to post-operative bleeding 
accompanied by a pulmonary hypertensive crisis; 7 cases of haematoma near 
the port site directly after placement, 2 plexus brachialis injuries, and 1 pneumo-
thorax.
Complication risk factors
Females tended to be associated with a longer complication-free period (P = 
0.076) and infection-free period (P = 0.074) compared to males. Also, a trend 
was found between patient age group and infection-free period, with the highest 
age group showing a reduced infection-free period  (P = 0.072). No other risk 
factors for either infectious or non-infectious complications could be identified. 
In addition, no clinical infectious characteristics (as described in table 2) were 
predictive for a positive blood culture.
 
 Consequences  
 N (total) Fatal (N) Serious (N) Moderate (N) Minor (N) 
Infectious complications      
  Port site infection 33  29 4  
  Bloodstream infection* 38  38   
  Sepsis   7 2 5   
Non-infectious complications      
  Cutaneous complications      
    Skin irritation 25  19 6  
    Skin perforation 18  18   
  Functional port complications  31  16 15  
  Peri-operative complications 23 1 19  3 
      
Total (%) 175 (100)      3 (2)      144 (82)      25 (14)      3 (2) 
 
Table 3. Complications due totally implantable access port use and their conse-
quences in PH patients
* Excluding sepsis
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TIAP survival
During follow-up, 98 of the 191 (51%) TIAPs were removed because of complica-
tions. Causes for TIAP removal were BSI (n=35), local port site infection (n=24), 
sepsis (n=7), skin irritation (n=5), skin perforation (n=16), functional port compli-
cations (n=8) and incorrect port placement (n=3). The median TIAP survival was 
677 days. The median survival of the first, second and third TIAP was 635, 667 
and 391 days, respectively.
Female patients showed a significantly longer TIAP survival for the first TIAP 
(median 761 days, range 6-2107) compared to males (median 283 days, range 
13-1905; P=0.004), with a 2.2 times higher risk for TIAP removal for men. 
Discussion 
Complications due to continuous use of an implantable port in PH patients have 
not been reported previously. In the present study we describe complication rates 
for the use of a totally implantable access port for continuous intravenous ad-
ministration of epoprostenol in the treatment of severe pulmonary hypertension. 
During a mean follow-up of 946 days and a cumulative follow-up of 104,992 
days, PH patients using a TIAP for epoprostenol treatment showed a median 
complication-free survival of 371 days and a median TIAP life of 677 days.  In 
this study, the most important TIAP-associated complications were port-related 
infections (including BSIs and local port site infections), skin perforation, port 
malfunction and incorrect port placement, with incidence rates of 0.26, 0.06, 0.11 
and 0.04 ppy, respectively. The incidence rate for sepsis in this series was 0.02 
ppy. Reported complication incidence rates for percutaneous tunneled catheters 
(Hickman or Broviac) used for continuous intravenous epoprostenol therapy are 
as follows: catheter-related infections 0.09-0.49, sepsis 0.1-0.64 and malfunction 
0.28-1.4 ppy, respectively.(6-14) Although no direct comparison can be made, TIAP 
complication rates compare favorably to these reported complication numbers.
Infectious complications
As expected, our results show that infections occurred most frequently. Sepsis 
was the complication with the most severe outcome, even though the incidence 
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rate of sepsis was low. Two out of 7 septic episodes resulted in the death of the 
patient. 
TIAP-related BSIs were caused by a smaller variety of microbial species com-
pared to previous reports on infections in epoprostenol treatment.(13,14) A recent 
report of the Centers for Disease Control and Prevention has suggested that 
PAH patients demonstrate an increase in BSI incidence rates when treated with 
treprostinil in comparison to patients treated with epoprostenol, particularly in-
fections caused by Gram-negative micro-isolates.(14) Our results confirm that 
Gram-negative infections (port site and bloodstream infections combined) are 
uncommon in patients treated with epoprostenol (0.02 ppy).  
In our series, the majority of the micro-organisms responsible for infections were 
Gram-positive bacteria, commonly found in skin flora – namely Staphylococcus 
aureus (47 cases, 61%) and coagulase-negative staphylococci (CNS; 17 cases, 
22%). It has to be notified that, based on our BSI criteria (table 2), some presumed 
BSIs (specifically caused by CNS) might have actually been port contaminations. 
Therefore, true bloodstream infection rates may have been overestimated. 
All PAH patients suspect for a BSI received empiric antibiotic therapy (either 
flucloxacilline or vancomycin) which generally does not cover Gram-negative mi-
cro-isolates. Patients that presented clinical signs of sepsis received additional 
Gram-negative coverage. However, since only 6 gram-negative infections oc-
curred, our results did not lead tot changes in empiric management. 
Strict device care measures are known to play a crucial role in the prevention of 
device related infections. In The Netherlands, we try to optimize this by training 
sterile technique and device care to all PH patients with a TIAP for epoprostenol 
therapy, using the same hospital and home care program throughout the country. 
However, data on the success of strict catheter care measures in epoprostenol 
therapy is limited.(22) Recently, Doran et al. have set up guidelines for the pre-
vention of catheter related BSIs with prostanoid therapy.(22) Nevertheless, future 
studies are needed to investigate the impact of catheter care on TIAP-related 
complications during continuous epoprostenol therapy.   
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Non-infectious complications
A concern in the continuous use of an implantable port may be irritation or dam-
age of the skin around the port site. Skin irritation (0.09 ppy) could be handled in 
most cases with skin care measures, including prophylactic local antibiotic cream 
and hypoallergic dressing. 
In 18 cases, skin perforation occurred at the port site (0.06 ppy). This compli-
cation is specifically related to TIAP use and a serious complication of this im-
plantable device. Two cases were associated with a bloodstream infection. Skin 
perforation appeared not to be related to age, Body Mass Index or the length of 
the port being in situ. By placing an additional TIAP, port use can be alternated, 
allowing the irritated or damages skin above the non-used port to recover and 
the TIAP to be salvaged. In this way, the occurrence of skin irritations and perfo-
rations could possibly be reduced.   Functional port complications showed a low 
incidence rate (0.11 ppy). Displacement of the port itself – a common complica-
tion for percutaneous tunneled catheters – was uncommon (0.01 ppy), mainly 
because the TIAP is a subcutaneously implanted port. 
In our study, a relatively high incidence rate was found for TIAP placement fail-
ure. 6% (12 cases) of all ports were placed incorrectly (0.04 ppy), which is more 
frequent than previously reported placement failure rates of this device (0-2%).
(23,24) Placement failure may be reduced by assigning implantation procedures to 
surgeons who are highly experienced in TIAP placement. 
 
 Local port site infection BSI* Sepsis 
Staphylococcus aureus  20 23 5 
Coagulase-negative staphylococci 6 10  
Diphtheroids 1 2  
Group A streptococcus   1  
Pseudomonas aeruginosa  1 1 1 
Enterobacter sp  1 1 
Klebsiella sp 1   
Missing† 4   
Table 4. Microbiological isolates from 73 infections in 43 patients.
* Excluding sepsis
† 4 culture results are missing. For 3 port site infections a skin swap was not taken. One local port site infection 
culture was unavailable. 
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In oncology settings, the occurrence of thrombosis is a known complication with 
TIAP use. In our series, no thrombotic events occurred with the use of a TIAP 
for epoprostenol delivery. A possible explanation could be the anticoagulative 
characteristic of epoprostenol itself, and in addition, most patients used antico-
agulants as a part of PH treatment.
Consequences of complications
Catheter failure is a serious problem for PH patients where unexpected interrup-
tion of continuous intravenous administration of epoprostenol may be life-threat-
ening.1-4 In our series the TIAP shows a long lifespan and a low device-associat-
ed mortality rate. 
When complications did occur, they were associated with considerable morbidity. 
82% of complications had serious consequences (0.50 ppy), which included hos-
pitalization and port removal. Never the less, patient quality of life is considered 
to be relatively high due to the easy-to-handle nature of the port itself. 
Infections were the leading cause for port removal with 66 ports removed due 
to infectious complications. In most cases a positive microbial culture was the 
reason for TIAP removal, in accordance with hospital protocol. However, accord-
ing to the literature, routine device removal is not needed in every patient and 
salvage of the port can be attempted under certain clinical conditions.(15) By 
improving salvage strategies, as previously described (15), port removal rates 
may possibly be reduced.   
Gender was the only risk factor for port survival that we could identify, with fe-
males having a longer first port survival period compared to males. Also, females 
tended to have a longer complication-free and infection-free survival time. Fur-
ther, a higher age group tended to be associated with reduced infection-free sur-
vival. One could speculate that these factors are related to differences in life style 
and thus catheter care. No parameters for disease severity could be identified as 
risk factor for port survival. 
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Limitations
This study has specific limitations inherent to its retrospective nature. In this ob-
servational study, we aimed to describe complication rates related to the use of a 
TIAP for continuous epoprostenol treatment. For this reason a direct comparison 
with reported complication rates for the use a Hickman catheter cannot be made 
and, in addition, was not a specific aim. Therefore, even though we describe 
promising results with TIAP use for epoprostenol therapy, prospective studies are 
needed for direct comparison between the two different venous access forms.  
Indication for blood culture was based on clinical suspicion for infection by the 
treating physician.  Therefore it is possible that some BSIs occurred unnoticed. 
However, these presumed infections must have resolved spontaneously since 
the occurred without consequences.
No prospective complication registration was used for this study. However due 
to the organization of care in the Netherlands (PH treatment and follow-up are 
performed in the same PH centre) and standardized treatment protocols, all com-
plications related to the use of the TIAP requiring medical attention were reported 
to and treated in (or in cooperation with) the referral centre. Consequently, no 
complications requiring medical attention occurred unnoticed. 
Conclusion
Continuous intravenous epoprostenol therapy in PH is associated with impor-
tant morbidity and mortality related to the need for uninterrupted central venous 
access. In our series, we describe for the first time the use of a TIAP for con-
tinuous intravenous epoprostenol treatment in pulmonary hypertension patients 
with a long-lasting port survival and relatively low complication rates. Infectious 
complications were mainly caused by Gram-positive micro-organisms. Our data 
suggest that TIAP use is well suited for continuous intravenous epoprostenol 
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Pulmonary Arterial Hypertension (PAH) is a leading cause of morbidity and mor-
tality in patients with CHD.(1, 2) In these patients increased pulmonary blood flow 
(due to systemic-to-pulmonary shunting) is seen as an essential trigger for the 
formation of pulmonary neointimal lesions and thus PAH development.(3) Al-
though well described histopathologically, the pathogenesis of PAH and its neo-
intimal lesions is largely unknown. 
To date, neointimal lesions are regarded incurable, making PAH irreversible once 
these lesions occur. This is because current PAH therapies are thought to mainly 
target vasoconstriction rather than the process of vascular remodeling. To devel-
op new therapies, the molecular mechanism of this specific form of pulmonary 
vascular remodeling must therefore be unraveled.
At the beginning of this thesis we faced the following questions:
− What animal models resemble human PAH most truly and which param-
eter do we need for drug exploration read out?
− Using more suitable animal models, are there molecular pathways that 
are specifically regulated by increased pulmonary blood flow in PAH?
− If so, what is the role of such a pathway in the development of pulmonary 
vascular remodeling in PAH and can it function as a therapeutic target?
What have we learned while reading this thesis?
After three decades of PAH pathobiology research the focus has shifted from 
vasoconstriction towards a mechanism of cancer-like angioproliferation. In this 
concept the role of disturbed blood flow is seen as an important trigger in the de-
velopment of vascular remodeling. For instance, in PAH associated with congen-
ital heart disease, increased pulmonary blood flow (i.e. systemic-to-pulmonary 
shunt) is an essential trigger for the occurrence of neointimal lesions and PAH 
development. Questions remain about the exact role of these blood flow char-
acteristics in disease progression. With the use of PAH animal models we can 
search for the answers of these questions. As for any preclinical model though, 
the pathophysiological mechanism and clinical course has to be comparable to 
Summery and General Discussion
159
the human disease that it mimics. In Chapter 2 we review the current knowledge 
of preclinical animal models of PAH that more truly resemble human disease. 
This means that animal models mimicking human PAH ideally are characterized 
by: a) a hit recognized in human disease (e.g. altered pulmonary blood flow), 
b) specific vascular remodeling that more closely resembles human neointimal 
lesions compared to historical animal models, c) and disease progression that 
leads to RV dysfunction and death. In this concept, PAH models of increased pul-
monary blood flow – that more closely resemble the human trigger and histopa-
thology – are well suited for PAH investigation. An example of one of these mod-
els is the monocrotaline/aortocaval shunt (flow-associated PAH) rat model. This 
model is characterized by a) an initiating trigger that is known in human disease 
b) occlusive lesions containing angioproliferative and apoptotic-resitant ECs and 
SMCs showing similarities with human disease and c) progressive disease de-
velopment that leads to RV failure and death. These characteristics make the 
MCT+Shunt model well suited for further PAH investigation.  
In chapter 2 we further go into detail on the possible mechanisms of increased 
pulmonary blood flow. Here we postulate that increased pulmonary blood flow in-
duces disturbed blood flow patterns in the pulmonary vasculature triggering spe-
cific cellular processes that result in the formation of neointimal lesions. These 
processes include EC proliferation and apoptosis-resistance of endothelial cells, 
induction of inflammatory processes and differentiation of endothelial cells into 
mesenchymal cells. Also, additional triggers may propagate neointimal develop-
ment. For example, in patients with increased pulmonary blood flow, additional 
increased pulmonary arterial pressure, as in non-restrictive post-tricuspid shunts, 
accelerates the progression of pulmonary vascular remodeling, as an apparent 
second trigger.
Investigation of the role of disturbed blood flow can provide us with relevant clues 
to further unravel the complex pathogenesis of PAH. Using models of increased 
pulmonary blood flow, new pathways can emerge which may lead to new thera-
peutic targets for patients with PAH. In Chapter 3 we aimed to identify those path-
ways that are specifically involved in the pathogenesis of increased pulmonary 
blood flow that lead to neointimal development in PAH. Using a semi-randomized 
crossover design microarray experiment of lung tissue in end-stage disease of 
our flow-PAH model, we identified gene expression profiles specifically related 
to the addition of increased pulmonary blood flow. In this profile, 1 gene was of 
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particular interest: Early Growth Response protein 1 (Egr-1). Egr-1 is a transcrip-
tion factor known to play a major role in a variety of cardiovascular processes 
including vascular remodeling such as intimal thickening, vascular proliferation 
and vessel inflammation.(4-6) However its role in pulmonary vascular remodeling 
in PAH had, until now, not been described. 
Since this micro-array analysis revealed Egr-1 to be upregulated in end-stage 
disease, our next question was whether Egr-1 would be expressed in the pul-
monary vasculature during disease development. To answer this question we 
aimed to characterize and localize Egr-1 expression in the pulmonary vascula-
ture during neointimal development in flow-associated PAH model. In Chapter 4 
the spatiotemporal analysis of Egr-1 expression in this model reveals that Egr-1 
is upregulated in the pulmonary arteries directly after induction of increased flow, 
but also later in the disease process. Egr-1 was initially expressed in arterial 
endothelial layer. During disease development, Egr-1 migrated throughout the 
vessel wall showing the strongest expression in end-stage neointimal lesions. 
This indicates that Egr-1 could not only instigate but also propagate neointimal 
development in PAH induced by increased blood flow. Finally, we confirmed that 
Egr-1 is only sporadically upregulated in pulmonary vessels non-flow non-neo-
intimal PH (monocrotaline-only rats). These results identify Egr-1 as a candidate 
gene to master the flow-induced pulmonary vascular remodeling process asso-
ciated with the development of neointimal lesions. But a direct role of Egr-1 in 
pulmonary neointimal development remained to be determined.   
Still, based on a) the characteristics of Egr-1, a ‘master regulator’ of vascular 
remodeling in systemic vessels, b) the observation that Egr-1 is directly upreg-
ulated by the same trigger, namely increased pulmonary blood flow, during ne-
ointimal development in PAH and c) the pattern of pulmonary vascular Egr-1 
expression during PAH progression, we hypothesized that Egr-1 plays a key role 
in the development neointimal lesions in flow-associated PAH. 
In Chapter 5 we aimed to test this hypothesis by in vivo inhibition of Egr-1 in the 
same PAH rat model as described above. Targeting Egr-1 has previously been 
described using specific gene silencing methods, such as short interfering RNA 
(siRNA) or catalytic oligodeoxynucleotides (DNA enzymes or DNAzymes).(7-10) 
However, siRNAs have some major concerns that arise regarding their applica-
tion in vivo, including tissue specificity and the ability to withstand degradation by 
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nucleases. DNAzymes have been described to be more stable in serum in vivo 
compared to siRNA.(7, 10) DNAzymes are able to bind to specific RNA sequences 
resulting in RNA degradation. In addition, structural modification can be made to 
the DNAzyme molecule to enhance stability and reduce degradation in vivo.(10) In 
chapter 5 we describe the use of these DNAzymes as methods to downregulate 
vascular Egr-1 expression in our rat model of flow-associated PAH. In this study 
intravenous administration of catalytic oligodeoxynucleotides (DNAzymes) atten-
uated pulmonary vascular remodeling, including the development of occlusive 
neointimal lesions. Improvement in vascular remodeling was accompanied by a 
reduction of vascular proliferation in early stage disease and increased apoptosis 
in end stage disease. These findings suggest that in PAH vascular Egr-1 expres-
sion leads to a specific form of neointimal development through both a prolifera-
tive and a anti-apoptotic response. This concept is consistent with observations 
in human PAH where intraluminal obstruction of neointimal lesions is character-
ized by vascular proliferation and the formation of apoptosis resistant endothelial 
cells.(11-13) The positive effects of Egr-1 inhibition on vascular remodeling resulted 
in attenuation of disease progression as shown by a reduced pulmonary vascular 
resistance, right ventricular (RV) systolic pressure and RV hypertrophy. 
The question remains whether Egr-1 could be a putative therapeutic target for 
future PAH treatment. In our hands, DNAzyme treatment did not show any major 
systemic side effects. In addition, Egr-1-null mice are known to have no obvious 
phenotype, making Egr-1 targeted therapy theoretically feasible. Still, since oligo-
deoxynucleotide therapy is not likely to be directly clinically applicable for some 
time, pharmacological downregulation of Egr-1 with clinically used drugs could 
be an interesting pursuit. Several drugs in current clinical use have been de-
scribed to inhibit Egr-1 expression or activity. These include cyclosporine(14), sim-
vastatin(15), and peroxisome proliferator-activated receptor-γ ligands  (PPAR-γ)
(16-18) Chapter 5 also describes the effects of PPAR-γ ligand (pioglitazon) induced 
Egr-1 inhibition on early pulmonary vascular remodeling in our flow-associated 
PAH model. Here, pioglitazon attenuated the development of neointimal lesions 
in a dose dependent matter and reduced RVH 1 week after increased pulmo-
nary blood flow indicating that pharmacological inhibition of Egr-1 is feasible in 
flow-associated PAH. These data combined identify Egr-1 as a gene that gov-




But does this mean that Egr-1 is also specifically associated with neointimal 
development in human PAH? To shed light on this question we investigated, 
as described in chapter 6, differences in pulmonary vascular Egr-1 expression 
between PAH patients with neointimal development (plexogenic arteriopathy), 
hypoxic PH patients with media hypertrophy (without neointimal development) 
and control vessels. For this study, we hypothesized that pulmonary vascular 
Egr-1 expression is specifically upregulated in plexogenic arteriopathy in PAH 
patients compared to other forms of pulmonary vascular remodeling such as 
in hypoxic PH and control vessels. In patients with PAH associated with CHD, 
pulmonary vascular Egr-1 expression was specifically increased in neointimal re-
modeling compared to medial hypertrophy remodeling in hypoxic PH and control 
vessels. This increase in Egr-1 expression was seen in both pre-acinar (large) 
and intra-acinar (small) vessels. Egr-1 expression was most abundant in the en-
dothelial cells, i.e. those cells that are in direct contact with disturbed flow in the 
pulmonary vasculature. 
Egr-1 could possibly be an important gene in the pathogenesis of other forms of 
PAH, which would make Egr-1 targeting in PAH treatment even more interest-
ing. In chapter 6 we additionally show that Egr-1 expression is also increased 
in the pulmonary vessels of iPAH patients with strong Egr-1 upregulation in the 
endothelial layer. This is in line with recent observations of Kwapiszewska et al 
that show Egr-1 mRNA and protein expression is increased in remodeled arteries 
of iPAH patients.(19) Unfortunately this study did not describe the localization of 
Egr-1 expression in the vessel wall and failed to compare the expression with 
non-neointimal PH. The fact that in human PAH, increased Egr-1 expression is 
a) specific for neointimal development and b) located at a key site of disease 
pathogenesis suggests that Egr-1 could play a major role in the development of 
neointimal lesions in PAH.
With the use of current PAH treatment survival of these patients is still grim, as 
described in Chapter 7. In this chapter we focused on one of the current PAH 
treatment strategies, namely the use of the prostacyclin analogue epoprostenol. 
Epoprostenol plays a major role in current PAH therapy and have shown to im-
prove 6 minute walking distance and survival in iPAH patients. (20) However use 
of epoprostenol has some major drawbacks mainly due to its short half life. This 
makes continuous intravenous administration mandatory. In general, percuta-
neous tunneled catheters, such as the Hickman or Broviac catheter, are used 
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for continuous administration of epoprostenol. However the use these catheters 
are associated with significant morbidity and mortality.(20, 21) The use of a totally 
implantable access port (TIAP) could be a promising alternative since the natural 
barrier of the skin is left relatively intact and the risk of complications has been 
demonstrated to be lower compared with percutaneous tunneled catheters in 
oncology settings. TIAP use for epoprostenol treatment has not been described 
in the setting of epoprostenol use in PAH. In chapter 7 we describe catheter relat-
ed complications in 111 consecutive patients with pulmonary hypertension who 
were treated with long-term, continuous epoprostenol using a TIAP. In this study, 
the most important TIAP-associated complications were port-related infections 
(including BSIs and local port site infections), skin perforation, port malfunction 
and incorrect port placement, with incidence rates of 0.26, 0.06, 0.11 and 0.04 
per patient year, respectively. The median complication-free survival was 371 
days. Although no direct comparison can be made, TIAP complication rates in 
this study compare favorably with reported findings for tunneled catheter use 
(Hickman or Broviac).
Our data suggest that TIAP use is well suited for continuous intravenous epo-
prostenol delivery in patients with pulmonary hypertension and could result in a 
reduced morbidity and mortality in this group. 
Future perspectives 
In this thesis the main findings are: 1) that to properly investigate the pathogen-
esis of pulmonary vascular remodeling in PAH, animal models need to be used 
that more truly reflect human disease; 2) using such an animal model (monocro-
taline-aortocaval shunt PAH model) genetic pathways can be identified that are 
specifically upregulated by triggers (such as increased pulmonary blood flow) 
that also initiate disease development in human PAH; and 3) one of these genes, 
the transcription factor Egr-1, plays a crucial role in the development of neoin-
timal lesions and disease development in flow-associated PAH. These results 
have given us more insight in the pathogenesis of pulmonary neointimal devel-
opment. Still, PAH remains a fatal irreversible disease and question remain re-
garding therapy improvement and patient outcome. 
Now we have shown the positive effects of Egr-1 downregulation on PAH de-
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velopment, the underlying mechanisms require further exploration in order to 
be completely understood. Egr-1 can be activated by various stimuli including 
disturbed shear stress as seen in PAH associated with systemic-to-pulmonary 
shunting. What biological mechanisms govern these distinct responses to flow 
disturbances (Figure 1)? Egr-1 is known to contain shear stress responsive ele-
ments (SSRE) in the 5’-flanking region. These have been described to be activat-
ed through activation of mitogen activated protein kinases (MAPKs) specifically 
extracellular regulated kinase (ERK) 1/2.(22, 23) However, it is unknown if this 
pathway is also activated in PAH. Investigating these Egr-1 upstream pathways 
in PAH associated with systemic-pulmonary shunting could give us insight on 
how Egr-1 is activated in other forms of PAH as described in chapter 6.  
Future projects should also focus on the downstream pathways (proliferation, ap-
optosis, inflammation) of Egr-1 and how these lead to the development of occlu-
sive neointimal lesions. These pathways could include a wide variety of genes, 
including the platelet derived growth factor (PDGF) family, Tissue Factor (TF), 
inflammatory cytokines IL-6 and IL1β, and transforming growth factor β (TGF-β) 
that all have been described in the pathogenesis of PAH(13, 24-26). TGF-β is of par-
ticular interest since this ligand can both induce Egr-1 expression (presumably 
via non-SMAD pathways(27) and can be activated by Egr-1(28) itself resulting in 
a positive feedback mechanism of Egr-1 expression. Mutations in the TGF-β 
superfamily have been genetically linked to PAH development. (29) For instance, 
70% of patients with hereditary PAH are heterozygous for a loss of function mu-
tation in the bone morphogenetic protein receptor type 2 (BMPR2), a member 
of the TGF-β superfamily growth factor receptors. In addition, pulmonary artery 
smooth muscle cells from PAH patients have shown increased proliferation in 
response to TGF-β signaling.(30) 
Whether and how the TGF-β/BMPR2 signaling pathway is disturbed in increased 
blood flow-induced PAH remains a pursuit for future investigation. Egr-1 (either 
via SMAD or non-SMAD activation) could play a crucial role in this signaling path-
way which could possibly also link the vascular pathogenesis of different forms 
of PAH together. Still, for activity, Egr-1 is also dependent on the expression of its 
repressors NAB1 and NAB2, as described in chapter 4. NAB2 is a downstream 
target gene of Egr-1. In this way Egr-1 controls its own biological activity to pre-
vent excessive transactivation of target gene expression (such as TGF-β) and is 
able to repress its own activity directly.(4, 27) Unraveling the further mechanisms of 
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Egr-1 induced vascular remodeling in PAH will give us more insight in pathway 
interactions and possible new treatment target options in the future.
Pharmacological inhibition of Egr-1 could be a promising pursuit. Especially by 
means of drugs in current clinical use (drugs in search of disease) since these 
could be clinically applicable in a relative short time interval. As shown in chap-
ter 5 as a proof-of-concept, PPAR-γ ligand use could be an interesting pursuit. 
Recent studies have suggested that failure to activate PPAR-γ due to BMPII2 
signaling dysfunction results in SMC proliferation in PAH.(31) On the other hand, 
activation of PPAR-γ been shown to prevent ERK phosphorylation in endotheli-
al cells(32) and SMCs(33) which could be of interest in Egr-1 activation pathways. 
Since Egr-1 can be activated by ERK1/2 phosphorylation (22, 23), PPAR-γ induced 
Egr-1 inhibition could possibly be a result of ERK phosphorylation prevention. 
However, other studies have suggested PPAR-γ as a direct downstream target 
of Egr-1, thereby functioning as a negative feedback regulator to inhibit Egr-1 
downstream signaling.(34, 35) These pathways still remain to be determined in 
PAH associated with increased pulmonary blood flow. 
Besides Egr-1, we found several other interesting pathways in our microarray 
analysis that could serve as possible targets for future PAH treatment. For in-
stance, the transcription factor AFT3 was specifically upregulated due to in-
creased blood flow. Just like Egr-1, ATF3 can be induced by shear stress and is 
known to play a role vascular inflammation and proliferation, both hallmarks of 
Figure 1 Switching off Egr-1 in PAH: Implications for future treatment Our results indicate 
that the transcription factor Egr-1 governs pulmonary vascular remodeling and the development of 
characteristic vascular neointimal lesions in flow-associated PAH. Egr-1 could therefore be a prom-
ising target for future PAH treatment. Future studies should focus on the underlying or downstream 
mechanisms (i.e. underlying circuit board) that result from ‘swithing off’ Egr-1 in PAH. 
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pulmonary vascular remodeling in PAH. Future studies should investigate the role 
of ATF3 in neointimal development in PAH. Also in this gene array, certain com-
ponents of the Wnt-pathway were affected by iloprost therapy, a PAH treatment 
current used in clinical practice. Target genes of the Wnt pathways include ma-
trix metalloproteinases, cyclo-oxygenase-2 and the VEGF-receptor. All of these 
substances are believed to play a role in the pathogenesis of PH. Whether the 
Wnt-pathway is involved in the development of the pulmonary vascular lesions or 
in the effect of therapeutic strategies remains to be determined in future studies. 
Lastly, when investigating novel treatment options, one must also evaluate wheth-
er the specific therapy is clinically applicable. Namely, most PAH patients present 
themselves when pulmonary vascular remodeling is already in an irreversible 
stage, namely when neointimal lesions have already formed. Therefore, future 
treatments should focus targeting on reversal of these so-called irreversible neo-
intimal lesions, something that has not been accomplished so far.   
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Pulmonale hypertensie (PH) wordt gedefinieerd als een gemiddelde druk in de 
arteria pulmonalis van > 25 mmHg in rust. PH is een symptoom dat voorkomt bij 
verschillende onderliggende aandoeningen en wordt geclassificeerd in 5 klinis-
che categorieën. De eerste categorie, Pulmonale Arteriële Hypertensie (PAH), 
is een ernstig progressieve longvaataandoening die gekenmerkt wordt door een 
verhoogde weerstand in de longvaten en gepaard gaat met een hoge morbiditeit 
en mortaliteit. PAH kan van de andere PH categorieën worden onderscheiden 
op basis van de unieke complexe veranderingen die optreden in de longvaten 
van patiënten met PAH, waaronder de zogeheten plexiforme laesies. Deze plex-
ogene laesies zijn uniek voor PAH en ontstaan door apoptotische dysregulatie, 
proliferatie van zowel endotheelcellen en gladde spiercellen, en inflammatie in 
en rondom het vaatbed.  Deze processen tezamen leiden tot de vorming van kar-
akteristieke neointima  in het longvaatbed - vergelijkbaar  met atherosclerotische 
laesies en re-stenose na angioplastiek in het systemische vaatbed. De longvaat-
weerstand neemt toe door deze vaatveranderingen, wat leidt tot hartfalen en 
uiteindelijk tot het overlijden van de patiënt.
PAH kan zich manifesteren als een intrinsieke longvaatziekte waarbij geen aan-
toonbare oorzaak wordt gevonden (idiopatische PAH), maar het is ook geasso-
cieerd met onderliggende aandoeningen, waaronder aangeboren hartafwijkin-
gen met grote links-rechts shunts. 
Uit ervaring die is opgedaan met patiënten met een congenitale hartafwijking 
blijkt dat bij een toegenomen pulmonale doorbloeding in combinatie met een 
verhoogde arteriële druk (zoals bij links-rechts shunts) de bovengenoemde ken-
merkende combinatie van pathologische afwijkingen ontstaan. De pathogenese 
van deze afwijkingen is echter nog grotendeels onbekend en een curatieve be-
handeling is tot op heden nog niet gerealiseerd. Hoewel medicamenteuze be-
handelingen de overleving van deze patiënten verlengt, is de levensverwachting 
van kinderen met PAH vooralsnog beperkt (< 10 jaar). Dit komt mede doordat de 
huidige PAH therapie er vooral op gericht is om vasoconstrictie tegen te gaan en 
niet zozeer om het proces van vasculaire remodelering aan te pakken. Om nieu-
we therapieën te ontwikkelen voor PAH, is het noodzakelijk om het moleculaire 
mechanisme van PAH beter te begrijpen. Hierdoor kunnen nieuwe aangrijping-
spunten doelgerichter gebruikt worden voor behandeling van PAH. 
Na ongeveer 30 jaar van PAH onderzoek is de hypothese van de onderliggen-
de pathogenese veranderd van puur een ziekte van pulmonale vasoconstrictie 
naar een mechanisme van angioproliferatie. In dit concept worden veranderin-
gen in pulmonale vaatdoorstroming (flow) gezien als een belangrijke oorzaak in 
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de vorming van longvaatveranderingen in PAH. 
Zo weten we dat aangeboren hartafwijkingen die gepaard gaan met een sys-
teem-pulmonale shunt (bijvoorbeeld een ventriculair of atriaal septum defect of 
een persisterende open ductus Botalli) leiden tot een toegenomen bloedstroom 
door de longen. Dit kan leiden tot een verhoogde druk in de longvaten en tot de 
ontwikkeling van de typische neointima laesies van PAH. Bij aangeboren hartaf-
wijkingen die niet gepaard gaan met een verhoogde longdoorstroming kan PH 
weliswaar ook voorkomen, maar hierbij worden nooit de karakteristieke neointi-
ma laesies gevonden die gezien worden bij PAH. 
Zogenaamde “pre-tricuspide shunts”, zoals een atriaal septum defect, leiden in 
eerste instantie tot een verhoogde bloedstroom, zonder dat er een verhoogde 
druk in de longvaten is. Onder invloed van de verhoogde bloedstroom in de long-
vaten ontwikkelt zich in de loop van 30-40 jaar ook PAH met de typische long-
vaatafwijkingen. “Post-tricuspidale shunts” leiden echter al kort na de geboorte 
tot flow-geassocieerde hypertensie in de longvaten en de karakteristieke long-
vaatafwijkingen van PAH ontwikkelen zich hier al in de eerste levensjaren.
Een verhoogde bloedstroom blijkt bij patiënten met een aangeboren hartafwi-
jking dus een noodzakelijke, luxerende factor te zijn voor het ontwikkelen van 
de karakteristieke vaatwandlaesies. Het bestaan van een verhoogde druk in de 
longvaten blijkt daarbij een accelererende rol te spelen. Hoe deze hoge longvaat-
doorstroming leidt tot de ontwikkeling van de karakteristieke neointima laesies is 
echter grotendeels onbekend. 
Een diermodel voor flow-geasscoieerde PAH is een zeer goed middel om dit 
mechanisme te onderzoeken. Vanzelfsprekend moet dit model, net als ieder an-
der preklinisch model, vergelijkbaar zijn met de humane situatie met betrekking 
tot het pathofysiologische mechanisme en het klinisch beloop van de ziekte. In 
hoofdstuk 2 bespreken we de huidige kennis ten aanzien van preklinische dier-
modellen die een humane ziekte adequaat reproduceren. Hieruit leren we dat 
diermodellen die humane PAH nabootsen idealiter aan de volgende kenmerken 
voldoen: a) het diermodel heeft een afwijking overeenkomstig met de humane 
ziekte (b.v. veranderde flow), b) er is specifieke vasculaire remodellering geli-
jkend op de humane neointima laesies, c) de ziekte is progressief en leidt uitein-
delijk tot rechterventrikel (RV) disfunctie en overlijden. Daarom zijn diermodellen 
met een verhoogde bloeddoorstroming door het longvaatbed zeer geschikt om 
PAH te onderzoeken, gezien de verhoogde bloeddoorstroming in de humane sit-
uatie een belangrijke luxerende factor is voor het ontstaan van de kenmerkende 
histopathologische afwijkingen. Een voorbeeld van een van deze modellen het 
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monocrotaline (MCT)/aortocavale shunt rattenmodel (flow-geassocieerde PAH 
rattenmodel). Dit model wordt dan ook gekenmerkt door a) een luxerende factor 
(namelijk verhoogde flow) die ook belangrijk is bij de ontwikkeling van de hu-
mane ziekte, b) de ontwikkeling van occlusieve leasies die, net als bij de humane 
ziekte, angioproliferatieve en apoptose-resistente endotheel- en gladdespiercel-
len bevatten en c) progressie van de ziekte die uiteindelijk resulteert in RV falen 
en overlijden. Deze eigenschappen maken dit MCT+shunt model zeer geschikt 
voor verder PAH onderzoek. 
In hoofdstuk 2 wordt ook dieper ingegaan op de mogelijke mechanismen ach-
ter de associatie tussen een verhoogde pulmonale bloedstroom en de vorming 
van de karakteristieke histopathologische laesies. We hypotheseren dat een ver-
hoogde pulmonale bloedstroom leidt tot een verstoord patroon van de bloed-
stroom, waardoor specifieke cellulaire processen worden aangezet die leiden tot 
de formatie van neointima laesies. endotheelcelproliferatie, apoptose-resistente 
endotheelcellen, inflammatoire reacties en de differentiatie van endotheelcellen 
in mesenchymale cellen dragen allemaal bij aan het op gang brengen van dit 
proces. Waarschijnlijk zijn er echter ook nog andere triggers betrokken bij de 
ontwikkeling van neointima laesies. Dit blijkt uit de observatie dat het proces van 
pulmonale vasculaire remodellering wordt versneld wanneer patiënten naast een 
verhoogde pulmonale bloedstroom ook een verhoogde pulmonale arteriële druk 
hebben. Deze situatie is te zien bij patiënten  met een non-restrictieve post-trisp-
idale shunt. De verhoogde arteriële druk werkt dan als een tweede trigger voor 
de vorming van neointima laesies. 
Onderzoek naar de rol van een verstoorde pulmonale bloedstroom geven ons 
meer inzicht in de complexe pathogenese van PAH. Door modellen met een ver-
hoogde pulmonale bloedstroom te gebruiken, kunnen nieuwe pathways ontdekt 
worden die potentieel als therapeutisch doelwit kunnen fungeren. In hoofdstuk 
3 hebben we getracht pathways in kaart te brengen die betrokken zijn bij de 
ontwikkeling van neointima laesies ten gevolge van een verhoogde pulmonale 
bloedstroom. Met behulp van een semi-gerandomiseerd cross-over microarray 
experiment met longweefsel van ons diermodel met flow-geassocieerde PAH, 
hebben we genexpressie profielen in kaart gebracht die specifiek gerelateerd 
zijn aan de toevoeging van een verhoogde pulmonale bloedstroom. Uit dit prof-
iel bleek een gen met name interessant te zijn: Early Growth Response protein 
(Egr-1). Egr-1 is een transcriptiefactor waarvan bekend is dat het een belangrijke 
rol speelt in meerdere cardiovasculaire processen, waaronder vasculaire remod-
ellering zoals intima verdikking, vasculaire proliferatie en inflammatie van de vat-
en. De rol van Egr-1 in PAH was tot nu toe nooit aangetoond. 
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Gezien met deze micro-array analyse upregaulatie van Egr-1 werd aangetoond 
bij PAH in eindstadium ziekte, was de volgende vraag of Egr-1 ook tot expressie 
zou komen in de longvaten tijdens de ontwikkeling van de ziekte. Hoofdstuk 4 
laat de spatiotemporale expressie van Egr-1 zien in het flow-geassocieerde PAH 
model. Hierbij zagen we dat in de pulmonaalvaten, Egr-1 zowel direct na aan-
leg van de AV shunt (verhoogde longvaatdoorstroming), als later in het ziekte-
proces aanwezig is. Hierbij werd Egr-1 in een vroeg stadium van de ziekte alleen 
gevonden in de endotheelcellaag, waarna gedurende de ziekteprogressie deze 
Egr-1 expressie migreerde naar de overige lagen van de vaatwand.  Tevens 
toonde we aan dat Egr-1 slechts sporadische voorkomt in de longvaten van PH 
rattenmodellen waarbij geen verhoogde longvaatdoorbloeding was en geen ne-
ointima laesies gevormd waren (rattenmodel met alleen monocrotaline, zonder 
shunt). Deze resultaten samen gaven aan dat Egr-1 een kandidaat gen was 
voor de regulatie van het flow-geinduceerde neointima vorming in de longvaten 
in PAH. Echter, een directe rol van Egr-1 tijdens de ontwikkeling van pulmonale 
neointima laesies bleef onbekend. Wij hypothetiseerden dat Egr-1 een hoofdrol 
speelt bij de ontwikkeling van neointima laesies in flow-geassocieerde PAH.
In hoofdstuk 5 hebben we deze hypothese getoetst door Egr-1 in vivo te remmen. 
Hierin beschrijven we het gebruik van zogenoemde catalytic oligodeoxynucleo-
tides (DNAzymes) bij de downregulatie van pulmonale vasculaire Egr-1 expres-
sie in ons rattenmodel van flow-geassocieerde PAH. Intraveneuze toediening 
van catalytische oligodeoxynucleotiden (DNAzymes) leidde tot remming van 
pulmonale vasculaire remodellering, waaronder de ontwikkeling van occlusieve 
neointima laesies. De vermindering van vasculaire remodellering ging gepaard 
met een afname van vasculaire proliferatie in een vroeg stadium van de ziekte 
en met verhoogde apoptose in het eindstadium van de ziekte. Deze bevindingen 
geven aan dat de vasculaire Egr-1 expressie bij PAH tot een specifieke vorm 
van neointima ontwikkeling leidt door zowel een proliferatieve als een anti-ap-
optotische respons. Dit concept komt overeen met de observaties die gedaan 
zijn bij humaan PAH, waar intraluminale obstructie van neointima laesies gek-
enmerkt worden door vasculaire proliferatie en de formatie van apoptose resist-
ente endotheelcellen. De positieve effecten van Egr-1 remming op de vasculaire 
remodellering leidde tot een reductie van de ziekteprogressie, wat blijkt uit een 
afgenomen weerstand in de longvaten, verlaagde systolische druk in de rechter 
ventrikel en verminderde hypertrofie van de rechter ventrikel.
Het blijft echter de vraag of Egr-1 een mogelijk therapeutisch doelwit kan zijn in 
de toekomstige behandeling van PAH. Aangezien een klinische behandeling met 
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oligodeoxynucleotiden voorlopig nog niet mogelijk is, zou de farmacologische 
downregulatie van Egr-1 met behulp van medicatie die al wel klinisch beschik-
baar zijn een mogelijk optie kunnen zijn. Er zijn meerdere huidige medicijnen 
die de expressie of activiteit van Egr-1 verminderen. Dit zijn onder andere: ciclo-
sporine, simvastatine en peroxisome proliferator-activated receptor-γ (PPAR-γ) 
ligands.  In Hoofdstuk 5 beschrijven we de effecten van PPAR-γ ligand (pioglita-
zon) geïnduceerde Egr-1 remming op vroege pulmonale vasculaire remodeller-
ing in ons flow-associated PAH model. Pioglitazon leidde tot een dosisafhankeli-
jke vermindering van de ontwikkeling van neointima laesies en een afname van 
rechter ventrikel hypertrofie. Hieruit blijkt dat de farmacologische remming van 
Egr-1 een realistische behandelingsmogelijkheid is bij flow-geassocieerde PAH. 
Uit onze bovengenoemde resultaten blijkt dat de transcriptiefactor Egr-1 pulmo-
nale vasculaire remodellering en de ontwikkeling van de kenmerkende vascu-
laire neointima laesies aanstuurt in flow-geassocieerde PAH. Egr-1 zou daarom 
een geschikt doelwit kunnen zijn voor toekomstige PAH behandelingen. Nieuwe 
onderzoeken zouden de focus moeten leggen op de onderliggende of down-
stream mechanismen die leiden tot het “uitzetten” van Egr-1 bij PAH. Deze data 
tezamen geven aan dat bij experimentele PAH de ontwikkeling van neointima 
aangestuurd kan worden door het Egr-1 in reactie op een verhoogde bloeddoor-
stroming in de longen.
Maar betekent dit ook dat Egr-1 een specifieke associatie heeft met de ontwik-
keling van neointima laesies bij humane PAH? Om deze vraag te beantwoorden 
hebben we, zoals in hoofdstuk 6 wordt beschreven, de verschillen in pulmonale 
vasculaire Egr-1 expressie tussen PAH patiënten met neointima ontwikkeling, 
hypoxische PH patiënten met mediahypertrofie (zonder neointima laesies) en 
controle vaten met elkaar vergeleken. Voor deze studie hadden we de hypothese 
opgesteld dat Egr-1 specifiek tot expressie zou komen in PAH patiënten (met 
neointima laesies) ten opzichte van andere vormen van pulmonale vasculaire 
remodeling, waaronder hypoxische PH vaten, en controle vaten (allen waar dus 
geen neointima laesies voorkomen). Bij patiënten met flow-geassocieerde PAH 
was de pulmonale vasculaire Egr-1 expressie tijdens neoinitima vorming hoger 
dan in de longvaten van hypoxische PH gepaard gaande met mediahypertrofie 
en controle vaten. Deze verhoging in Egr-1 expressie werd in zowel pre-acinaire 
(grote) en intra-acinaire (kleine) vaten gezien. Egr-1 kwam het meest tot expres-
sie in de endotheelcellen en dit zijn dan ook de cellen die direct in contact staan 
met een verstoorde bloedstroom. 
Egr-1 zou ook een belangrijk gen kunnen zijn binnen de pathogenese van an-
dere vormen van PAH, wat Egr-1 als behandelingsdoelwit nog interessanter zou 
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maken. In hoofdstuk 6 laten we tevens zien dat Egr-1 expressie ook verhoogd 
is in de longvaten van idiopatische PAH patiënten, met een sterke upregulatie 
van Egr-1 in de endotheelcellaag. Dit komt overeen met de recente bevindingen 
waar werd aangetoond dat de mRNA en eiwit expressie van Egr-1 verhoogd is 
in de pulmonaalvaten van iPAH patiënten. Gezien verhoogde Egr-1 expressie bij 
humaan PAH a) specifiek is voor de ontwikkeling van neoinitima laesies en b) 
gelokaliseerd is op de plaats waar de ziekte ook daadwerkelijk tot uiting komt, 
lijkt Egr-1 een belangrijke rol  te spelen bij de ontwikkeling van neoinitma laesies 
bij PAH. 
De prognose van patiënten met PAH is met de huidige behandelingen nog steeds 
slecht, zoals beschreven wordt in hoofdstuk 7. In dit hoofdstuk focussen we op 
een van de huidige therapieën voor PAH, namelijk de prostacycline analogue 
epoprostenol. Epoprostenol heeft een belangrijke plaats binnen de bestaande 
PAH behandelingen en verbetert de 6 minute walking distance en de overleving 
van iPAH patiënten.  Er kleven echter wat nadelen aan deze behandeling die met 
name te wijten zijn aan de korte halfwaardetijd waardoor intraveneuze toedien-
ing noodzakelijk is. Over het algemeen worden percutane getunnelde katheters 
(b.v. de Hickman of Broviac katheter) gebruikt voor de continue intraveneuze 
toediening van epoprostenol. Deze katheters gaan echter gepaard met signif-
icante morbiditeit en mortaliteit, met name door infecties. De toepassing van 
een  totally implantable access port (TIAP; Port-a-Cath) zou een veelbelovend 
alternatief kunnen zijn aangezien het de natuurlijke barrière van de huid relatief 
intact laat en het binnen de oncologie gebleken is dat het risico op complicaties 
lager is dan percutane getunnelede katheters. De toepassing van TIAP is nog 
niet beschreven als toedieningsmiddel van epoprostenol bij PAH. In hoofdstuk 
7 beschrijven we de katheter-gerelateerde complicaties die optraden bij 111 op-
eenvolgende patiënten met PH die voor een lange termijn behandeld werden 
met continue toediening van epoprostenol  via een TIAP. Deze studie toonde dat 
de belangrijkste TIAP-geassocieerde complicaties bestonden uit TIAP-gerela-
teerde infecties (waaronder bacteriemie en lokale catheter infecties), huidperfo-
raties, TIAP dysfunctie en incorrecte plaatsing van de TIAP, met incidentiecijfers 
van respectievelijk 0.26, 0.06, 0.11 en 0.04 per patiënt per jaar. De mediane 
complicatie-vrije overleving was 371 dagen. Hoewel een directe vergelijking niet 
gemaakt kon worden, lijken deze cijfers gunstiger te zijn dan de complicatieci-
jfers bij het gebruik van getunnelede katheters (Hickman of Broviac). Onze data 
impliceren dat de toepassing van TIAP geschikt is voor de continue intraveneuze 
toediening van epoprostenol bij patiënten met PH en dat het gebruik ervan zou 




De belangrijkste bevindingen van dit proefschrift zijn: 1) diermodellen die een 
goede afspiegeling vormen van de humane ziekte zijn noodzakelijk om de patho-
genese te onderzoeken van pulmonaire vasculaire remodellering bij PAH; 2) een 
monocrotaline-aortacavale shunt PAH model is een diermodel dat een goede 
reflectie vormt van humane PAH en waarmee genetische pathways geïdentifi-
ceerd kunnen worden die ook specifiek worden geupreguleerd door de luxer-
ende factoren (zoals een verhoogde pulmonale bloedstroom) die humane PAH 
induceren; en 3) dat een van deze genen, de transcriptiefactor Egr-1, een cru-
ciale rol speelt bij de ontwikkeling van neointima laesies en ziekteontwikkeling 
in flow-geassocieerde PAH. Deze resultaten hebben ons meer inzicht gegeven 
in de pathogenese van pulmonale neointima ontwikkeling. PAH blijft echter een 
fatale ziekte en vragen betreffende de verbetering van de behandeling en de 
uitkomst voor patiënten blijven onbeantwoord. 
Hoewel we nu de positieve effecten van Egr-1 downregulatie op de ontwikkeling 
van PAH hebben aangetoond, dienen de onderliggende mechanismen hiervan 
verder onderzocht te worden om het volledig te begrijpen. Egr-1 kan door ver-
scheidene stimuli geactiveerd worden, waaronder gestoorde shear stress wat 
gezien wordt bij PAH gepaard gaande met systemisch-naar-pulmonale shunts. 
Welke biologische mechanismen deze specifieke reacties aanvoeren is echter 
nog niet bekend. Toekomstige projecten zouden ook de nadruk moeten leggen 
op de downstream pathways van Egr-1 (proliferatie, apoptose en inflammatie) en 
op de manier waarop deze pathways leiden tot de vorming van de occluderen-
de neointima laesies. Deze pathways  zouden een verscheidenheid aan genen 
kunnen bevatten, waaronder de platelet derived growth factor (PDGF) familie, 
Tissue Factor (TF), inflammatoire cytokines IL-6 en IL1β, en transforming growth 
factor β (TGF-β), waarvan van allemaal beschreven is dat ze betrokken zijn bij 
de pathogenese van PAH.  TGF-β is hierbij met name interessant aangezien dit 
ligand zowel Egr-1 expressie kan induceren (voornamelijk via non-SMAD path-
ways)  als zelf geactiveerd kan worden door Egr-1, wat resulteert  in een positief 
feedback mechanisme van Egr-1 expressie. Mutaties in de TGF-β superfamilie 
zijn genetisch gekoppeld aan de ontwikkeling van PAH. Zeventig procent van de 
patiënten met hereditaire PAH zijn bijvoorbeeld heterozygoot voor een loss of 
function mutatie in de bone morphogenetic protein receptor type 2 (BMPR2), die 
lid is van de TGF-β superfamilie growth factor receptors.
Of en hoe de TGF-β/BMPR2 signaling pathway verstoord is bij flow-geindu-
ceerde PAH, blijft een belangrijk onderwerp voor toekomstig onderzoek. Egr-1 
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(via SMAD of non-SMAD-activatie) zou een cruciale rol kunnen spelen in deze 
pathway dat mogelijk ook de vasculaire pathogeneses van verschillende vor-
men van PAH kan verbinden. Door het mechanisme achter Egr-1 geinduceerde 
vansculaire remodellering bij PAH te ontrafelen zullen we meer inzicht krijgen in 
de interacties tussen verschillende pathways en in nieuwe behandelingsopties.
Het farmacologisch remmen van Egr-1 is veelbelovend, zeker wanneer dit zou 
worden gedaan met medicatie die vandaag de dag gebuikt wordt aangezien 
deze op korte termijn beschikbaar kunnen zijn voor klinische doeleinden. Zoals 
in hoofdstuk 5 als een ‘proof of concept’ werd beschreven, zou het gebruik van 
PPAR-γ agonisten potentie kunnen hebben voor behandeling van PAH. In re-
cente onderzoeken wordt geopperd dat falen van PPAR-γ activatie kan resul-
teren in SMC proliferatie bij PAH. Andere studies hebben echter geopperd dat 
PPAR-γ als een directe downstream target van Egr-1 fungeert, waardoor het als 
een negatieve feedback regulator functioneert om Egr-1 downstream signaling te 
remmen. Deze pathways moeten echter nog verder worden onderzocht bij PAH 
geassocieerd met een verhoogde pulmonale bloedstroon.
Naast Egr-1 hebben wij verscheidene andere interessante pathways gevonden 
in onze microarray analyse die als toekomstige doelwitten bij toekomstige PAH 
behandelingen zouden kunnen dienen. De transcriptiefactor AFT3 was bijvoor-
beeld specifiek opgereguleerd door verhoogde bloedstroom. AFT3 kan net als 
Egr-1 geïnduceerd worden door veranderde shear stress en het is bekend dat 
het een rol speelt bij vasculaire inflammatie en proliferatie, wat beide kenmerken 
zijn van vasculaire remodellering bij PAH. Toekomstige studies zouden de rol die 
AFT3 speelt bij de vorming van neointima PAH moeten onderzoeken. Bij deze 
gene array  werden ook bepaalde onderdelen van de Wnt-pathway beinvloed 
door de behandeling met iloprost, wat een behandeling voor PAH is die vandaag 
de dag wordt toegepast bij PAH target genen van de Wnt-pathways zijn matrix 
emtalloproteinases, cyclooxygenase-2 en de VEGF-receptor. Of de Wnt-path-
way betrokken is bij de vorming van pulmonale vascuclaire laesies of bij het 
effect van therapeutische strategieën dient nader te worden onderzocht.
Tot slot zou bij onderzoeken naar nieuwe behandelingsopties ook rekening ge-
houden moeten worden met de vraag of de specifieke therapie ook beschikbaar 
is voor klinisch gebruik. Bij de meeste PAH patienten die voor het eerst gezien 
worden is pulmonale vasculaire remodellering namelijk al in een onomkeerbaar 
stadium, dus wanneer de neoinitma laesies zich al gevormd hebben. Derhalve 
zouden toekomstige preklinische studies zich moeten focussen op de reversibi-
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